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Q u a l it y A ssu r a n c e
Michael R. Weaver

Abstract
Intraocular melanoma is a rare form of cancer with a high mortality rate and limited
effective treatment options. It causes death in 45% of patients within 15 years, typically
within 6 - 9 months of the first signs of metastatic spread. Plaque brachytherapy is
one of the most common treatments, and has proven to be quite successful at local
tumour control. It involves temporarily stitching a small, radionuclide-bearing device,
called an eye plaque, on the surface of the eye above the tumour.
The accuracy of treatment planning and dose verification procedures remains suboptimal, due to the very high gradient of the radiation field immediately adjacent
to the sources. Ideally, the dose distribution should be directly measured using the
actual plaque and brachytherapy sources via a high-resolution spatial dosimetry sensor.
The reverse-biased silicon diode has proven to be particularly well suited to real-time,
accurate dosimetry due to the high tissue-equivalence of silicon.
The current recommended treatment planning process is based on TG-43U1 for
malism, which assumes infinite water surroundings and does not account for material
heterogeneities. Plaque brachytherapy treatment, however, includes regions of high
Z f f materials, including bone and the plaque, which have been shown to significantly
affect dose. An accurate dose verification system for plaque brachytherapy would have
great potential for improved treatment efficacy and reduced damage to healthy tissue
through dose optimisation and encouraging patient-specific plaque customisation.
The project aimed to develop a high-precision, volumetric dosimetry system, the
P a n o p te s , based on silicon detector technology. Two variants of the concept were
developed and validated experimentally; the first with a single-diode detector, and the
second with a pixelated detector array.
When tested with a brachytherapy plaque fitted with ten 125I seeds, the dose
measured with the single-diode detector was within 4% of the TG-43U1 formalism at
distances greater than 3.0 mm from the plaque.
Medipix detectors demonstrated the potential of using pixelated detectors and
spectroscopic dosimetry in 125I plaque brachytherapy by showing a correlation within
1% between event counting and charge modes. This illustrated that event counting
would be a feasible dosimetry technique in the subsequent design of the P a n o p t e s .
Depth-dose measurements using the P a n o p t e s showed agreement within ~ 4%
with Monte Carlo simulations, Plaque Simulator software and the TG-43U1 formalism
along the central plaque axis. A volumetric dosimetry tool, such as the P a n o p t e s ,
could offer much to improve current dose verification and treatment planning practises
in eye plaque brachytherapy.
K E Y W O R D S : ophthalmic, eye, plaque, brachytherapy, I-125, dosimetry, Medipix,
pixelated
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Chapter 1
Introduction
There are three classes of people: those who see, those who see when they are
shown, those who do not see.
— Leonardo Di Vinci

Uveal melanoma is the most common of the intraocular cancers, and yet is a disease
that few are likely to be aware of. It affects a relatively low number of people worldwide,
with age-standardised incidence rates in Australia being amongst the highest, at around
seven people per million[1]. However, despite its low incidence, the prognosis for the
disease can be very serious, with metastasis, or the development of distant secondary
malignant growth, commonly occurring in the liver and affecting approximately 50%
of uveal melanoma patients[2]. Metastatic disease is rarely responsive to treatment
with death usually occurring within six to nine months of the first signs of metastatic
symptoms[3]. Patients whose cancer is successfully treated still often suffer degradation
in vision or pain in the affected eye.
There are several treatments aimed at controlling intraocular cancers, the most
common of which include enucleation and radiotherapy. Enucleation involves com
plete removal of the globe of the eye and is often used in treating large tumours, in
cases where maintaining useful vision is unlikely. The two most common forms of
1
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radiotherapy are external beam therapy and plaque brachytherapy. External beam
therapies, particularly proton and heavy ion beam therapies, have been shown to have
good efficacy[4-7], but are limited in availability. Plaque brachytherapy is much more
widespread and has been shown to have similar clinical outcomes to enucleation, with
the advantage of preservation of the eye and vision[8,9].
In plaque brachytherapy, a small, metallic partially-spherical cap, called a plaque
with small embedded radionuclide sources is sutured onto the eye, above the tu
mour. Here, it delivers a therapeutic dose of radiation to the tumour whilst shielding
the surrounding healthy tissue.

The plaque remains in place long enough to de

liver the prescribed dose, usually 85 Gy to the tumour apex, at a rate of around
0.6 G y h -1 to 1.05 Gy h-1 [10]. The sources used are usually either iodine-125 (125I),
palladium-103 (103Pd) or ruthenium-106 (106Ru).
Plaque brachytherapy has been shown to have excellent local tumour control, or
eradication of clonogenic tumor cells, in around 90% of cases, with an overall mean
survival of approximately 84% after five years [8>9>11-17l. The treatment is associated
with a number of radiation-induced side effects such as retinopathy, optic neuropathy,
choroidopathy, cataract, and scleral necrosis as well as loss of visual acuity[18] and
chronic pain or discomfort in the treated eye[19]. Furthermore, large tumours have also
proved difficult to treat, with the recommended treatment being enucleation[10].
Currently in plaque brachytherapy, treatments are planned using the Task Group
43U1 formalism[20], as recommended by The American Association of Physicists in
Medicine (AAPM ) and the American Brachytherapy Society (ABS). The TG-43U1
protocol is a set of dose calculation formalisms that are used by clinicians to predict
dose distributions of the radiation sources used in brachytherapy, known as seeds.
These calculations form the basis for the treatment plans for patients and ultimately
determine the success of the treatment. While this dosimetry formalism has been
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supplemented as recently as 2007[21] to accommodate concerns such as calculating
down to distances of 1.0 mm with low-energy brachytherapy sources, some major
caveats remain.
The TG-43U1 and its supplement, TG-43U1S1, are limited in their practical ac
curacy as they assume an environment of infinite homogeneous water medium and
do not account for the material heterogeneities inherently present in and around the
treatment area. These heterogeneities occur due to surrounding structures such as
the metal backing of the plaque and the bony structures around the eye, and cause
variable attenuation of the delivered dose due to differences in their atomic properties.
O f the few treatment planning systems that can provide heterogeneity-corrected
dose calculations, such as Plaque Simulator[22], none has yet received certification by
either the Conformite Europeenne (C€) or the U.S. Food and Drug Administration
(FDA). Until such certification is granted, the AAPM will not recommend the treatment
planning software as a primary dose calculation tool.
Without a reliable and certified treatment planning system (T P S) that accounts for
material heterogeneities, there is a need for the development of methods for preoperative
treatment verification, such as a reliable tool capable of high resolution, real-time
dosimetry for physical simulation of treatment plans.
Intraocular tumours are intrinsically difficult to treat due to their small size and the
presence of nearby structures that must be avoided or protected in order to preserve
vision. Ideally, when treating with radiotherapy, dose delivery to tumour cells should
be maximised and dose to healthy tissue should be avoided or minimised. O f course,
this degree of selectivity is rarely feasible; however since normal cells have better repair
mechanisms, they are able to survive higher doses than cancer cells[23]. This illustrates
the delicate balance between success and failure in radiotherapy and the importance
of accurate dosimetry.
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Various techniques have been used in the literature for plaque dosimetry including
thermoluminscent dosimeters (TLDs), polymer gels, radiochromic films, liquid scin
tillators, plastic scintillators and semiconductor diodes. No existing ocular plaque
dosimetry technique provides fast, high-quality sampling of the 3D dose distribution,
particularly close to the plaque surface.
Several limitations and uncertainties in plaque radiotherapy currently remain.
These include an absence of preoperative treatment verification, imprecision in the
surgical placement of the plaque, the lack of any certified treatment planning that
can account for heterogeneous materials, source-related uncertainties, and, to some
extent, measurement of tumour geometry. The current lack of research and develop
ment into plaque brachytherapy treatment verification can be, in part, attributed to
the relatively low financial incentive resulting from low rates of incidence of the disease
in addition to the inherent technological challenges. Despite this, the high individual
patient cost provides a compelling reason to focus research attention on developing
better treatment tools, in this under-investigated field. Development of a practical
plaque treatment verification system is now technologically feasible and will offer many
benefits for plaque brachytherapy.

1.1

Objectives and Scope

The overall aim of this thesis is to address the current lack of preoperative treatment
verification in plaque brachytherapy. This aim is further subdivided into the following
strategic elements:

• Identify the shortcomings of the quality assurance systems in plaque brachyther
apy;
• Experimentally assess the validity of using a single silicon diode detector for
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plaque brachytherapy dosimetry;
• Experimentally assess the validity of using a pixelated silicon detector for plaque
brachytherapy dosimetry with an existing device;
• Optimise detector design for two plaque brachytherapy dosimetry concepts: trans
lational and rotational;
• Integrate the detector into an electronic readout system for real-time measure
ments; and
• Evaluate the developed dosimetry system in plaque brachytherapy treatments.

1.2

Thesis Structure

To address these objectives, this thesis is divided into three parts:
P a rt I,

which focuses the study, providing relevant context and a semiconductor
dosimetry background;

P a rt II,

which provides validation of the various concepts used in the research
problem; and

P a rt III, which details the development and evaluation of a novel dosimetry sys
tem for plaque brachytherapy called the P a n o p t e s (Pixelated Auto
mated Nuclear Ophthalmic Plaque Treatment Evaluation System).
These parts are further divided into seven chapters making up a total of nine
chapters in the thesis.
Part I is comprised of Chapter 2 and Chapter 3 , and provides context, background
information and project motivation. Chapter 2 provides a review of the current litera
ture relating to intraocular melanoma, treatments and dosimetry techniques associated
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with plaque brachytherapy. Chapter 3 provides a brief background on semiconductor
radiation detector systems and their application in dosimetry.
Part II is comprised of Chapter 4 and Chapter 5 and details validation studies of
single and multiple detector concepts, respectively. Chapter 4 evaluates the concept
of using a single silicon detector to measure surface dose of an eye plaque. Building
on this, Chapter 5 proposes and evaluates two concepts of using pixelated silicon
semiconductors to generate dose volumes using translation and rotation, respectively.
These chapters have resulted in the following publications:

• M. Weaver, J. Green, M. Petasecca, M. .L .F. Lerch, D. Cutajar, D. R. Franklin,
J. Jakubek, M. Carolan, M. Conway, S. Pospisil, T. Kron, P. Metcalfe, M. Zaider,
and A. Rosenfeld, “Three-dimensional dosimetry imaging of I-125 plaque for
eye cancer treatment,” Nuclear Instruments and Methods in Physics Research
Section A : Accelerators, Spectrometers, Detectors and Associated Equipment, vol.
633, pp. S276-S278, May 2011.
• M. Weaver, M. Petasecca, M. .L .F. Lerch, D. Cutajar, J. Jakubek, S. Pospisil,
and A. Rosenfeld, “Dosimetry verification in eye brachytherapy using silicon
pixelated detectors,” Radiation Measurements, vol. 46, no. 12, pp. 2010-2013,
Dec. 2011.

The final part, Part III, details the design through to testing of the P a n o p te s and
consists of Chapters 6 to 8. The design and development details of the P a n o p te s and
its constituent parts are presented in Chapter 6. Chapter 7 characterises the P a n o p te s
detector using several methods to establish expected outcomes and dosimetric accuracy
and reliability. The work from Chapter 7 resulted in the following publication:

• M. Weaver, M. Petasecca, D. L. Cutajar, M. L. F. Lerch, G. De Geronimo,
D. Pinelli, A. Cullen, D. Prokopovich, V. Perevertaylo, and A. Rosenfeld, “Panoptes:
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Calibration of a dosimetry system for eye brachytherapy,” Radiation Measure
ments, vol. 71, pp. 310-314, Dec. 2014.

The performance of the P a n o p te s is evaluated in Chapter 8 through comparison
of dose volume measurements against both calculated and simulated results.
The final chapter in the thesis provides a summary of the outcomes of each chapter,
and provides some recommendations for further improvements to plaque brachytherapy.
This document structure is depicted in Figure 1.1, showing the relationship of the
parts and chapters and detailing the primary outcomes for each chapter.
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Figure 1.1: Summary of each chapter within the thesis.

Part I
Focusing the Study
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Chapter 2
Literature Review
This chapter provides a background on the anatomy of the eye, intraocular cancer in
cidence and outcomes and several common treatments including plaque brachytherapy.
It also reviews current dosimetry practises and the limitations of plaque brachytherapy,
including a review of previously used dosimetry techniques.

2.1

Ocular Cancer

This section introduces some fundamental concepts in ocular oncology, including the
anatomy of the human eye, and the prevalence, pathology and mortality rates of
intraocular cancer. Australia, like many other places in the world, does not have access
to the full range of available treatments for uveal melanoma. Plaque brachytherapy
is the most common radiotherapy treatment for the disease and has proven to have
very good clinical outcomes. Despite this, rates of side effects are still high and there
are several limiting factors in the treatment process that could be improved, including:
accurate definition of the tumour geometry; surgical placement of the plaque; treatment
planning; and uncertainties in source placement.

10
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Ocular Anatomy

The human eye is a complex sensory organ which focuses incident light onto a pho
tosensitive layer of specialised cells, so that the resulting image can be converted
into electrical signals for interpretation by the brain as vision. Anatomically, it com
prises three concentric tunicae, or layers, as shown schematically in Figure 2.1. From
outermost to innermost, these are:

• the fibrous layer consisting of the cornea and sclera;
• the vascular layer, called the uvea, consisting of the iris, the ciliary body and the
choroid; and
• the retina.

Within the retinal layer is the vitreous body, a transparent, gelatinous substance
that does not contain any vital cells.
The cornea covers the most anterior part of the eye, including the anterior chamber,
the iris and the lens. It functions as a barrier against foreign materials and also as
a powerful refractive surface, providing approximately 65% - 75% of the eye’s total
focusing power.

Figure 2.1: Schematic of human eye including the a) outer layer (sclera and cornea)
b) vascular uveal layer (iris, ciliary body and choroid) c) retinal layer d) central vitreous
body.
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The sclera is contiguous to the cornea and is observed as the white of the eye. It
is approximately 1 mm thick and is made up of strong, dense connective tissue that
gives firmness and structure to the globe. The sclera also provides insertion points for
the extraocular muscles, assists in controlling the intraocular pressure and acts as a
form of mechanical protection for the intraocular features. The sclera is capable of
tolerating extremely high radiation doses[24].
The uvea, or uveal tract, is made up of the iris, the ciliary body and the choroid.
The iris is the coloured layer located anteriorly on the globe. It serves as the aperture
for the ocular optics by controlling the size of the hole in its centre called the pupil.
Contiguous to this is the ciliary body which contains the ciliary muscle fibres and
ciliary processes, used for focusing the lens and generation of the aqueous humour.
The other side of the ciliary body is met by the choroid. The choroid makes up the
majority of the uvea and is highly vascular, providing blood for the ocular structures.
The retina comprises a number of layers of densely packed cells which convert light
into neural signals. One of the most critical parts of the retina is the macula. It
is located temporal to the optical nerve at a distance of approximately 3 mm and is
responsible for the sharpest central region of vision. The optic nerves are responsible
for conveying all vision signals to the brain.
Although intraocular tumours can develop throughout the eye, uveal melanomata
are the most common due to their vascular prominence and include tumours which
have developed in the iris, ciliary body or the choroid[3].

2.1.2

Intraocular Cancer

The symptoms of intraocular cancer tend to include pain within the eye and loss in
vision or visual acuity. The disease seriously threatens the life of the patient if local
tumour spread cannot be controlled or metastatic disease occurs, for which there is
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no cure[25]. There are several types of intraocular cancer that can occur, each with
differing incidence frequencies.
Metastatic melanoma of the uvea is the most common primary intraocular cancer
in adults and the second most common primary malignant melanoma which occurs
in the b o d y I26,27). Of the melanomata occurring in the uveal tract, 80% - 90% are
located within the choroid I3,28’29!, while occurrence of metastases within the iris, ciliary
body, retina, optic disc and vitreous humour are rare[30].
The highest incidence rates of uveal melanoma have been observed in Northern
Europe and Australia while the lowest rates have been observed among Asian, Hispanic
and dark skinned populations t31,32l. The age-standardised incidence rates in Australia
for men are 0.80 per 100,000 (95% CI 0.71 - 0.89) and for women are 0.61 per 100,000
(95% CI 0.53 - 0.69)[1]. By comparison, the mean, aged-adjusted incidence of uveal
melanoma in the United States is 0.51 per 100,000 and has remained unchanged from
1973 - 2008[29]. Overall, the incidence rate of uveal melanoma has remained relatively
stable across Europe, North and Central America, Asia and Oceania over the period
1983 - 1997 t31l
Metastasis occurs vascularly, spreading to the liver and other parts of the b o d y [3].
Even in cases where local tumour control of primary uveal melanoma is successful,
the dangerous cells can remain dormant for many years[33]. Of these cases, metastatic
disease will still occur in about 40% - 50% of uveal melanoma patients[2,34]. The
prognosis of metastatic spread is extremely poor, with fatalities usually occurring
within around six to nine months of the first signs of symptoms[3].
Uveal melanoma related mortality is 31% by 5 years and is 45% by 15 years[35].
Earlier diagnosis and management is associated with better outcomes and a better
chance of salvaging the eye and vision t3,36l. The size, shape and location of the tumour
also affect the treatment outcome I37-40l.
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The prognoses of uveal melanomata typically worsen with increasing tumour thick
ness. Estimates of 5-year mortality rates following enucleation (removal of the eye)
were 16% for small, 32% for medium, and 53% for large tumours[37] (Table 2.1).

2.2

Current Treatments

Modern treatment of choroidal melanoma offers good preservation of vision in most
cases [3,6,411. Despite this, there has been no improvement in survival rate over the last
25 years[42]. This is thought to be due to latent acting dormant circulating malignant
cells which can be established in the system prior to tumour control[2].
There are a number of treatments for intraocular cancer which may be selected
based on factors such as the size, shape and location of the tumour and treatment avail
ability. These include transpupillary thermotherapy, photodynamic therapy, orbital
exenteration, and, in further-progressed tumours, chemotherapy, and immunotherapy.
However, the most common treatments for intraocular cancer are enucleation, endoresection and radiotherapy. There are two main types of radiotherapy that are used for
the treatment of ocular cancers: external beam radiotherapy, and plaque brachytherapy,
the latter of which is the focus of this thesis.
Table 2.1: Choroidal melanoma estimates of 5-year mortality following treatment with
enucleation (removal of the eye) based on tumour size[37]. The 95% confidence intervals
are displayed in brackets.
Tumour Size

Basal Diameter

Height

5-y Mortality, %

Small
Medium
Large

< 10 mm - 11 mm
< 15 mm - 16 mm
> 15 mm - 16 mm

< 2 mm - 3 mm
3 mm - 8 mm
> 8 mm

16 (14 - 18)
32 (29 - 34)
53 (50 - 56)
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Enucleation

Enucleation is a process that involves the removal of the entire globe of the eye. Today,
this treatment is used for advanced tumours, when there is little hope for salvaging
useful vision. It is also occasionally used where tumour development has led to a
blind, painful eye or when more conservative methods of treatment have not been
successful. The empty socket is filled with an implant and rehabilitated for six weeks,
after which a prosthetic eye is inserted t43,44l. Despite the irrevocable and severe nature
of the procedure, the 5-year mortality is up to 53% for large tumours (see Table 2.1
for further details)[37].

2.2.2

Endoresection

Endoresection, or local resection, refers to the surgical removal of the tumour from
within the eye and can be achieved either through the scleral surface or the retina.
Trans-scleral resection describes access to the tumour mass through a lamellar flap
incised in the sclera above the tumour, while transretinal resection enters through the
retina. Trans-scleral resection of an ocular tumour is surgically difficult, but in some
cases is still regarded as the best option. Depending on the location of the tumour, this
technique offers conservation of the central vision or temporal field, where radiotherapy,
as an alternative, has a higher risk of optic neuropathy[45]. Recurrence rates at 4 years
for trans-scleral local resection range from 6% to 58% depending on the risk factors
present[46,47].

2.2.3

External Beam Radiotherapy

External beam therapy treats intraocular cancers by delivering a beam of charged
particles, such as protons or helium-ions, through air, usually into the anterior side of
the eye. As depicted in Figure 2.2, these heavy charged particles deliver dose with a
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Figure 2.2: A depiction of external hadron beam radiotherapy, showing the effect of
the spread out Bragg peak on dose distribution (colour).

distribution that follows the spread out Bragg peak, depositing maximum dose close
to the end of the particle’ s path through the tumour.
Due to the incident direction of the treatment, the anterior features of the eye and
the ocular adnexa receive, on average, 70% of the dose delivered to the tumour. This
undesirable dose can lead to adverse affects such as eyelash loss, dry eye, keratitis,
corneal ulceration, iris neovascularization, iridocyclitis, cataract, and glaucoma I18,48-50!.
In comparison to proton therapy, plaque brachytherapy is less expensive, less time
consuming and less likely to cause discomfort and cosmetic deficit from conjunctival
and eyelid irradiation[3]. In addition to this, proton and heavy ion therapies are un
available in many places, including Australia, unlikely plaque brachytherapy. However,
plaque brachytherapy results in higher rates of recurrence compared to external beam
radiotherapy (1.5% - 1 5 % t51-53] versus 3% - 4 % t6,54,55!).

2.2.4

Plaque Brachytherapy

Radiotherapies are the most common treatments for uveal melanoma, and of these,
plaque brachytherapy is the most prevalent treatment. This treatment option is selected
based on the size, shape and location of the tumour, tending to be preferred in the
case of medium-sized choroidal melanomata. In plaque brachytherapy, a device called
a plaque, which contains a radioactive source, is sutured to the eye adjacent to the
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tumour, where it is kept in place for a predetermined treatment duration (Figure 2.3).
The shape of the plaque is based on a shelled spherical cap to fit the surface of the
eye. It delivers dose through either:
• ' seeds’ of a radionuclide within an insert in metal backing (Figure 2.4); or
• a radionuclide layer deposited onto a backing metal (Figure 2.5).
Typical radionuclides used for the seeds include iodine-125 (125I), palladium-103
(103pd) or cesium-131 (131Cs), whilst ruthenium-106 (106Ru) is used for the uniformly
coated plaques. Table 2.2 provides a summary of radionuclides detailing their emission
type, energies and half-lives. In both plaque styles, material with a high atomic number
such as gold, silver or stainless steel is used as a shield on the outer side. This shield
protects posterior features such as the brain and improves safety for surgeons and
handlers. Figure 2.3 shows an example of the dose distribution of a seeded plaque.
These plaques also incorporate various design features including flanges, eyelets and
notches to fit around the optic nerve.
Several designs of eye plaques are currently in use throughout the world. The Radi
ation Oncology Physics and Engineering Services Pty. Ltd., Australia (ROPES)t57-59]
series plaques are commonly used in Australia; whilst the Eckert & Ziegler BEBIG
GmbH, Germany[56] plaque series are popular in Europe; and the Collaborative Ocu-

Figure 2.3: A depiction of plaque brachytherapy showing an example of contoured
dose gradients within the eye (colour).
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Figure 2.4: ROPES 15mm seed-bearing plaque, showing the metal backing (left),
acrylic insert (right) and assembled device ( centre).

Figure 2.5: A sample of BEBIG 106Ru eye plaques that illustrate different designs,
targeting specific locations on the eye.[56]

Table 2.2: A list of common radionuclides used in plaque
brachytherapy, including their radiation type and energies.
Radionuclide
125I
103Pd
131Cs
106Ru

Primary emission
Y
Y
Y
P

Energy
28.51 keV a
20.74 keV a
30.3 keV a
3.5 MeV b

Half-life (days)
54.9
17.0
9.7
373.6

a Weighted mean energy
b Maximum energy
N ote: These values are nominal assuming typical encapsulation of sources.
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lar Melanoma Study (COMS) plaque series is commonly used throughout the world.
Despite the large variations in plaque design, the treatment has proven to have good
clinical outcomes.
The COMS Group demonstrated that there were no survival differences between
patients treated with 125I plaque brachytherapy and those treated with enucleation[8].
There has since been a strong trend towards radiotherapy as the main treatment for
uveal melanoma (1.8 % for 1973 - 1975 vs. 62.5 % 2006 - 2008), with no change in the 5year relative survival rate in the United States from 1973 - 2008[29]. The COMS Group
reports recommend 125I for use in ophthalmic brachytherapy plaques[60] and it gained
subsequent widespread usage in practice.

Four years later, the radionuclide 103Pd

became available and subsequent studies have demonstrated good patient outcomes in
areas including local control and visual acuity results compared to charged particle, 125I
or 106Ru plaquesI16,61]. Due to the 103Pd source having a lower weighted mean energy
(20.74 keV) than 125I (28.37keV) palladium photons have a shorter range in tissue,
allowing adequate dose delivery to targeted regions whilst better avoiding normal
tissue for medium sized plaques.

2.2.4.1

Plaque Brachytherapy Treatment Planning

Treatment planning for plaque brachytherapy is conducted by determining geometric
details of the tumour, selecting an appropriate plaque, calculating the dose and, in
some institutions, verification in software.
The geometry of a tumour can be determined through the use of fundus photography,
A-scan (one-dimensional) and B-scan (two-dimensional) ultrasonography[62], fluorescein
angiography[63], X-ray computed tomography (CT) or magnetic resonance imaging
(MRI) I3,64].
Plaque selection is made after the tumour position, size and shape have been
determined. During this process, the prescription point is determined and the model,
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activity and number of seeds are chosen. The selected dose rate usually falls within
the range recommended by the ABS in 2003, 0.6 Gy h-1 - 1.05 G y h -1 [10]. Using this
rate, the implant duration, usually 3 d - 7 d, can be calculated in order to deliver
the prescription dose. The original COMS trials recommended a prescription dose of
100 Gy to the apex of the tumour, but this has since been revised to 85 Gy t10,65].
Treatment parameter recommendations were re-evaluated in 2012, considering the
biological effective dose as a function of position, dose, radionuclide and implant
duration[66]. The study found that shorter implant durations may correlate to better
outcomes compared to seven day implants when treating small or medium tumours.
For additional verification, some institutions support their dosimetry calculations with
the use of a treatment planning system.
The most common TPS in plaque brachytherapy is Plaque Simulator, available
from BEBIG GmbH[22]. Plaque Simulator allows for the planning of plaque brachyther
apy treatments using the standard TG-43U1 formalism[20] or using updated dosimetry
calculations, where the user can include some heterogeneity effects of the seed holder
insert, metal backing and air-eye interface. The accuracy of Plaque Simulator has
been evaluated and shown to be in good agreement with radiochromic film t67,68], diode
dosimeters[69] and thermoluminescent dosimeters[70]. Despite this, the Plaque Simula
tor documentation states that it is

intended for treatment simulation only [and] is neither [Conformite Europeenne

) ] certified nor [U.S. Food and Drug Administration (FD A)]

approved as a treatment planning software. Dose data extracted for planning
have to be verified by the physicist.[22]

As such, the Plaque Simulator is not recommended by the AAPM or the ABS as a
primary dosimetry calculation approach.
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Treatment Limitations of Plaque Brachytherapy

Currently in Australia, planning for plaque brachytherapy is typically performed using
the recommended TG-43U1 formalism dose calculations with the optional support of a
TPS. There is only limited potential for physicists to confidently customise the plaque
layout or design for a particular patient and further refining dose distributions based
on factors such as tumour shape, location and proximity to vital structures. While
plaque brachytherapy is a good treatment candidate for ocular cancer management,
some significant challenges remain, in particular:

1. Loss of vision and other side effects
Plaque brachytherapy requires not only tumour control but management of
iatrogenic side-effects and complications which affect normal tissue. In fact, the
success of local tumour control in the treatment means there is a shift in focus
towards reduction and management of these side effects[71].
Such complications tend to increase in likelihood with tumour size due to the
greater overall treatment dose and control of dose distributions. They can include
radiation-induced retinopathy, optic neuropathy, choroidopathy, cataract, and
scleral necrosis [14,18,40,72-78].
Despite preservation of the eye, a relatively large portion of patients lose useful vi
sion after treatment[18,79] and only around 17% of patients with large melanomas
will avoid blindness for at least two years[80]. According the COMS Group[8,9,11-13],
at three years 57% of patients treated with 125I retained at least 20/2001 vision
which worsens over tim e[15,81]. By comparison, studies showed about 76% of
patients treated with 103Pd retained acuity of at least 20/200[16,82]. Vision must
often be sacrificed for survival where tumours are large[40,76,80] or surround the
1If a person has a visual acuity o f X /Y , that person can resolve the same level o f detail at a
distance o f X that a normal person could at a distance o f Y.
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optic nerve[72>83]. Here, enucleation is more commonly used in place of plaque
therapy.
2. Inability to treat large tumours
Large ocular melanomata are a significant threat to patients (see Table 2.1). For
tumours with a basal diameter greater than 16 mm and/or thickness greater than
8 mm, the recommended treatment is enucleation[10]. A ten year follow-up study
by Shields et al.[40] showed that amongst 354 patients with large tumours (greater
than 8 mm thick), enucleation was necessary in 34 % of patients and metastasis
developed in 55 % of cases. For patients with large uveal melanomata who were
treated using 125I plaque brachytherapy, only 26% (95% CI, 16% - 37%) had
avoided blindness at 2 years[80].
Dose gradients can vary dramatically between tumours of different sizes. For
example, for a tumour with a thickness of 10 mm treated with 125I and receiving
85 Gy at the apex, the inner sclera receives 644 Gy (10 mm away from apex). By
contrast, treatment of a tumour with a thickness of 3 mm with the same apex
dose would deliver a dose of 166 Gy to the inner sclera. Similarly for 103Pd, 85 Gy
to tumour apexes of 10 mm and 3 mm delivers inner scleral doses of 766 Gy and
164 Gy, respectively[71,84]. This is a base-apex dose ratio of about 8 : 1 and 9 : 1
for 10 mm tumours treated with 125I and 103Pd, respectively; and about 2 : 1
for 3 mm tumours for both radioisotopes. These steep dose gradients are even
more exaggerated for the beta-emitting 106Ru source[18]. The phenomenon makes
treating large tumours a difficult task when attempting to spare normal, healthy
structures.
3. Failure to eliminate the tumour threat
Local treatment failure for plaque brachytherapy, defined as tumour growth,
recurrence or extrascleral extension, was reported in the COMS study to be
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as low as 10.3% (95% CI, 8.0% - 13.2%) by five years[12]. A summary of
plaque brachytherapy clinical studies is presented in Table 2.3, showing local
control, distant failure and overall survival outcomes. This data demonstrates
that although the treatment outcomes are very good, the disease is a significant
threat to the patient with local control and overall survival averaging about 90 %
and 84 % at five years, respectively2. In some cases enucleation is performed
after plaque brachytherapy treatment either due to failure to control the tumour
or as the result of radiation-induced pain or other side-effects like neovascular
glaucoma.
In general, early failures may have been due to geometric misalignment of the
plaque over the tumour while late failures could be related to a radiation-resistant
tumour or lack of sterilisation[18]. Tumours with greater thickness or in close
proximity to the foveal avascular zone, in the macula, have a greater failure
risk[12].

2Calculated as the mean of local control and overall survival data at five years from all categories
reported in the literature presented in Table 2.3.

Table 2.3: Summary of plaque brachytherapy clinical study outcomes
Nuclide

Study

No. of
patients

Mean dose
(Gy)

106Ru

Heindl et al. [89]
Damato et al.[6]

100
458

—

Gunduz et al.[14]
Wilson and
Hungerford [53]
Seregard et al.[90]
Lommatzsch[91]
125i

115

Mean
follow up
(mo)
—
46.8a

Mean initial
lesion
dimensions
—
10.6/3.2 (D/T)a

Local control
(%)

Distant failure (%)

Overall survival
(%)

10 (5 yr)
—

—
—

(D)<10, 4 (T)a

93 (5 yr)
99 (2 yr), 98 (5
yr), 97 (7 yr)
91 (5yr)

630

—

62.4

—

45.3

9.7/4.2 (D/T)

88.6

12 (5 yr), 22 (10
yr)
5

140

100

266
309

100
100

43
80

10/4.4 (D/T)
COMS-S (100%)

11 (4 yr), 14 (5 yr)
12.9 (7 yr)

83.1
87.1

317
657

104
85

55.5
60

10.1/3.9 (D/T)
11.4/4.8 (D/T)

90
84 (5 yr), 69.9
(6.7 yr)
89.3, 91.5 (5 yr)
90

Literature average
COMS [8,9,11-13]

85.1
82 (5 yr)

Leonard et al.[17]

37

85

100

Correa et al.[92]

120

83

50.4a

Jensen et al.[19]

156

—

74.4a

12.3/6.3 (D/T),
T2 (81%)
12.2/5.9 (D/T),
COMS-M (73%)
—

12 (5 yr)
10 (5 yr), 18 (10
yr)
13.5

95.3 (2 yr), 88.4
(5 yr)
92 (5 yr)

Lumbroso-Le Rouic
et al.[52]
Nag et al.[93]

136

112

62a

10.3/4.7 (D/T)

98.5

78

85-100

49a

93 (5 yr)

Jones et al.[94]
Char et al.[5]
Wilson and
Hungerford [53]
Quivey et al.[95]

63
449
190

85-100
70
100

36
—
47.3

COMS-M
(100%)
4.5(T)
4.6 (T)
10.2/5.9 (D/T)

9.5 (2 yr), 20.3 (5
86.7, 94.4 (2 yr),
yr)
84.1 (5 yr)
10 (5 yr), 27 (10
80, 83 (5 yr)
yr)
5.9, 1.7 (2 yr), 4 (5 89, 93.8 (2 yr), 88
yr)
(5 yr)
86 (5 yr)
—

84
87
95.8

4.8 (3 yr)
—
3.7

—
—
94 (8.3 yr)

150

95

68

9.7/3.7 (D/T)

17.3 (5 yr)

78

Fontanesi et al.[81]
Quivey et al.[96]

144
239

79
70

46
36

975 (V)
10.9/5.5 (D/T)

Char et al. [4]
Packer et al.[15]

98
64

70
91

41
64

10.7/5.5 (D/T)
—

Petrovich et al.[97]

85

102.6

37

6.1 (T), T2/T3
(96%) COMS-M
(100%)

81 (5 yr), 78
(5.6 yr)
97.7
91.7 (3 yr), 82
(5 yr)
86.7
92.2 (5 yr), 87.5
(5.3 yr)

76

81 (6.7 yr)

59.5
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5.5 (4 yr)
—
7.5 (3 yr), 12 (5
—
yr)
8.2 (4.2 yr)
80.6 (4.2 yr)
15.6 (5 yr), 17.2 (6 82.8
yr)
11, 10.6 (8 yr)
88, 88 (5 yr), 84 (8
yr)
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Summary of plaque brachytherapy clinical study outcomes (cont.)
Nuclide

Mean initial
lesion
dimensions
11.55/5.5 (D/T),
10.5/4.35 (D/T)

Local control
(%)

Distance failure
(%)

Overall survival
(%)

92

Mean
follow up
(mo)
52, 59a

93.5, 88.1 (5 yr)

84, 94.1 (2 yr),
83.8 (5 yr)

5

85

22.5

100

Finger et al. [98]
Finger et al. [16]

24
400

84.1
73

35.5, 30a
51

131Cs

400
11

73
85

43.3
20

96.3
91

4.1 (6 yr)
6, 3.3 (2 yr), 7.4 (5
yr), 13.4 (10yr)
N/A
0

91.7
87

Literature average
Leonard et al.[17]

Other

Shields et al.[40]b

354

—

—

10.6/2.7 (D/T),
T2 (80%)
2.6 (T)
T1/T2 (85.5%),
COMS-M (92%)
N/A
12.6/5.4 (D/T),
T2/T3 (82%)
(T)>8

8.4, 3.7 (2 yr), 6.2
(3 yr), 12.7 (5 yr)
22.5 (10 yr)
0

De Potter et al.[72]c

93

90-110

78

3<(T)a<6

Lean et al.[99]d

56

94.5

39

30 (5 yr), 55 (10
—
yr)
12 (4 yr), 13 (5 yr), 81
16 (10 yr)
9 (4 yr)
—

Literature average

168

N/A

59

13.2/6.8 (D/T),
T3 (68%)
N/A

91 (5 yr), 87 (10
yr)
84 (5 yr), 73 (10
yr)
91
91, 87.5 (5 yr),
80 (10 yr)

10.5 (4 yr), 21.5 (5
yr), 35.5 (10 yr)

103Pd

Study

No. of
patients

Mean dose
(Gy)

Literature average

170

Leonard et al.[17]

95.9
96.7

100

87
100

2.2.

a Median value
b 125I and 106Ru
c 125I (n = 63), 192Ir (n = 15), 60Co (n = 12) and 106Ru (n = 3)
d 1251and 192Ir
Note: Literature averages were calculated as the means of the reported values from the available data and, where appropriate, over specified duration.
diameter = D (mm); thickness = T (mm); volume = V (cm3); N/A = not applicable
COMS-S: 1.5mm < T < 2.5 mm and 5mm < D < 16mm;
COMS-M: 2.5mm < T < 10mm and D < 16mm;
COMS-L: T > 10mm and D > 16mm[85-87].
T1: T < 2.5mm and D < 10mm;
T2: 2.5 mm < T < 10mm and D < 16mm;
T3 and T4: T > 10mm or D > 16mm[10’88].
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Uncertainties in Plaque Brachytherapy

Dose verification for plaque brachytherapy systems has attracted relatively little re
search attention due to the low rates of incidence of ocular melanoma compared to
other cancers and the intrinsic technical difficulty of accurate estimation of dose in
this environment.
The literature shows that, for plaque brachytherapy, local control and overall
survival are very good, as shown in Table 2.3. Despite this, there is much potential
for improvement, as patients still frequently need to undergo enucleation and/or suffer
from significant radiation-induced side effects such as cataract, radiation induced
maculopathy and retinopathy.

This has directed current research efforts towards

reducing such radiation induced side effects to normal tissue[71] by addressing the
remaining uncertainties in plaque brachytherapy. These uncertainties include:
1. Tumour geometry
The dimensions of shape, size and location of the ocular tumour have some
margin of error imparted by the imaging modality used. The most common
methods for tumour dimensioning are ophthalmoscopy (62 % used as primary
method), B-scan ultrasonography (18% ) and nomography (12% ) [100]. The
COMS ultrasound protocol is a standard method of tumour measurement which
has been highly reliable in treatment planning[100,101]. New generation, highresolution B-Scan probes have operating frequencies that range from 20 MHz 100 MHz and provide resolution in the range of 23 pm - 75 pm [102,103]. Three
dimensional ultrasonography has been reported to have a resolution of 150 pm
axially and 270 pm laterally[104].
Despite these good resolutions, in a study of 644 patients with unilateral medium
sized choroidal melanoma, clinical and echograph measurements agreed to within
± 2 mm of histopathological in only 90 % and 57% of cases for tumour height and
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longest basal diameter, respectively[100]. It has also been shown that ophthal
moscopy can misrepresent some choroidal tumours as mild, normally pigmented
elevations of the retina[71]. However, in these cases, ultrasonography can be
used to provide the additional dimensional information required. In cases of
photography based fluorescein or indocyanine green angiography, the tumour
basal dimension can be overrepresented[105,106]. Currently, CT and MRI images
are limited in both spatial resolution and accuracy for delineation of ocular
tumours[71].
The development of image fusion tools for plaque brachytherapy and more reliable
imaging technologies will allow for three dimensional modelling of patient data
with clearer representation of the tumour. Such a system would prove useful for
providing information to potential preoperative dose verification tools.
2. Plaque placement
Surgical placement of the plaque on to the eye is the origin of the largest uncer
tainty between planned and actual source location in relation to patient anatomy.
Plaque misalignment is more profound in certain difficult regions such as adjacent
to the optic nerve. Currently, there are a number of slotted plaques available
which attempt to accommodate this issue.
Placement of the plaque can be verified through a number of methods; namely,
ultrasonography, scleral depression and transillumination[105,106]. When place
ment verification is performed using ultrasound imaging, it should be done in 2D
or 3D along the longitudinal and transverse meridian lines[107].
A 2003 ABS report[10] recommends that an additional 2 mm - 3 mm be added
to the tumour basal margin for placement can help mitigate the potential of
tumour volume underdosing. It has been shown that better tumour coverage is
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achieved through a gross-tumour-volume to planning-tumour-volume total basal
expansion of 3 mm or greater and/or prescribing beyond the tumour apex[61].
Whilst this will improve tumour control, it will also increase unwanted dose to
normal tissue. Preoperative dose verification is needed to optimise outcome and
reduce the extent of side effects.
3. Treatment planning
Currently, the AAPM and A BS[10] both recommend that treatment planning be
undertaken using the dosimetry formalisms from the reports, TG-43U1 (2004)
and TG-43U1S1 (2007)[20,21]. These reports are limited to the use of homogeneous
water as a surrounding medium and do not account for the effects of heterogeneous
materials, including high Zeff materials such as the plaque insert or backing, or
surrounding bony structures. The minimum dose calculation distance for these
formalisms is 1.0 mm (updated from the 5.0 mm minimum of the 1995 TG-43
Report[65]).
The treatment planning software, Plaque Simulator[22], is widely used to aid in
treatment planning though it has not received FDA or Conformite Europeenne
(C€) certification. As such, it is not recommended by the AAPM and ABS for
use as a primary dose calculation tool. There have been many studies showing
significant discrepancies between homogeneous and heterogeneous dose calcula
tions and measurements, especially when plaque presence is considered[70,108-114].
The AAPM and ABS recommend calculating homogeneous and heterogeneous
dose separately.
A preoperative volumetric dosimetry approach to plaque brachytherapy would
be of great benefit as it would inherently account for heterogeneous materials
and complement existing TPS tools.
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4. Source uncertainties
Prior to a plaque brachytherapy treatment, the radionuclide sources should be
verified using a well-type ion chamber which has been appropriately calibrated
as per recommendations from the AAPM Low Energy Brachytherapy Source
Calibration Working Group[115]. The AAPM Task Group No. 138 have calculated
that for the dose at 1.0 cm on the seed’s transverse plane, the k = 2 expanded
uncertainty for low-energy sources is 8 .7 % [116]. This is calculated considering the
uncertainty from SK (air-kerma strength) measurements, measured dose, Monte
Carlo dose estimate, TPS interpolation uncertainties, and total dose calculation
uncertainty.

Development of accurate and reliable methods for preoperative dose verification and
enhancing the accuracy and capabilities of treatment planning would be a significant
contribution to addressing some of the above problems. Greater confidence in treat
ments allow for an increased degree of patient specific plaque customisation, aimed at
improved conformity of dose to tumour geometry and a reduction in dose delivered to
non-cancerous tissues. Plaque customisation could be implemented through changing
seed numbers and configurations along with combining seeds of different radionuclides
and activities in existing plaques, or complete plaque redesign if the facilities are
available.

2.3

Dosimetry

Radiation is frequently used for imaging and therapy and it is essential to measure
and understand the relationship between dose and effect.

Though treatments are

undertaken for their therapeutic qualities, they come hand-in-hand with an associated
risk of detrimental side-effects.
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These iatrogenic, or treatment-induced side effects can be deterministic or stochas
tic. The severity of deterministic radiation-induced tissue damage, such as radiation
burns to the skin, increases with increased dose. The probability of the occurrence
of stochastic effects, such as radiation-induced mutations, is dependent on dose but
the severity of the effect is not. Consequently, even for small doses of radiation there
is some possibility of serious detrimental side effects, of which the most concerning is
secondary cancer induction[117].
The aim of radiotherapy is to kill cancerous cells through damage inflicted by
ionising radiation. Both cancerous cells and normal tissue are affected by radiotherapy
but the success of the treatment lies in the fact that the normal tissue cells have
more effective repair mechanisms and can thus withstand a significantly higher dose.
G ood radiotherapy treatment outcomes depend upon careful management of the dose
such that the cancer cells are destroyed without causing irreparable harm to healthy
tissue. These conflicting requirements put tight restrictions on the temporal and spatial
distribution of the applied dose.
When irradiating tumours that are close to critical structures, steep dose gradi
ents are needed, resulting in very little margin for error. Through measurement and
calculation of the absorbed dose in these regions, radiotherapy treatments may be ver
ified and, if necessary, modified to optimise treatment efficacy and minimise collateral
damage[118].
In plaque brachytherapy, steep dose gradients are necessary if the tumour is to
receive the full prescribed dose while avoiding overdosing structures such as the optic
nerve, lens, iris or cornea. When healthy tissues are affected, function of critical organs
can be diminished or the patient may experience pain or discomfort.
For irradiation of tumours close to the optic nerve, special plaques with an ac
commodating notch are typically used[70,119-121]. It has been recognised that notched
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106Ru plaques can overdose the optic nerve with doses of 50 Gy or greater; in some
cases this leads to radiation damage to the optic nerve causing a loss of vision (optic
neuropathy)[39]. Custom, collimated plaques have also been designed to offer a more
homogeneous dose gradient and limit dose to the sclera and adjacent structures[70].
To preserve the useful function of the eye, accurate delivery and dosimetry in this
region is critical. Simulation of dose distributions from complex plaque designs is both
difficult and time-consuming. The ability to perform accurate experimental dosimetry
in three dimensions using a physical simulation of the proposed treatment will therefore
provide the opportunity for rapid and precise confirmation of planned dose delivery
profiles for quality assurance purposes.
A number of methods currently exist for plaque dosimetry, although most have
shortcomings which preclude their use in real-time dosimetry.

These methods are

reviewed in the following section.

2.3.1

Plaque Dosimetry

The dose gradients in the eye resulting from ocular brachytherapy plaques are neces
sarily very steep. Therefore, it is desirable to be able to accurately characterise the
spatial dose profiles for treatment verification and optimisation. The dose profiles
are significantly affected by the choice of plaque and tumour geometries, which cause
significant differences in maximum and mean dose rates[12,18,40,80,84].
In order to develop a clinically valid system for pretreatment verification of plaques,
the adopted dosimetry technique should be reliable, accurate, fast and straightforward.
A recent review of dosimetry of plaques for intraocular tumours was included in the
Task Group 129 report[71]. Table 2.4 presents a summary of studies demonstrating
various dosimetry techniques used in plaque brachytherapy, including thermolumines
cent dosimeters (TLDs), polymer gel, radiochromic film, liquid and plastic scintillators,
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diodes and some other less commonly used techniques.
TLDs [70,108-112,122-127] have been used for dosimetric measurements in ophthalmic
plaques and other types of brachytherapy. Although TLDs are sufficiently com
pact for this application, they are impractical for real-time clinical use.
Polymer gels [128] provide good spatial resolution in three dimensions, however they
are not practical for this application due to their cost, long imaging time, sensi
tivity to light, temperature and oxygen and requirement of a magnetic resonance
scanner for readout.
Radiochromic film [67,68,70,124,129-131] is a well-known two-dimensional dosimetry tech
nique, which provides good accuracy and spatial resolution. However, it requires
an impractically long processing time to be used for everyday preoperative plaque
dosimetry.
Liquid scintillators [130] have been used in few studies for plaque dosimetry. They
have the benefit of accommodating plaques of any shape, but are reported to
have large regions of low accuracy in dose measurement, especially at the plaque
edges and at distances greater than 10 mm from the plaque.
Plastic scintillators have been used for the surface dose mapping of 106Ru plaques.
They were shown to have excellent resolution (0.15° in azimuthal, and 0.01° tilt
angles) and quite low uncertainty in water (< 7 %). The process requires complex
positioning mechanisms whose plaque loading requirements limit the practicality
of this method for real-time applications[132-134].
Diodes have yielded good dosimetric results[135-137], although when implemented as
single devices, they are not convenient for volumetric dosimetry. The technology
interfaces well with digital systems for fast and effective readout[69,113,114,124,130].
The planar fabrication process[138,139] is well developed and has enabled the
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production of two dimensional devices, extending beyond the capabilities of
single diodes.

These dosimeter technologies each have advantages and disadvantages, and offer
varying degrees of usefulness to plaque dosimetry. To address the dosimetric and clinical
needs of plaque brachytherapy, a technology with high resolution, high accuracy, large
dynamic range and real-time readout is required.
Silicon diodes were selected as the preferred dosimeter for this project as they
met the above requirements and due to their relative achievable resolution, design
flexibility and strong institutional expertise over the other dosimeter technologies.
Plastic scintillators, whilst offering many of the features of silicon diodes, were relatively
less suited to measuring well defined sensitive volumes.

Table 2.4: Review of ophthalmic plaque dosimetry techniques
Method

Source

Details

TLD

Weaver[108], Luxton

LiF (powder and blocks) determine plaque scattering and effect of backing with 125I

et al.[109]

seeds; plaque presence and absence of backing decreased dose.

Wu et al.[110]

LiF TLD-100, 1 x 1 x 1 mm3; 125I source; backing causes dose enhancement at close
range.

Harnett and

125I source; compared to calculated dose with close correlation; gold backing had no

Thomson[122]

influence.
1 mm3 68 TLDs used in 24 mm eye phantom for 3D dosimetry; 85 % of measured data

Alberti et al.[123]

within 10% of calculated data.
Chiu-Tsao et al.[111]

LiF, 1 x 1 x 1mm3; 125I source; silastic and/or gold in a plaque used in a head
phantom caused dose reduction; silastic alone showed similar results to silastic and
gold.

de la Zerda et al.[112]

LiF in two sizes, 1mm3 cubes and 1.0 x 1.0 x 0.5 mm3; 125I seed in COMS 20 mm

Astrahan et al.[70]

LiF (1 mm x 1 mm 0 rods) and radiochromic film; create slotted plaques for extended
collimation effect; produces more homogeneous dose distribution to tumour and

DOSIMETRY

ment due to backscattering material placed opposite plaque.
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plaque; dose reduction along central axis, relative to homogenous case, dose enhance-

reduces dose to uninvolved adjacent structures and dose to sclera by up to 50%
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compared to conventional plaque design.

Review of ophthalmic plaque dosimetry techniques (cont.)
Method

Source

Details

Soares et al.[124]

LiF:Mg, Ti of the type MTS-N (1 mm/3 mm thick x 5 m ^ ); 15 s prereadout, 12 s
readout, 3h annealing; overall uncertainty 8% - 10% depending on phantom.

Bilski et al.[125]

LiF:Mg,Ti and LiF:Mg,Cu,P. 0 2 mm x 500 pm thick; radiosensitive layer 65 pm 80 pm thick; almost tissue equivalent, dose threshold 100 pGy. Dose mapping on eye
plaque axis from 0.1 mm - 10 mm depth

Olko et al. [126,127]

300 pm thick 2D TLD films, Spatial resolution of 500 pm, limited by TL light propa
gation along the surface of the film

Polymer gel

Chan et al.[128]

Polymer gel forms phantom and detector; 3D dose distribution with good spatial
resolution (pixel size 300 pm) Requires MRI to readout - unable to determine dose
near edges.

Radiochromic film

Astrahan et al.[70]

to determine dose to critical structures.
Radiochromic and TLD used to evaluate collimated plaque design; see[70] above.

Soares et al.[124]

Two types of film used; variations in inter-sheet thickness led to measurement uncer
tainties of 7.5% (1ct) for absorbed dose; see[124] above for further detail.

DOSIMETRY

Good spatial resolution but requires processing and analysis; used with 125I plaque
2.3.

Wu and Krasin[129]
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Review of ophthalmic plaque dosimetry techniques (cont.)
Method

Source

Details

Krintz et al.[67]

Film type MD-55 (Nuclear Associates); scanned with laser densiometer; 100pm pixel
size; 125I seed; film saturates at 200 Gy; suitable for 125I brachytherapy dosimetry;
compared to Plaque Simulator[22] which disagreed with dose distributions along sclera
due to inadequate silastic insert transmission factor.

Kirov et al.[130]

HD-810 film; requires 5 h - 65 h irradiation and 48 h development time; reproducibility
of 10% - 15% for film in region of interest; see[130] above.

Acar[131]

GAFCHROMIC ® EBT film; 125I seeds loaded in COMS plaques (14 mm, 16 mm,
18 mm and 20 mm); film gave 13% dose decrease compared to Plaque Simulator[22].

Poder and Corde[68]

GAFCHROMIC ® EBT film; 125I seeds loaded in ROPES plaques; Stainless steel
plaque backing uniformly reduced dose by 4 %; No backing film measurements matched
Plaque Simulator and RADCALC® within 2% and 4%, respectively.

Kirov et al.[130]

Liquid scintillator acts as a detector material and a phantom; Accommodate plaque

close to and > 10 mm from plaque; within 25% of film and diode dose measurements;
see[130] above.
Plastic scintillator

Fluhs et al.[132]

A 1 mm3 detector used in mixed 106Ru and 125I radiation field gave an uncertainty of
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15%.
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of any shape; 3D dose distribution by tomographic reconstruction; inaccurate very
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Liquid scintillator

Review of ophthalmic plaque dosimetry techniques (cont.)
Method

Source

Details

Fluhs

BC-400 Scintillator (Saint-Gobain Crystals) with R647-01 PMT (Hamamatsu Photon

et al.[133], Eichmann

ics); BEBIG GmbH CCB 106Ru Plaque[56]; plaque surface dose measurement aimed

et al.[134]

at quality assurance; mechanical positioning; uncertainty in dose rates to water < 7%;
complex and time consuming process.

Diodes

Cygler et al.[113]

2.5 mm x 60 pm thick; plaque backing caused increase in dose when close to backing
and decrease when further away; diode response relates to photon energy and highly
sensitive to geometric changes.

Meli and

p-type Si diode (Scanditronix, GR-p); 1251 source; compared to water, gold backing

Motakabbir[114]

causes dose reduction and silver backing causes dose enhancement.

Knutsen et al.[69]

Stereotactic diode (size 2.5 x 2.5 x 0.3 mm3) showed agreement with the Bebig TPS
within 4 % - 11 %.
p-type Si diode, 0.2 mm3 sensitive volume; sources of 90Sr-90Y and 106Ru-106Rh; with

Kirov et al.[130]

500 pm stereotactic diode, current integrated over 30 s; BEBIG GmbH CCX 106Ru
plaque[56]; good agreement with film measurements from approximately 5.4 mm 10 mm from inner plaque surface; matched film and 3D scintillator within 25% for
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most points.
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10% - 151% of dosimeters tested.

2.3.

Soares et al.[124]

Review of ophthalmic plaque dosimetry techniques (cont.)
Method

Source

Details

Weaver et al. [140,141]

Medipix2 detector family[142,143]; high resolution; 256 x 256 pixels of 55 pm x 55 pm
pitch; good agreement between charge collection mode, count mode and TG43U1;
fast readout.

Other

Soares et al.[124]

Series of aforementioned dosimeters tested in addition to alanine, small ion chamber
and diamond detectors; intercomparison indicated a measurement uncertainty of
10% - 15% at 1mm for ophthalmic plaque dosimetry.

2.3.
DOSIMETRY
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In addition to the experimental techniques for determining dose mentioned in Table
2.4, other methods for dosimetric planning are also frequently used, such as calcula
tion and superposition using the aforementioned TG-43U1 formalism [20>21>65>84>144-147],
Monte Carlo modelling[84>m >120>148- 155] and discrete ordinate calculations[156>157].
Experimental dosimetry in ocular radiotherapy, where tumours are small and can
be close to critical structures such as the optical nerve, demands high spatial resolution
dosimetry and high detector dynamic range due to the steep dose gradients involved.
Whilst some error exists in defining precise tumour geometries and surgical plaque
placement, recent advances in semiconductor dosimetry now offer the potential for
improvements to treatment planning and verification, including:
• decreasing dose to normal ocular structures;
• reducing dose to the apex of the tumour;
• increasing the dose gradient outside the tumour; and
• reducing the target volume[71].
Such a system would allow for continued research and development of the treatment
through an increased capability to reproducibly measure quantitative dose volumes for
outcome comparison. It would also encourage the increased development of customised
plaques, especially with current 3D printing technologies. This will become increas
ingly useful as future developments with slotted and otherwise customised plaques
may allow for reduced dose to normal tissue, improve local control and preserve eye
function [83>93>121>132].
The focus of this study is to provide pretreatment quality assurance for plaque
brachytherapy through practical, high spatial resolution real-time dosimetry. Figure
2 .6

depicts the various aspects of the research problem and their relationships for this

study.
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Figure 2.6: The aim of this study is based upon the need for preoperative dose
verification for use in a clinical environment. For this to be realised, the project
requires the design, development and evaluation of a suitable radiation measurement
system.

2.4. CONCLUSION |41

2.4

Conclusion

Ocular cancer is a relatively rare disease which seriously threatens the lives of those
afflicted. One of the most common and widespread treatments for the disease is plaque
brachytherapy. This treatment involves placing a radionuclide source over the tumour
and keeping it in place for several days until the prescription dose is delivered to the
tumour, after which the source is removed.
Whilst there are several major challenges in using plaque brachytherapy, one of
the most significant is accurate and precise dose delivery. The dose gradients from the
plaque must be very steep to deliver maximum dose to the tumour, whilst minimising
dose to the normal surrounding structures.
These steep dose gradients make dosimetry a challenging task.

A number of

technologies have been used for measuring plaque dose distributions. Currently there
is no method used for real-time preoperative dose verification of assembled plaques
that is capable of measuring such steep gradients.
Due to favourable characteristics in speed, reliability, design and interfacing flexi
bility and institutional expertise, this study will focus on using silicon diodes detectors
for the development of a volumetric dosimetry tool for plaque brachytherapy.

Chapter 3
Semiconductor Dosimetry
In the previous chapter, it was concluded that plaque brachytherapy currently lacks any
practical form of rapid preoperative dose verification, and that silicon semiconductor
detectors would be a suitable candidate technology for such a system. This chapter
provides a background on the fundamentals of semiconductors and their use in radiation
detection for dosimetry.
Semiconductor detectors have been successfully used for dosimetry in low dose rate
brachytherapy [135>158>159] and provide a good platform for dose verification in plaque
brachytherapy.
Radiation detection systems are made up of a series of subsystems, each performing
specific tasks in the process of measuring radiation. As depicted in Figure 3.1, most
modern semiconductor detector systems use the following basic processes for a radiation
measurement:

1. Signal formation: Incident ionising radiation creates a number of charge carriers
within the detector, proportional to the deposited energy.
2. Charge collection: Charge carriers are collected and measured as a small current
pulse.
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Figure 3.1: Basic detector functions: Radiation is absorbed in the sensor and converted
into an electrical signal. This low-level signal is integrated in a preamplifier, fed to a
pulse shaper, and then digitised for subsequent storage and analysis[160].

3. Preamplification: The current pulse is converted to a voltage signal and ampli
fied.
4. Analogue processing: The voltage signal is shaped into a standardised Gaussian
pulse to simplify data acquisition; pulse height is now approximately proportional
to deposited energy.
5. Digitisation: The pulses are characterised as desired - typically by digitally mea
suring the pulse amplitude and/or time of arrival.
6. Digital handling: Recorded pulses are logged or binned in a histogram for further
processing.

The early stages of the process chain ( 1 - 4 ) are considered to be the analogue
front end and are one of the most critical aspects of the system. Each stage in the
process causes some change in the signal to make it usable by subsequent stages and
to eventually create some form of interpretable information. The stages, along with
the relevant theory, will be detailed over the next sections of this chapter.
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3.1

Signal Formation and Charge Collection

When an ionising particle interacts with a semiconductor, such as silicon, it deposits
energy into the material through the generation of charge carrier pairs along the par
ticle’s path. The process involves the incident particle causing a negatively charged
electron to move from the valence band to the conduction band and leave an effectively
positively charged hole in the crystal lattice. Together these charge carriers are referred
to as an electron-hole pair. The energy required to create an electron-hole pair is inde
pendent of the energy and type of the incident particle and is a function of the material
and its temperature. For silicon this value is GSi= 3.62 eV/electron-hole pair[161].
With the stimulation of an applied electric field, the electron-hole pairs are separated
and swept to opposite ends of the device where they are read out by ohmic contact
terminals, before they can recombine. This process is depicted in Figure 3.2, with
applied electric field VBias and signal current, i.
If an ionising particle deposits all of its energy in the active area of a detector,
the number of electron-hole pairs created is proportional to the incident energy of the
particle, and thus signal charge measured. Further details of the physical processes
are discussed in Section 3.1.1.
In plaque brachytherapy, typical dose rates are in the range of 0.6 Gy h - 1 - 1.05 Gy h - 1 [10]
and source activities can be in the order of hundreds of megabecquerels.

When cou

pled with low latency readout, high acquisition rates allow these high event rates to
be read out as single events, which is an attractive feature in dosimetry devices.
In order to optimise the design and function of a semiconductor dosimeter, it is
essential to have an understanding of the fundamental electrical and physical charac
teristics. The following sections provide some theory on band energy, semiconductors,
p-n junctions and diode detectors.
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Figure 3.2: This figure shows the basic function of a single detector, where incident
radiation causes ionisation of the detector’ s sensitive volume and leads to the generation
of charge. It is subsequently read out through an amplification system.

3.1.1

Semiconductor Sensor Physics

The theory of energy bands in solids can be used to explain the electrical conduction
properties of semiconductor materials. By changing the type and concentration of
impurities in semiconductors, these properties can be manipulated. This phenomenon
is used in semiconductor junctions and can be utilised for the field of medical radiation
physics, as it provides a means for the measurement of energy deposited in matter by
ionising radiation. More complex arrangements of these modified semiconductors are
used to create other devices and are covered at the end of this section.

3.1.1.1

Band Structure in Solids

The electrons of an isolated atom have atomic orbitals and take on discrete values called
energy levels. When such atoms are brought together to form a molecule, these atomic
orbitals split and become molecular orbitals, each with a discrete energy level as a
result of the Pauli exclusion principle. The number of molecular orbitals is proportional
to the number of energy levels that occur within the molecule. In solids, the number
of atoms and hence the number of molecular orbitals is often extremely large (usually
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Figure 3.3: Energy bands for metals, semiconductors and insulators have different band
gaps sizes affecting their respective properties of conduction. Each band is actually
made up of a large number of closely spaced energy levels.

in the order of 1023). This means that the number of discrete energy levels is also very
large and, as a result, the differences between these levels is very small. This causes
the energies to appear as a continuous band rather than a set of individual energy
levels.
Generally in solid-state physics, materials are classified as conductors, semiconduc
tors or insulators of electrical current, depending on the allowable energies in their
bands. The highest band that is totally filled with electrons at a temperature of abso
lute zero is called the valence band. The lowest energy band that contains no electrons
or is partially filled with electrons at absolute zero is called the conduction band. The
space between these bands is called a band gap.
If the bands overlap, electrons can easily be excited to move from the valence band
into the conduction band. This contributes to the conduction of electrical current in
the presence of an electric field. Materials with these properties are good conductors
and often metals. If the valence band is completely full and there is a large gap to
the next energy band, typical electric fields will not excite electrons enough to move
up into the conduction band. This type of material is known as an insulator. When
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the band gap is very small, electrons can be excited to move from the valence band
to the conduction band, thermally or otherwise, allowing conduction. Materials which
exhibit this band structure are known as intrinsic semiconductors. Figure 3.3 shows a
simplified depiction of the energy bands for conductors, semiconductors and insulators.

3.1.1.2

Semiconductors

The properties of a semiconductor material provide a useful mechanism for controlling
the resistivity of that material using an applied voltage or current.

For intrinsic

semiconductors, such as silicon crystal, each of the four valence electrons is bound to
a neighbouring silicon atom, causing the conduction band to be scarcely populated.
Through a process known as doping, which involves the controlled addition of impurities
to intrinsic semiconductors, extrinsic semiconductors can be created. Doping involves
the addition of atoms with either more or less valence electrons.
By replacing one of the silicon atoms in the lattice with a donor atom that has five
valence electrons, such as arsenic, four of the donor electrons bind to the surrounding
silicon atoms whilst the fifth remains free. This type of semiconductor is known as
an n-type semiconductor because the major charge carriers are negative electrons[162].
The diagram labelled ‘ n-type’ in Figure 3.4 depicts a silicon crystal lattice with an
extra electron contributed by a donor atom. The energy level of this additional of this
electron lies slightly below those in the conduction band and, when stimulated into the
conduction band, provides an appreciable level of conductivity (see n-type in Figure
3.5). The level of doping used in typical semiconductors is low enough that the effects
from radiation interactions from the dopants are insignificant.
If the impurity atom is an acceptor and has a valency of three, such as gallium,
its three electrons will bind to only three of the neighbouring silicon atoms, leaving
a vacant site or a ‘hole’ in the lattice (see p-type in Figure 3.4). This causes energy
levels to exist just above the valence band which accept electrons from the valence
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Figure 3.4: Doped semiconductor crystal lattice structures showing the extra electron
in n-type doping and the missing electron in p-type doping.
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Figure 3.5: Doped semiconductors showing electrons in the conduction band and holes
in the valence band. For temperatures above 0K , intrinsic semiconductors have equal
numbers of electrons and holes as charge carriers. In n-type semiconductors, electrons
are the majority carrier, while in p-type semiconductors holes are the majority carrier.
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band (see p-type in Figure 3.5). When the hole from this impurity atom is filled with
an electron, the hole can effectively move about the lattice contributing to electrical
conduction. This type of semiconductor is called a p-type semiconductor as its major
charge carriers are ‘positive’ holes. The higher concentration of electrons in n-type
semiconductors and holes in p-type semiconductors means that their majority carriers
are electrons and holes, respectively.

3.1.1.3

Semiconductor Junctions

A p-n junction is defined as the boundary between p-type and n-type semiconductors
in a single crystal. It is a two-terminal device featuring an anode at the p-type contact,
and a cathode at the n-type, and forms the basis of most semiconductor devices.
. Charge carriers are able to diffuse across the interface of the p-type and n-type
semiconductors in a process called diffusion. This occurs as the charge carriers move
along the concentration gradient to regions of lower concentration in an attempt to
establish equilibrium. Electrons will diffuse from the n-type material towards the ptype region, leaving positively charged ions at their donor atoms. Similarly, holes will
diffuse from the p-type material to the n-type material, instead leaving their acceptor
atoms negatively charged.
As the mobile carriers cross the junction, the fixed ions that remain establish a
built-in electric field at the junction. This electric field causes some of the charge
carriers to move in the opposite direction of the movement caused by diffusion. Here
the net current flow becomes zero when equilibrium is reached. This area in which
no net current flows is depleted of mobile charge carriers, and so aptly named the
depletion region, as shown in Figure 3.6.
The depletion region offers useful properties for radiation detection. Any electronhole pairs that are generated in this region will be forced towards opposite sides of
the junction by the in-built electric field that exists across the region. Electrons are
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Figure 3.6: The p-n junction is an interface which has an inherent voltage potential
across the so-called depletion region.

swept to the n-type side and holes are swept to the p-type side. When incident ionising
radiation generates an electron-hole pair within the depletion region, the charges are
carried out by the inherent electric field, resulting in an electrical signal[163].
The above describes the effect of a p-n junction with no externally applied electric
field. In practise, this can be an ineffective method of measuring deposited energy
(spectroscopy), as a portion of the electron-hole pairs generated will recombine before
full charge collection can occur. The yield of the measured charge can be increased by
applying an external electric potential across the junction in a process called reverse
biasing. This occurs as the electric field acts to increase the speed of the electrons,
reducing the travel time and, thus, the likelihood of recombination prior to measure
ment.
In their basic form, p-n junctions are called diodes and essentially give little resis
tance when a voltage is applied in one direction, known as a forward bias, and very high
resistance in the other, known as a reverse bias. This process is illustrated in Figure
3.7 where current flow from the device is plotted against applied electric potential, and
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Figure 3.7: The current-voltage curve of a p-n junction, or diode. Forward biasing
( orange) occurs when a voltage is applied across the device with the higher potential
at the anode (p-type material). Reverse biasing (blue) occurs with the lower potential
at the anode, and when the magnitude of this potential is large enough, breakdown
occurs. Note: The positive and negative current axes have different scales, and the
negative voltage axis contains a break.

is called a current-voltage (I-V) curve. It is a useful measure of the operation of many
devices and is used during characterisation in Chapters 4 and 7.
When a diode is forward biased, a voltage is applied across its junction with the
positive side of the source connected to the p-type material and the negative to the
n-type. By convention, the positive side indicates the point of relatively higher voltage
and the direction from which positive charge (holes) moves, towards the lower potential
at the negative terminal. The contrary is true for electrons moving towards the point
of higher potential. Therefore, a forward biased diode will cause electrons to be forced
towards the p-type material and holes to the n-type.
As like charges have a repulsive effect, the forward biasing process effectively
reduces the width of the depletion region. When a large enough voltage is applied
across the junction in this manner, the depletion region becomes sufficiently thin for
the inherent junction resistance to become significantly reduced. This reduction in
resistance permits the flow of current.
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For a diode operating in reverse bias mode, the higher potential of the supply
voltage is connected to the n-type material, and the lower potential to the p-type.
The process has the opposite effect of forward biasing and further inhibits the flow of
current, increasing the depletion region width. This extended depletion region therefore
increases the available sensitive volume in which ionising radiation can be collected.
A junction in which the depletion region extends through the entire thickness of the
semiconductor wafer is said to be fully depleted.
When a reverse bias voltage is applied to a semiconductor junction, even in the
absence of an ionising radiation source, a very small amount of leakage current will
flow. Typically, this is a product of current contributions from both the surface and
bulk of the detector.
Bulk current is generated through two means,

a) continuous transportation of

minority carriers across the junction, due to the imposed electric field; and b) thermally
generated electron hole pairs in the sensitive volume. Both of these sources of current
increase proportionally with the geometry of the junction and as a result, larger diodes
will yield more leakage current. Surface leakage current occurs at the edges of the
junction and while it is effected by surface contamination, it can be reduced with the
use of a guard ring[163].
The leakage current of a reverse biased junction is a strong function of temperature,
as shown in the following equation [163>1641:

where i = leakage current, C = proportionality constant characteristic of material,
T = absolute temperature, Eg = band-gap energy of material and k = Boltzmann
constant.
If the reverse bias voltage is great enough, the electric field is sufficient to strip
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electrons from their atomic bonds and accelerate them across the junction. The mobile
electrons cause other electrons to break loose, forming more electron-hole pairs and
causing avalanche breakdown to occur, whereby significant current beings to flow.
While this effect is reversible, thermal damage may be disastrous to circuits when
unintentional.

3.1.1.4

Diode Detectors

Many variations of the p-n junction have been developed to improve performance in
specific applications, one of which is called the p-i-n diode. The p-i-n diode is commonly
used for dosimetric radiation detection, and is characterised by the addition of an
undoped, intrinsic ( i) semiconductor layer between the p-type and n-type materials
of the diode junction.
The p-type and n-type regions are heavily doped and act as ohmic contacts for the
device, whilst the i-type region is not truly an intrinsic semiconductor material, but is
lightly doped. In reality, however, no practical semiconductor is free from impurties
and this intrinsic layer is approximated with either lightly doped, high resistivity p-type
(called ff-type) or n-type (called ^-type) material. [165>1661 The addition of the intrinsic
layer makes the diode a poor rectifier but its width gives it a low capacitance when it
operates in the reverse biased mode. The larger depletion region also means that the
sensitive volume of the detector is larger. Fundamentally, this occurs in three stages:

1.

incident radiation causes generation of electron-hole pairs (carriers) within the
depletion region;

2

. transportation of carriers across the junction by an applied electric field; and

3. output of signal through extraction of carriers at device terminals.
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The geometric and electrical properties of the p-i-n diode gives it several benefits
over the p-n diode as a radiation detector, including the following:
• larger in sensitive volume of the detector due to the enlarged width of the
depletion layer;
• reduced leakage current, yielding a better signal to noise ratio;
• reduced junction capacitance, C j, due to the enlarged width of the depletion
layer; and
• faster drift processes carry a greater proportion of the generated current due to
a reduced ratio between the diffusion length and the drift length of the device.
The increased width of the depletion layer comes at the expense of increased
carrier transit time. This increased time limits the readout rate and means charge
recombination is more likely to occur, diminishing signal quality.
As it is almost free from impurities and charge carriers, the intrinsic layer of a p-i-n
diode is nearly fully depleted at zero or low reverse bias voltages. Here, the capacitance
per unit area is defined as [163>1651:

(3.1)
It can be seen that the depletion capacitance, Cdep, is a function of the depletion
width of the semiconductor junction, W , and the substrate permittivity, ts. The
depletion width is a function of applied reverse bias voltage, V , doping level, N , and
the electron charge, e, as per the following relationship:

(3.2)
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The depletion capacitance is thus a function of reverse bias voltage and substrate
properties as shown in Equation 3.3.

Cdep ~ ^

(3.3)

Equation 3.3 shows that the capacitance of the junction is inversely proportional to
the reverse bias voltage, Cdep a

, meaning that, whilst below breakdown voltages,

the junction capacitance decreases with increasing reverse bias. Practically, the full
depletion voltage can be determined by the point at which the capacitance ceases to
change significantly with increasing bias voltage. Detector capacitance has a major
influence on signal quality and the design of the preamplifier stage in the signal
processing chain.
The p-i-n diode is compact, relatively rugged and allows for real-time readout,
making it well suited for the dose verification needs of eye plaque brachytherapy. When
exposed to x-ray or gamma radiation the detector produces pulses from secondary
photoelectrons which can be processed through analogue and digital electronics to
provide a convenient form of dosimetry.

3.2

Preamplifier

The current pulse collected in the first stage of the signal processing chain is extremely
small, requiring a special interface circuit known as a preamplifier (or preamp). This
circuit acts as an interface between the sensor and the subsequent processing stages.
The preamp prepares the signal for subsequent processing by converting the very small
current pulse into a relatively large voltage pulse. The primary function of the preamp
is to extract the signal from the sensor with minimal degradation of the signal-to-
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noise ratio. To do this, the capacitance loading to the preamp should be minimised
by placing it as close as possible to the detector and hence shortening the electrical
connections.
While there are many designs of preamplifiers, they essentially fall into one of two
configurations, voltage-sensitive or charge-sensitive. Voltage-sensitive preamplifiers, see
Figure 3.8, generate a low impedance output whose voltage amplitude is proportional
to the input current as received from the detector. The relationship between output
voltage, Vo, measured charge, Q*, and the input capacitance, C*, is Vo = Qi/Ci. The
input capacitance is that which is seen by the input terminals of the preamplifier,
i.e. from the detector and connections to the preamplifier. This configuration is fine
for most detectors; assuming that C* remains constant, the output voltage is entirely
dependant on the input charge. As discussed in Section 3.1.1.4, the capacitance in
a semiconductor detector varies with operational parameters, including bias voltage,
which means the decoupled relationship between Vo and Q* does not exist.
This problem can be overcome using charge-sensitive preamplifiers whose output is
independent from input capacitance. The output voltage of the ideal charge-sensitive
preamplifier, shown in Figure 3.9, is proportional to the input charge deposited in the
feedback capacitor. The output voltage of the amplifier is Vo = —AV*, where Vo is the

Figure 3.8: Simplified voltage-sensitive preamplifier schematic. The diagram labels
the detector, Cdet, input voltage, V , measured charge, Q*, feedback resistance, R f ,
input resistance, R*, transimpedance gain, A, and the output voltage, Vo. Assuming
A > > Rf/Ri, then Vo ~ —(R f/Ri)Vi.
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Figure 3.9: Simplified charge-sensitive preamplifier schematic showing the input charge
pulses and the corresponding output voltages with long pulse-tails. The diagram labels
the detector, Cdet, input voltage, Vi, input capacitance, C*, input charge, Qi, feedback
resistance, R f , feedback capacitance, C f, transimpedance gain, A, and the output
voltage, Vo.

output voltage, A is the amplifier gain and V* is the input voltage. The voltage across
the feedback capacitor is then given by Vf = V*(A + 1). The charge, Q f , deposited on
the feedback capacitor is then Q f = Cf Vf = Cf V*(A + 1). In an ideal amplifier, there
is an infinite input impedance and no current flow in, so Q f must equal Q*, giving

c =

I

= m

i +

i = Cf ( A +

1)

The transimpedance of the circuit is the output voltage per input charge as shown
in Equation 3.4. By reducing this further, it shows that the output voltage is effectively
dependant on the feedback capacitance. In the case of semiconductor detectors this
conveniently leads away from the issues with dependency on input capacitance. As
long as the time constant, t = R f C f, is sufficiently large with respect to the duration
of the input pulse, the output voltage is proportional to the charge measured from
ionisation events.
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VO =
-A V i
Qi
Cf Vi(A + 1 )
~ ^
Cf

(3.4)
J

1

(if A >> 1)

One of the most important aspects of preamplifier design is the minimisation of
inherent noise. The feedback resistor, R f , is a significant factor in preamp noise due to
its associated Johnson (thermal) noise. This noise decreases with increasing resistance,
however this causes an increase in the time constant and thus the tail pulse length of
the voltage output.
As shown in Figure 3.9, the output voltage has a very short rise time, but long pulse
tail. In most cases, this prevents the output voltage from returning to the baseline
before subsequent charge events cause further increases to the output voltage.
The following stage in the signal processing chain after the preamplifier, often a
linear amplifier (shaper), is designed to handle these baseline offsets. At some point,
pulse pile-up will occur due to large pulses coming too frequently for the baseline drop
sufficiently low again. When this happens the output voltage reaches a saturation
point where it cannot increase further as it is limited by the voltage rails, and no
further pulses can be output from the preamplifier.
At the cost of noise, the feedback resistor can be reduced to increase the pulse tail
decay rate. Alternatively, R f can be removed altogether and replaced with an active
reset circuit, eliminating its associated Johnson noise altogether.
An active reset circuit provides a means for the preamplifier to prevent pulse
overflow by resetting the baseline back to zero. Transistor reset is a popular method
of active reset, where the feedback capacitor, C f, is discharged through a transistor
when the output reaches an upper threshold [160>1631.
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3.3

Analogue Processing

The detector signal is converted by the preamplifier into a more robust form for further
amplification and handling during the following stages of the signal processing chain.
One of the most common components to follow the preamplifier is the linear amplifier
which provides pulse shaping and signal amplification. After this stage, it is often
necessary to select pulses that fall within a specific energy range using a discriminator.

3.3.1

Linear Amplifiers

Linear amplifiers, or shaper amps, are used to convert the signal from the preamplifier
into a form that can be processed easily. The output voltage signal from the preamplifier
has an amplitude below practical limits for analysis, typically in the order of millivolts,
and is also subject to instability as a result of pile-up of events[163]. The linear amplifier
provides this signal with a significant voltage gain to boost it into the range of Volts,
and shaping to reduce the pulse width and flatten the peak for greater readability.
Whilst older standards for modular instrumentation were limited in their output
voltages, such as the NIM standard[167], which was 0 V - 10 V for microsecond analogue
signals, modern designs offer much more flexibility. Using NIM as an example, this
means that gains of around 100-5000 are needed to adequately boost the preamp signal.
Ideally, the shaped signal output will fall within this 10 V range, if the input signal is
too great, peak clipping will occur and the amplification will be non-linear. Pulse gain
and shaping occur by passing the signal through filters. A simple pulse shaper, known
as a CR-RC shaper, is depicted in Figure 3.10. It is made up of a high-pass filter (CR)
and a low-pass filter (RC). Whilst real linear amplifiers are made up of more complex
and sophisticated systems, the C R-RC shaper shares most of their features and will
be used in explanation.
The high-pass or CR filter is a system that simultaneously inhibits low frequencies
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Figure 3.10: A simple CR-RC pulse shaper, comprising of a high-pass filter (CR) and a
low-pass filter (RC) in succession. The brief pulse from the detector is passed through
the preamplifier where it takes on the shape of a step function before being fed into the
high-pass filter which defines a new pulse width, and then the low-pass filter, where it
is shaped for ease of measuring.

and allows high frequencies to pass through it. If a step function is considered as the
input into the CR filter, with voltage Vi = Q/Ci at t = 0, then the output is given as

v
Vcr = tQv e- f d
Ci

for t > 0 where Td = R dCd

The output signal is represented as an exponential decay, as depicted in Figure 3.10
and has decay time, Td. It is impractical to measure the amplitude of such a signal
bearing a sharp cusp, as the peak voltage is only present for a short time. In addition
to this issue, unwanted high frequency noise components will still remain mixed within
the signal, reducing its signal quality.
By passing the signal through a low-pass or RC filter the high frequency noise can
be reduced while allowing low frequencies to pass, smoothing out the cusp for ease
in signal sampling. The exponential decay shaped response from the CR filter is fed
directly into the input of the RC filter. The voltage output from the RC filter alone,
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if a step function is applied at the input, with voltage E at time , t = 0, is given by

__t_

VRC = E (1 — e

Ti

)

for t > 0 where Ti = RiCi

This function is analogous to the voltage measured across a charging capacitor with
time constant, Ti and applied voltage E .
The overall system response of the CR-RC filter resembles a semi-gaussian curve.
The rise and fall times can be controlled by choosing appropriate values for Td and Ti.
The optimal combination of having a flat pulse top (for low ballistic deficit : ) and a
short tail pulse (for minimum pile up) occurs when Td = Ti. As this condition also
results in the maximum signal-to-noise ratio, it is nearly exclusively used[170]. With
initial input voltage Vi = Q/Ci at time, t = 0, the output voltage from the amplifier is
given by:

Vcr - rc = n ( QTd— r(e Td — e T )
Ci(Td — Ti)

for t >

0

(3.5)

where Td = R dCd and Ti = RiCi

More sophisticated shaper amplifiers are used in practice, such as higher order semiGaussian (C R — (R C )n) shapers, double RC differentiation ( ( CR) 2 —R C ) shapers, ac
tive filter pulse shapers, triangular shapers, trapezoidal shapers and delay line shapers,
to name a few I160,163,170!.
1 Ballistic deficit is a measure of the fractional loss of pulse height due to inefficiency in inte
gration. It occurs due to variations in rise-time in the detector signal that propogate as amplitude
fluctuations after the signals pass through the linear amplifier. In semiconductor detectors, these
rise-time variations are often the result of the distribution of charge origins within the detector,
field inhomogeneities or charge trapping I168,169!. As noise is independent of input signal, there is a
reduction in the signal-to-noise ratio with increasing ballistic deficit I160,170!.
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3.3.2

Baseline Holders

When a signal is passed through a series capacitor, the capacitor filters out all DC
components of that signal. After it has passed through the CR (high-pass) filter, the
DC component is removed and the signal takes a baseline that is centred with an
average value of zero[160]. The amount by which the output voltage shifts away from
its true zero is known as baseline shift. Baseline shift offset is greatest when the signal
has high pulses at a high rate. When these heights and rates vary, as is the case in a
real system, the baseline shift must vary too. This effect is depicted in Figure 3.11.
To mitigate the effect of baseline shift, electronics system known as baseline restorers
are used. The purpose of a baseline restorer is to recover the true zero value of the
signal. There are several types of restorers that can be used depending on the design
specifications, these include the simple diode restorer, the Robinson restorer[171] and
the Gere-Miller restorer[172] among others I173-176!.

3.4

Digitisation and Digital Processing

Once the signal is transformed into a robust and measurable form, it can be further
processed so it can be represented digitally. This is a desirable practise for a number
of reasons including the immense flexibility and ease of processing along with the
efficiency and ease of storage. Each pulse from the detector holds a significant amount
of information and, depending what the function of the system is, little or much of
this can be extracted.
For simple pulse counting systems, pulses with a voltage peak above a specified
level will trigger logic pulses that are recorded by incrementing a counter. When two
thresholds levels, a lower and an upper, are specified to create an energy window,
only pulses within this region are counted. This type of filter is called a differential
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Figure 3.11: Baseline shift occurs when a series capacitor filters out the DC component
of a signal. The magnitude of the shift is dictated by the pulse heights and frequency.
The average value of the signal must equal zero, e.g. the area above and below the
zero value are equal in the top diagram. As a result, variations in pulse heights
and frequency create variations in the baseline shift as seen in the bottom diagram.
Adapted from Knoll[163].

discriminator or single-channel analyser (SCA).
A combination of multiple SCAs, whose thresholds are contiguously spaced, can
be used concurrently to produce a pulse height (energy) histogram and create a mul
tichannel analyser (MCA). By measuring the duration that a pulse’s height exceeds
a predetermined threshold level using a digital clock, information pertaining to the
energy of the pulse can be determined.

3.4.1

Pulse Discriminators

Once the output of the shaper has produced a suitably measurable signal, any pulses
that do not fit the criteria of interest can be discarded. From Section 3.3.1 above,
the pulse height output from the shaper amplifier (usually 0 V - 10 V) is shown to be
proportional to the charge and hence the energy of its input. A discriminator allows
for the exclusive selection of pulses that fall in a specified energy range.
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3.4.1.1

Integral Discriminators

An integral discriminator, or low-level discriminator, is analogous to a high pass filter,
in that pulses below a specified energy level will be rejected, and those above will
trigger a logic pulse output.

By choosing an appropriate threshold level, the low

energy noise can be ignored, while the desirable pulses are processed further. This
concept is depicted in Figure 3.12 where the blue and oranges pulses are accepted or
rejected, respectively.

3.4.1.2

Differential Discriminators

In many situations, it is necessary to select pulses that fall within a specified range,
rather than simply above a threshold level. To accommodate this need, a differential
discriminator, or single-channel analyser, can be used. Here, two separate threshold
levels are specified, a lower and an upper, and pulses outside the threshold range are
ignored. Figure 3.13 shows the logical function of the differential discriminator, the
blue horizontal bar illustrates the region of pulse heights that are accepted. Pulses
with an amplitude that is too low are ignored, as are those whose amplitude exceeds
the upper threshold.

Figure 3.12: Concept of the integral threshold discriminator. Only pulses with a height
that lies above the discriminator threshold level (blue) create an output response. The
pulse height spectrum illustrates how the pulses of low height (usually low energy
noise) can be ignored.
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Figure 3.13: Concept of the differential threshold discriminator. Only pulses with
a height that falls between the lower and upper energy thresholds (blue pulse) are
processed further, other pulses (orange) are ignored.
3.4.1.3

Time Slew

The discriminators described above are subject to an issue known as time slew or time
walk, where timing differences occur between the input pulse and the logical output
pulse[170]. As the input pulses have some finite rise time, the lower threshold level logic
of a differential discriminator must trigger prior to the upper threshold logic. The dead
time between these stages can be erroneously triggered as a false positive logic output,
shown in Figure 3.14. In this case, the input pulse exceeds the acceptable height limit,
yet incorrectly produces an output pulse.
In some forms of spectroscopic dosimetry, events that occur within a specified
energy threshold window are used to calculate dose. If time slew is present there can
be a misrepresentation of energies.

Integral discriminator
(U pper threshold)

_U_

O
Integral discriminator
(Lower threshold)

__
L

O

J=L

Figure 3.14: Block of the differential threshold discriminator illustrating the effect of
time slewing, where the time delay between triggering of the lower threshold discrimi
nator and the upper level discriminator causes an incorrect output response.[170]
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The effect of time slewing can be handled in numerous ways, such as delaying and
shortening the output pulse from the lower discriminator or using flip-flop based logic
circuits[170].

3.4.1.4

Counters

The logical output pulses from the discriminators are temporarily stored in counters.
A counter is a device that generally consists of a series of flip-flops and, when enabled,
increment a value stored in binary. A counter that uses

12

binary digits is said to have a

bit depth of 12, which is equivalent to 212(4096) logical combinations and hence, values.
Counters need to be read prior to exceeding their maximum value, or overflowing, so
they can be reset although this often causes dead time in the overall measurement.

3.4.1.5

Time-Over-Threshold

Although there are many alternatives, one method for measuring the charge of a pulse
is using a process called time-over-threshold (TOT). TO T is employed by the Timepix
detector[143] which was used in this project.
In this type of analogue processing, the width of a pulse (which is proportional to
initial signal charge) is digitised at a particular threshold level, using a discriminator
and an adjustable analogue threshold. The width of the logical output pulse from the
discriminator corresponds to the width of the input pulse. The logical pulse is used to
enable a counter that increments based on a fast digital clock, in the order of 100 MHz.
The resultant value can then be passed through logical processing or binned using
digital comparators. The time-over-threshold process is illustrated in Figure 3.15.

3.4. DIGITISATION AND DIGITAL PROCESSING |67

► _r

r
Discrim.
Analogue
threshold

Ref.
Clock

Tim e-over-threshold
Counter

Figure 3.15: The time-over-threshold process; the preamplifier signal is passed through
a discriminator, compared with an analogue voltage threshold and the output is timed
using a fast reference clock, C L K ref . Adapted from W ong[177]

3.4.2

Digital Processing

The previous stages of the processing chain (signal formation, charge collection, pream
plification, and analogue processing) are carried out by the analogue front end elec
tronics. Once the analogue signal has been represented in digital logic there are many
potential advantages; it is free to be processed, duplicated or stored as necessary. Digi
tised data, such as the counter values as measured by discriminators, can easily be
stored and presented as desired.
If certain factors, such as the number of detectors, acquisition rate, digital precision,
computing power and required processing are within acceptable limits, then data can
be handled in real-time. Real-time dosimetry requires the conversion of measured
signal into user readable doses with sub-second timing.
W ith growing technology capabilities, digital pulse processing is becoming more
viable and offers great advantages. Here, the output from the detector and amplifier
are passed through an analogue-to-digital converter where the pulse shape is preserved
and represented in the digital domain. Any analogue signal filtering or manipulation
is replaced with digital signal processing, which offers endless flexibility. Though this
technique is not adopted in the study, its future adoption may provide considerable
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opportunity for dosimetry in eye plaque brachytherapy.

3.5

Dose Equivalence

Absorbed dose is defined as the energy deposited in a material per unit mass. The
International System of Units defines dose in units of the Gray (Gy) as:

1 Gy = 1 J = 1 m 2 /s 2
kg
In treating cancer, it is critical to understand and deliver the correct amount of
dose to the treatment target, too little and the threat remains, too much and serious
side-effects occur, see Section 2.3. In the context of this study, the term dosimetry
refers to the measurement and calculation of absorbed dose in a specific medium, at a
specific location.
In order to create a system that can accurately determine the dose in a specified
area, the interactions of ionising radiation with matter must first be understood. To
accomplish this, it is also necessary to be aware of the types of radiation that are
present in the treatment and will affect the dosimetry. In plaque brachytherapy, either
beta (0) or low energy gamma (y) radiation is used through a variety of nuclides. The
most commonly used radionuclide in the United States and Australia is

125 I,

whilst

106Ru tends to be more common in Europe. Other, more recently developed sources,
such as 103Pd and

131 Cs,

are also becoming increasingly popular I10>18>1781. Some common

radionuclides used in plaque brachytherapy have been provided in Table
2

2 .2

of Chapter

.
The biological effectiveness of the dose deposited in a material is dependant on

the type of radiation. For the same energy deposited per unit mass, heavy charged
particles produce greater biological damage than beta-particles.
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This occurs because heavy charged particles have a higher linear energy transfer,
or energy deposition per unit length, than beta-particles. Gamma-rays deposit their
energy in the form of beta-particles and, as such, behave in the same manner. The
effective biological dose of a type of radiation, called the dose equivalent, is accounted
for by weighting its absorbed dose. For the energies and radiation types used in context
of this study, the absorbed dose is approximately equal to the dose equivalent[163].

3.5.1

Dose in Silicon

It is a challenging task to measure the energy deposited in tissue. However, by using
detectors that respond to radiation similarly to tissue, dose can be more accurately
measured and calculated as if it were tissue. In addition to this, it is useful to know
the radiation interaction processes within the detector and surrounding materials to
optimise the design. Figure 3.16 shows the gamma-ray interaction processes that occur
within silicon as a function of energy. Around the energies of interest for 125I plaque
brachytherapy, ~ 20keV - 35keV, photoelectric absorption is the dominant gamma
interaction in silicon, meaning less partial deposition of energy is observed as a result
of Compton scattering.
Radionuclides that emit beta particles (electrons or positrons), do so over a con
tinuum of energies. For the majority of these energies, the depth-dose curves follows
an approximately exponential decay, beyond an initial build-up region. This occurs as
lower energy electrons are absorbed at a faster rate than those with higher energy. In
comparison to gamma-rays, beta particles are more ionising, yet have less range in a
material.
As the mass of the beta particles are equal to that of the orbiting electrons they
are interacting with, large depositions of energy can often occur in a single interaction.
These interactions also cause large deviations in the trajectory of the incident beta
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Figure 3.16: Energy dependence of 7 -ray interaction processes in silicon including,
Compton scattering, photoelectric absorption, nuclear pair production and the summed
total including coherent scattering. The dominant process at the low energies used in
ophthalmic brachytherapy is photoelectric absorption. Source: Berger et al.[179]
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particle, known as scattering. Scattered electrons only partially deposit their energy and
may then exit the material altogether. This effect strongly influences the apparent dose
absorbed in a detector. Beta-emitting plaques have less focus than gamma-emitting
plaques in this study.
When performing dosimetry for plaque brachytherapy, the appropriate energies
and depth-dose curves need to be considered, not only to account for the detector and
readout electronics, but the various other materials surrounding the detector.

3.5.2

Anthropomorphic Phantoms

When measuring dose in radiotherapy, it is often not practical or possible to do so
during the treatment. In many cases, such as plaque brachytherapy, it is not currently
viable to adaptively modify the treatment once it has commenced, consequently there is
little point in performing in vivo (in body) dosimetry. Instead, the treatment dosimetry
is improved by calculating the expected dose and then modifying where necessary prior
to being performed. This is process is called preoperative dose verification.
In conducting preoperative dose verification, estimations and assumptions need
to be made regarding the physical model of the treatment. It is common practise to
use materials which geometrically resemble patient anatomy and have a dosimetric
response similar to that of the appropriate type of tissue.
There are many commercially available anthropomorphic phantoms which aim to
provide tissue equivalence, though due to its similarities, water is often considered tissue
equivalent. Materials used in these phantoms are fabricated to meet the needs of specific
energy regimes. Plaque brachytherapy requires a material with water equivalence in
response to low energy photons, for the purposes of this study. There are several
available options which may be suitable including Plastic Water L R [180], Gammex 457
Solid Water(Gammex Inc., USA), and Virtual Water(Med-Cal Inc., USA) or the less
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accurate poly(methyl methacrylate) (PMMA) [181>1821.

3.6

Conclusion

Silicon semiconductors are suitable for use in real-time, room temperature radiation
detection. The signal processing chain used for such detectors involves measuring the
energy deposited from incident radiation and conducting analogue processing which
allows it to be represented in the digital domain. The analogue front end electronics
and detector play a critical role in determining the quality of the radiation signal
measured and hence the dosimetry outcomes. Characterisation of a radiation detector
system needs to be undertaken to ensure that its operation is correct and can be
optimised.
Given the positive outcomes in the literature and the institutional expertise in
the field, the following chapters investigates silicon p-i-n diodes as radiation detectors.
Several concepts are considered and evaluated starting with a single detector system
used for spectroscopic dosimetry. This extended upon through the investigation of
pixelated (multi-pixel) silicon detector systems for the improvement of quality assurance
in plaque brachytherapy.

Part II
Concept Validation

73

Chapter 4
Single Detector Concept
The previous chapter provided a background overview on the operation of silicon
diode radiation detection systems, while this chapter demonstrates the feasibility in
using such a device for plaque brachytherapy.

Specifically, the study undertaken

in this chapter used a single p-i-n diode together with a readout system and water
phantom for spectroscopic dosimetry. The detector characteristics were measured and
the dosimeter concept was evaluated in terms of dose response and angular dependence.
The work presented in this chapter resulted in the development of a prototype plaque
brachytherapy dosimeter, and justified the extended development of more complex
pixelated detector designs. This was accomplished through the following aims;
• illustrating the dosimetry concept and hardware;
• determining the operational characteristics of the detector; and
• characterising the system and assess its performance.
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Figure 4.1: A single p-i-n diode is lowered towards an inverted eye plaque in increments
along the central axis of the plaque. The resulting depth-dose curve is a simple and
convenient method of preoperative dose verification.

4.1

Concept and Hardware

Accurate dosimetry can be achieved through observing the spectrum of energies de
posited in a detector and calculating dose by considering only those energies which
are expected from the source. This ensures that the false events, derived from noise,
do not contribute to the calculated dose. The technique is a form of spectroscopic
dosimetry and has been used in the past in prostate brachytherapy[183]. This section
aims to illustrate the proposed and evaluated single detector concept, and to provide
an overview of the detection hardware used to perform this.

The concept used a

water phantom, together with a detector, readout system and positioning system to
accurately measure the depth-dose response of a brachytherapy plaque, as shown in
Figure 4.1.
The detector, a silicon p-i-n diode, was mounted on an elongated printed circuit
board (P C B ) probe and sealed watertight. By submerging the detector end of the
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Figure 4.2: Photograph of the assembled probe (top) with the detector located on the
tip at the right (not visible) and cable running to the readout system (left). A sample
of the diode detectors are located below the probe.

Figure 4.3: A schematic diagram of the single detector system’s subsystems
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probe in the water phantom, as depicted in Figure 4.1, the dose-rate was measured
at the central axis of the plaque loaded with 125I seeds. The opposite end of the
probe consisted of the preamplifier electronics which was connected via a cable to
a readout system, as seen in Figure 4.2. The readout system was used to provide
real-time feedback of dose rate to the operator. The flowchart in Figure 4.3 depicted
the subsystem relationships, where the operator controlled the position of the detector,
which was used to measure dose from the brachytherapy source via the phantom.
This method allows for depth-dose curves to the surface of the plaque to be mea
sured, which when coupled with lateral movement offers potential for surface dose
mapping. The distance between the detector and the plaque is controlled manually,
but could easily accommodate computer controlled operation. The system concept
shown is in Figure 4.1, where the detector is situated at the end of an extended ‘stem’
protruding from the preamplifier module. The plaque is inverted within a water phan
tom with its active side facing up towards the detector and is located centrally within
a tissue equivalent phantom. The tip of the detector travels incrementally along a
plaque axis, and can be positioned directly against the plaque’ s surface. During this
process, dose measurements are made at user defined locations and intervals.
The detector is one of the most critical factors of the design. The system detailed
in this chapter used a p-i-n diode, the workings of which are described in Section
3.1.1.4. The external geometry of the diode was 1.0 mm x 1.0 mm x 1.2 mm, and it
featured a thin p+-type implanted layer (630 pm x 630 pm) on one side and an n+-type
implantation covering the entire other side. A cross sectional schematic of the diode
is detailed in Figure 4.4, showing the p-i-n diode topology. The diodes were designed
at the Centre for Medical Radiation Physics (CM RP), University of Wollongong and
fabricated at the CMRP microelectronics foundry, SPA BIT.
The diode was coated in an epoxy resin to improve its robustness by protecting
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Figure 4.4: A schematic cross section of the single p-i-n diode detector. The size of the
sensitive volume was primarily governed by the geometry of the p + region and applied
reverse bias voltage. For electrical connectivity, thin aluminium wires were fixed to
the device contacts using conductive glue.
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Figure 4.5: A photograph of the single p-i-n diode detector used in this study showing
the black epoxy coating. The ruler units are in millimetres.
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the sensitive wire bonds and creating a seal against water. A sample of diodes with
their epoxy coatings can be seen below the probe in Figure 4.2 and in Figure 4.5. The
detector was further protected against water with a thin layer of hot-melt glue and
shielded from radio frequency (RF) noise with a 70 pm aluminium shrouding once it
was mounted to the preamplifier board.
In addition to the detector, the preamplifier formed part of the probe. The pream
plifier was mounted within a cylindrical aluminium housing, with the detector at one
end, and a cable protruding from the other. This housing was used for shielding the
sensitive electronics against electromagnetic interference, see Figure B.1 of Appendix
B for schematic designs. The after the signal was enhanced in the preamplifier, it was
passed to the readout electronics for dosimetric calculation.
The readout electronics were used for the calculation of dose rate through pulse
analysis and counting in a method termed as spectroscopic dosimetry [159>1831. In order
to calibrate the device for dosimetry, a low level discriminator was set, and the count
rate was adjusted to give dose rate. The discriminator value was chosen to ignore lowenergy noise events, after observing the output spectrum. The device was calibrated by
placing a single 125I seed of known activity (0.0116 mCi) at a known distance

(1 0

mm)

in water and adjusting the reader’ s calibration factor, which acted to ignore pulses
randomly at a set rate, to match that given by the TG-43U1 formalism.
To assess the feasibility of a single detector design for plaque brachytherapy, the
detectors needed to be characterised and the performance of the assembled system
measured.

4.2

Characterisation and Performance

Studying the functional response of the detector and the overall system is important
to indicate its suitability for practical dosimetry. This section aimed to characterise
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the operation of the detector, and was achieved by measuring current-voltage and
capacitance-voltage curves. Measurement of performance of the readout system was
carried out through depth-dose curves, energy spectra and angular response.

4.2.1

Detector

Current-voltage curves were taken to determine the typical leakage current in addition
to the reverse breakdown voltage of the detector. Capacitance-voltage characteristics
were also measured to give an expectation of the signal quality.

4.2.1.1

Current-Voltage Characteristics

Diode leakage current was measured for the detector as a function of reverse bias
voltage from 0.0 V - 50.0 V in 1.0 V increments. To achieve this, the diode was placed
inside a dark Faraday box from where it was routed through to a Keithley Model
230 Programmable Voltage Source, for applying reverse bias voltage and then to a
Keithley Model 614 Electrometer, for measuring the leakage current. The voltage
source was controlled through the IEEE-488 interface[184] and a PC with LabView[185].
The measurements were digitised using the same IEEE-488 interface with a Keithley
Model 199 System DMM/Scanner connected to the electrometer, see Figure 4.6.
The recorded current-voltage response for the chosen detector is presented in Figure
4.7. Here, the curve shows an initially steep increase in leakage current with applied bias
voltage. It then increases linearly, with a least squares fit calculated for values greater
than 15 V as m = 6.75 p A V -1 , which corresponds to a resistance of ~ 148 GQ1. Such
I-V characteristics are determined primarily by the series resistance of the undepleted
region which is long enough (~

1

mm) to be considered a long-base p-i-n diode, in

which partial recombination occurs prior to collection at the ohmic contact regions. In
1
As the gradient o f the line is determined to have a conductance of 6.75 p A V -1 and from Ohm ’s
law (R = V / I), the diode junction resistance is ~ 148 G fi.
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Figure 4.6: Schematic representation of the test circuit used for measuring the leakage
current-voltage characteristics of the detector diodes.

Reverse bias voltage [V]
Figure 4.7: Current-voltage characteristics for the single detector. Linear regression,
with slope, m, calculated using values 15 V and greater.
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a short-base p-i-n diode, a V V relationship is usually observed as recombination losses
are negligible.

4.2.1.2

Capacitance-Voltage Characteristics

It is important to understand the implications of the junction capacitance of a semi
conductor detector. This detector capacitance strongly affects the energy resolution of
spectroscopy measurements; if it is too high the device may be unsuitable for radiation
detector and dosimetry. Further details regarding diode capacitance are presented in
Section 3.1.1.4.
Using a Boonton 7200 Capacitance Meter[186] a reverse bias voltage was applied
to the detector and incrementally changed from 0.0 V - 50.0 V (below the breakdown
voltage) in 1.0 V steps. Prior to the measurement, the capacitance metre was zeroed
to account for the test circuit capacitance. The capacitance was recorded at each step
through National Instruments, LabVIEW [185] and the IEEE-488 interface[184]. The
electrical connection for the test circuit is diagrammed in Figure 4.8.
The measured capacitance-voltage characteristics of the detector are displayed in
Figure 4.9, where 1/C2 is plotted against V , a relationship that is usually linear
for diodes.

This detector has long-base diode geometry and does not exhibit the

characteristics of saturation.

The p-i-n diode capacitance decreased with applied

bias voltages greater than 2 V. Given both the increase in leakage current and the
decrease in capacitance with increasing bias voltage, 30 V was selected as an acceptable
operating voltage that did not require modification of the readout system to achieve.
At this voltage, the capacitance was measured to be ~ 1 pF and the leakage current
was ~ 300 pA.

4.2. CHARACTERISATION AND PERFORMANCE |83

Figure 4.8: Schematic representation of the test circuit used for measuring the
capacitance-voltage characteristics of the detector diodes using the Boonton 7200
Capacitance Meter[186]

Reverse bias voltage [V]
Figure 4.9: Capacitance-voltage characteristics for the single detector.
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4.2.2

System

The final aim of the chapter was to characterise the single detector system and assess its
performance. Characterisation of the detector, preamplifier and the readout electronics
as a whole system included: measuring the energy response through pulse height
analysis and measuring the angular dependence of the detector. The performance of
the system was assessed through the comparison of a measured depth-dose response,
and the TG-43U1 formalism.
Prior to taking measurements with the system it needed to be calibrated and have
a low-level discriminator set to exclude noise. The device was calibrated by placing a
single 125I seed of known activity (0.0116mCi) at a known distance ( 1 0 mm) from the
tip of the detector to the central axis of the seed in water. The reader converted the
number of counts that fell within an energy window (corresponding to 22keV - 35keV,
the major photon peaks of

4.2.2.1

125 I)

to absorbed dose in water.

Energy Spectrum

The energy spectrum measured and processed by the detector and readout electron
ics gave an indication of the energy resolution of the system and, thus, dosimetric
capabilities. For example, as the 125I spectrum lies within a relatively narrow window
(~ 15keV wide), a single calibration factor in conjunction with a low level discrim
inator is sufficient when calculating dose. This has been previously demonstrated
through spectroscopic dosimetry[159>1831. When low energy noise can be excluded, the
detector can operate in count mode, where the count rate measured is approximately
proportionally to the dose rate.
The front of the detector was positioned in close proximity to 5 x 125I seeds and
the surrounding medium, air, was used as it had minimal attenuation effects on the
spectrum. During measurement, the shaped spectroscopy pulses were output from the
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Figure 4.10: The spectrum of 5 x 125I seeds as measured in air by the single detec
tor system. The spectrum was calibrated using the 22.0 keV, 27.0 keV, 31.0 keV and
35.5 keV peaks and their corresponding locations within 1024 energy bins of the MCA.
The three dominant peaks where fitted to gaussian curves (illustrated in colour) using
the non-linear least squares method.

readout electronics and fed into a 1024 bin multichannel analyser, where a frequency
histogram (MCA spectrum) of the pulse heights2 was generated.

A measurement

time of about 38min (2.300ks) was used to ensure suitable statistics for a low noise
spectrum given the seed activity (0.32 mCi).
The energy spectrum measured (Figure 4.10) shows that noise increases with de
creasing frequency, close to the lower cut-off threshold. From energies of approximately
19 keV and greater, a set of distinct peaks of differing heights is depicted. These cor
respond to the 125I seed’s 35.5 keV

7

transition line, 27.0 keV and 31.0keV internally

converted x-rays and 22.0 keV fluorescent peak from the seed’s internal silver rod. At
energies greater than the edge of the highest energyp e a k , no counts are recorded.
2
The voltage output, measurable as the pulse height is proportional to deposited energy. For
further information, see Section 3.2
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4.2.2.2

Angular Dependence

The angular response of a detector provides information that is important for assessing
the detector’s suitability for use in dosimetry.

When a detector is considered to

have angular dependence, its response will vary in accordance to its orientation with
respect to the source. The geometry of the detector and surrounding structures are
primary influences on the angular response of a detector. This is due to differences
in effective attenuation, and hence measurable spectra deformation, that occurs at
different directions of incident radiation.
To conduct this characterisation, the probe was positioned centrally within a cylin
drical water phantom using a retort stand and clamp, as seen in Figure 4.11. The
phantom had a diameter of 130 mm, a height of 180 mm and a usable volume of approx
imately 2.0 L. It was placed centrally on a rotary platform which allowed for manual
orientation control at sub-degree precision. A single 125I seed of activity 0.101 mCi was
fixed vertically to a PMMA holder within the phantom in line with of the detector and
at a distance of 20 mm. The rotary platform was zeroed to a reference point on the
detector casing. From this point, measurements were made by rotating the platform
and seed about the stationary detector in 15° increments until a complete 360° sweep
around the detector was made. This motion is shown in the sub-schematic within
Figure 4.11. Other rotational axes of the detector were not considered due to the detec
tor always having an ‘end-on’ orientation with respect to the source during operation.
Each measurement consisted of a set of 5 x

10

s acquisitions. The spatial resolution

and integration time selected here were sufficient to illustrate the large dependency
effect of the detector, and further detail would not have provided deeper insight.
The results of the angular dependence measurements are shown in Figure 4.12.
The data shows the deviation of the mean response at each angle, from the mean
response from all measurements. Each datum point is accompanied by error bars of
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R otary platform

Figure 4.11: Diagram of the angular dependence experiment concept. The detector
was vertically aligned with a single 125I seed which was then rotated completely about
the detector’s axis. The top-down sub-schematic shows the seed-detector orientation.

Angle [degrees]
Figure 4.12: Normalised angular dependence of the single detector system measured
with a single 125I seed. Each point is the average of five measurements (errors to ±1^ ),
calculated as the percentage difference from the mean of all measurements.

4.2. CHARACTERISATION AND PERFORMANCE |88

one standard deviation each way, calculated across the five measurements.

4.2.2.3

Depth-Dose Response

To determine the dosimetric validity of the system, the dose rate of the central axis of
a plaque loaded with 10x 125I seeds, measured from the detector system, was compared
to that calculated using the TG-43U1 formalism. The plaque used was a standard
ROPES 15 mm model, the insert layout of which is illustrated in Figure 4.13. It was
fully loaded with ten Oncoseed 6711 125I seeds[187], giving a total activity of 0.116 mCi.
The vertical detector-plaque distance was varied within a phantom to generate a
depth-dose response from the detector system.
The detector probe was fixed to a linear micrometre positioner to allow for alignment
over the plaque and phantom and control of the vertical detector-plaque distance. The
phantom consisted of a high density polyethylene (HDPE) container filled with water.
The container was a 120 mm x 120 mm x 120 mm cube, in which a PMMA plaque
holder was placed at the bottom.

The plaque holder comprised a machined layer

of PMMA, and was used to position the plaque centrally within the phantom. The
detector was aligned over the centre of the plaque and zeroed to the plaque’ s surface
prior to starting measurements. See Figure 4.14 for a depiction of the experimental
apparatus.

4
^

&
I

Figure 4.13: An illustration of the acrylic insert for the ROPES 15 mm eye plaque that
was used in conjunction with its metal backing (not depicted) to provide a source for
the depth-dose curve. All ten seed slots were filled with Oncoseed 6711 125I seeds[187],
giving a total equivalent activity of 0.116 mCi.
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Figure 4.14: Diagram of the depth-dose experimental apparatus. The detector probe
was fixed to a linear positioner and aligned centrally over the plaque. The plaque
was fully loaded with ten 125I seeds and kept in place with a PMMA insert. The first
measurement was taken directly on the surface of the plaque to act as a reference
point for subsequent measurements, which were taken with the detector positioned at
increasingly greater distances from the plaque. The Virtual eye represents the position
of the patient’s eye relative to the plaque during the actual treatment.
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Measurements were taken for detector-plaque distances ranging from 1.0 mm 22.0 mm and were repeated to reduce error. Each point in the mean measured dose
rate series in the top plot of Figure 4.15 represents the average of 4 x 10 s intervals
for every given distance. The associated error bars to two standard deviations are
displayed for each point in the measured dose rate series.
As a comparison to current plaque brachytherapy treatment planning, a calculation
of the corresponding TG-43U1 formalism is also displayed in the top plot of Figure
4.15 with the percentage difference at each point from the measured values shown
in the bottom plot. In order to determine the dose from the plaque using the TG43U1 formalism, a software tool was written using C + + [188] and Digia’s Qt interface
libraries[189] to generate the super-positioned total from the ten seeds at their respective
orientations and positions within the ROPES plaque.

4.3

Discussion

The concept of using spectroscopic dosimetry for plaque brachytherapy was feasibility
tested using a single, silicon p-i-n diode. First, the detector was characterised in terms
of its current-voltage and capacitance-voltage characteristics. The detector was then
tested whilst integrated with the preamplifier and readout electronics in three methods:
energy response, angular dependence and depth-dose response.

4.3.1

Current-Voltage Response

Measuring the current-voltage response characteristics is a fundamental test for many
electronic structures. The expected current response of the p-i-n diode is similar to
that of the p-n junction shown in Figure 3.7. However, the main region of interest
for radiation detection lies between zero volts (unbiased) and the reverse breakdown
voltage. The data in Figure 4.7 shows that leakage current increased rapidly from
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Figure 4.15: Depth-dose plot of the single detector system is compared to the TG-43U1
protocol in the top plot. The percentage difference of TG-43U1/measured dose rates
is presented below in the bar graph, along with the corresponding scale errors ( 2 a).
The experiment involved the use of a fully loaded ROPES 15 mm plaque with each
125I seed having an activity of 0.116mCi.
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zero to ten volts, and then linearised to a constant rate of around 6.75 p A V -1 . The
device demonstrated expected behaviour as the measured IV curve was consistent
with that of an undepleted 1.2 mm long-base diode.

The operational bias voltage

used in the readout electronics was 30 V which pertained to a leakage current value of
approximately 300 pA. This lay within acceptable limits because it had not exceeded
the reverse breakdown voltage.

4.3.2

Capacitance-Voltage Response

The capacitance-voltage response of the p-i-n diode can be used to develop an expecta
tion of the signal quality. As explained in Section 3.1.1.4, a lower detector capacitance
helps to improve signal quality by improving the signal-to-noise ratio and more ac
curate dosimetry. The data displayed in Figure 4.9 shows capacitance (in pF) as a
function of reverse bias voltage.
The non-ideal shape of the curve, which should ideally follow a C a \J1/V relation
ship, can be attributed to an increase in sensitive area with voltage. This occurred due
to an edge effect that was significant as the geometric dimensions of the p-n junction
were similar to those of the lateral depletion, and lead to an increase in the effective
area of the p-n junction. This can be explained through the equation of the parallel
plate capacitor, C = trt0A/d which shows that capacitance is proportional to sensitive
area (A) and inversely proportional to depletion width (d). In addition to this, the
wafer thickness was large enough

(1

mm) that full depletion could not be reached before

breakdown occurred. This effect was seen as capacitance continues to decrease with
increasing voltage.
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4.3.3

Energy Resolution

Observation of the energy spectrum can give a good indication of the signal quality
and how distinguishable it is from low energy noise. Figure 4.10 shows the measured
photon spectrum of Oncura model 6711 125I seeds in air at room temperature with a
cut-off threshold energy of 15 keV. Gaussian curves were fitted to the dominant peaks
using the nonlinear least squares method. The full-width at half-maximum (FWHM)
values were calculated using the relationship FWHM = 2^2ln(2)a. The largest of the
peaks, at 27keV, yielded a FWHM of 2.1 keV, or about

8

%, and demonstrated the

acceptably low noise of the readout electronics. The 22.1 keV and 25.2 keV peaks were
emitted as fluorescent x-rays from the seed’s internal silver rod [187].
For this system to be used for practical dosimetry, the cut-off threshold should be
set around 19 keV to exclude as much unwanted noise as possible, whilst including the
full 125I spectrum. This is only possible through sufficient peak resolution, such as that
demonstrated here.

4.3.4

Angular Response

Angular dependence arises as a result of incident radiation becoming attenuated by
differing amounts, depending on the angle of arrival due to material type and thickness.
Thus, the extent of the attenuation that occurs is strongly dependant on the geometry
and topology of the silicon detector.
The angular dependence of the detector is plotted in Figure 4.12. It follows an
approximately sinusoidal shape with overall deviations ranging as much as ±3 0 % .
The shape of the data can be explained by the partial depletion of the long-based
detector (~

1

mm) which lead to strong attenuation of low energy photons emitted by

125I seeds, causing about a 60 % difference in count rates. Additionally, the globular
epoxy packaging of the detector may also have been a contributing factor for individual
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device asymmetry. This variation in material thickness would have also hindered the
correct centralisation of the detector and, hence, the distance between the effective
point of measurement and the seed, further affecting outcomes by possible eccentricity
in the rotation.

4.3.5

Depth-dose Response

The dosimetric functionality of the single detector system was evaluated by comparing
depth-dose measurements with the TG-43U1 formalism. From the literature reviewed
in Table 2.4, most dosimetry techniques have an uncertainty of between

8

% - 15 %. The

calibrated and normalised depth-dose curve shown in Figure 4.15 matched well, with
the TG-43U1 with points coinciding by less than around 4% for distances > 3.0 mm.
Distances less than this under-responded due to limitations in the ability of the TG43U1 algorithm to account for medium heterogeneities. This occurred, as the presence
of the metal plaque backing affected the backscattering conditions predicted in the
algorithm. Additionally, the uncertainty in the thickness and symmetry of the epoxy
packaging of the detector increased the error in small detector-source distances.
There are mixed accounts in the literature regarding the effects of plaque presence,
including: under-dosing I108,109!, overdosing at short range I110,113), backing material
dependent dose changes[114] or no effect at all[122]. Monte Carlo simulations have
shown that dose decreases occur at distances of 5 mm -

6

mm from the inner sclera

along the eye’s central axis in the range of 4 % - 20 % depending on the radionuclide
and backing material used. A sound dosimetry treatment planning and verification
method is needed to ensure consistency in the clinical community.
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4.4

Future Research

The concept of the system and its performance yielded promising results and established
justification for extended development into more complex detector designs. Despite
this, the single detector system offers for simple dosimetry solutions such as surface
dose measurements and depth-dose verification of plaques. A number of aspects of the
design could be optimised for future designs, including: the detector design, positioning
system and the information interface.

4.4.1

Diode Design

The existing detector design could be improved for dosimetric use by enabling closer
surface measurements and having less angular dependence.
In creating a system that is to be used in providing the depth-dose characteristics
of an assembled plaque, it is essential that it be capable of measuring most, if not
all, regions of interest. The sclera is an area that is subject to extreme dose and, as
such, profiling the dose in this region is critical. One limiting factor of the detector
investigated is the minimum distance at which dose can be measured from the plaque
surface (~ 1mm). By modifying the geometry of the detector and its packaging to
reduce unnecessary material, dose closer to the inner surface of the plaque could be
measured.
In addition to modifying the size and shape of the detector for positioning purposes,
the angular response of the device must also be considered. When vertically depleted,
the active implanted region (p+-type) should also provide full lateral depletion. A diode
with a very small, yet fully depleted, volume (0.5 x 0.5 x 0.1 mm3) would provide good
angular response and spatial resolution. The packaging of the detector and surrounding
probe need to be water equivalent minimise angular dependence and waterproof to
prevent damage. A suitable implantation and biasing configuration study should also
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be conducted to improve detector selection.

4.4.2

Positioning System

The accuracy could be improved in the positioning of both the diode and the plaque,
along with their relative distances. Whilst the linear positioner used operated at the
micrometre level, aligning the detector to the plaque was difficult as it was a manual
process and relied on vision. Using a common base plate, the phantom and positioner
could both be fixed and, given their known positions, detector localisation would be
inherently accurate. Unique phantom inserts would be required for each style of plaque
to ensure correct positioning and orientation of the plaque within the phantom.
Control over the vertical axis should be automated and computer integrated, pro
viding depth-dose curves with little need for attention during measurements. Extension
from such single dimensional, vertical measurements, to two or three dimensional posi
tioning could achieved through the computer controlled guidance of lateral positioning
systems. Such control would allow for plaque surface scanning and measurements of
planes, volumes and regions of interest. Mechanical operation of this system may be
much more time consuming and probably not optimal for everyday clinical practice.
Accurate detector zeroing could be determined using some form of proximity feedback,
such as a force, capacitance or optical sensor.
Some combination of automated and manual control would be suitable for clinical
use, depending on costs and dosimetry needs. A prototype positioner featuring auto
mated position control in the vertical direction was proposed and is depicted in Figure
4.16.
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Figure 4.16: Future development of a single detector system could include a gantry
using modular components. This figure shows an automated vertical positioning system
using a stepper motor for depth-dose sweeping functionality.

4.4.3

Software integration

The dosimetry system would benefit from software integration of its output, especially
when in conjunction with position controlling. Measured values could be sent to a
computer interface for real-time statistical analysis and curve plotting using position
values directly. Such software could improve plaque verification efficiency by integrating
it either directly, through an application programming interface (API) or through a
plug-in into current treatment planning software such as Plaque Simulator.

This

would provide the opportunity to make comparisons to the treatment plan for plaque
modification or acceptance in real-time.
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4.5

Conclusion

The single detector concept aimed to provide a simple dose verification tool for use
in clinical environments, in addition to determining the feasibility of continuing de
velopment into more complex and advantageous detector designs. To do this, a de
tector system comprising a p-i-n diode detector, preamplifier and readout electronics
was assembled. The aim to determine the operational characteristics of the detector
was achieved through measurement of both current-voltage and capacitance-voltage
responses. Furthermore, through the measurement of energy response, angular depen
dence and depth-dose response of the assembled system, the aim of characterising the
system assessing itsperformance was also fulfilled.
These experiments demonstrated the feasibility of the proposed concept of eye
brachytherapy dosimetry on the central axis of the plaque. Despite this, the p-i-n
diode used was suboptimal for this type of dosimetry. For further improvement, the
detector should allow for full depletion of the geometric volume which would reduce
the angular dependence of the detector response. The size of the detector should be
as small aspossible for two reasons:
1.

to provide high spatial resolution, which is needed due to the steep dose rate
gradient closer to theplaque surface, and

2

. to cause negligible perturbation of the radiation field without compromising
sensitivity of the detector.

To meet these requirements, the detector should be around 0.5 x 0.5 x 0.1mm 3 in
size. Additionally, under full vertical depletion, the active implanted p + region should
provide full lateral depletion. This would reduce attenuation of the low energy photons
from 125I seeds positioned laterally from the detector. Unfortunately, doing this would
also cause an increase in the surface leakage current as a guard ring cannot be placed
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around the p + region. The packaging of the detector should be water equivalent for
minimal effect on dosimetry and waterproof for protection during submersion.
To perform three-dimensional dosimetry, an eye phantom should be fitted with
multiple detectors sufficient for reconstruction to be performed.
It is not possible to satisfy all these design requirements simultaneously. For a
single detector probe, substrate material is required with pins for wire bonding. The
detector can be mounted on a thin waterproof probe and used within a water phantom.
The probe is long enough to allow for scattering conditions that resemble infinite water,
when used within a water phantom such as that in Figure 4.16.
For 3D dosimetry it would be impractical to use numerous individual detectors due
to the connection and interfacing logistics. Pixelated, monolithic silicon detectors offer
a solution to this issue, and also provide excellent definition of the pixel geometries.
However, the presence of the silicon substrate laterally surrounding each pixel is
disadvantageous for dosimetry.

The following chapter investigates the concept of

spectroscopic dosimetry with pixelated detectors.

Chapter 5
Pixelated Detector Concept
The previous chapter demonstrated the successful use of a single silicon detector for
spectroscopic dosimetry in plaque brachytherapy. The study is developed further in
this chapter, where pixelated detectors were investigated for their effectiveness in event
counting three-dimensional (volumetric) dosimetry of brachytherapy sources.
Two concepts for volumetric dosimetry were explored, both of which involved
creating numerous planar dosimetric images, whilst incrementally moving a pixelated
detector relative to the plaque. The first concept translated a rectangular detector
plane in a linear motion, while the second rotated a semicircular detector plane about
its axis. These concepts were tested using existing pixelated detectors from the Medipix
family [142’143].
Overall, this chapter aimed to assess the validity of using pixelated silicon detectors
for plaque brachytherapy dosimetry, and to offer improvements for detector design.
This was achieved through the following specific aims:
• assessing the feasibility of volumetric dosimetry;
• comparing count mode and charge mode dosimetry;
• assessing the activity variance in seeds;
100
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• determining the required spatial resolution;
• determining the affect of back scattering andphantom design; and
• measuring the accuracy of dose measurement of beta sources.

5.1

Pixelated Detectors

Since the early 1980s, planar fabrication processes have provided a means for devel
oping complex semiconductor devices [138>1391. They have since become popular for
studying ionising radiation events for dosimetry and many other applications [190>1911.
The pixelated semiconductor detector is a device that is fabricated with discreet sensi
tive elements, or pixels, and provides additional two-dimensional spatial information
about the measured radiation events. While there are benefits in having small sensitive
elements, there are also trade-offs with complexity in areas, including the readout
electronics.
With decreasing size of the sensitive volume of a semiconductor detector, there is an
associated decrease injunction capacitance and leakage current, as explained in Section
3.1.1.4. The decrease in these parameters leads to a decrease in the inherent noise,
thus improving the signal quality and providing more accurate dosimetry. Another
advantage of low leakage current is that devices may be operated without cooling at
room temperature, where otherwise thermal noise would be too great.
One issue faced when using detectors where pixels are both numerous and small
is the increase in complexity of connectivity to the readout electronics. When the
geometry of the detector permits, electrical connections using metal tracks on the
surface can be made between the individual pixels and the edge of the wafer for wire
bonding.

However, this method can result in losing too much active area on the

detector surface. As an alternative, a double-metal process can be employed where
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tracks are formed on two layers separated by an insulating glass layer, allowing for
more complex designs[192]. Track length affects the quality of the signal through the
increase in input capacitance it causes.
To mitigate these adverse noise effects whilst maximising the active area of the
detector, the readout electronics can be connected directly to one side of the detector,
forming what is called a hybrid detector.

This is achieved through designing the

readout elements to match the size of the individual detector pixels and bump bonding
them together. The design and fabrication of such a device is a relatively complex
and expensive process in circumstances when the simpler method of surface track
connectivity may suffice. For many applications, however, low noise hybrid detectors
such as those in the Medipix family are a very attractive technology.

5.1.1

The Medipix Detector

The Medipix detectors are a family of hybrid detectors that have been in development
since the Medipix1 Collaboration was formed in the early 1990s. There have since been
a number of successors and offshoots of the technology, including the Medipix2[142]
(see Figure 5.1), Timepix[143] and Medipix3[193].
Silicon pixelated detectors such as the Medipix2 and Timepix have been success
fully used in radiography, neutronography and micro-tomography I194-196! and are cur
rently being investigated for eye plaque dosimetry at the Centre for Medical Radiation
PhysicsI140,141!. These devices each consist of an array of 256 x 256 individual pixels
with a pitch of 55 pm x 55 pm and are capable of high resolution imaging with low
noise.
For deposited charges smaller than 50 ke- , the Medipix2 can operate up to a
maximum count rate of 1 MHz per pixel without pile-up[142], which corresponds to
a maximum activity of about 1 Ci, far beyond the normal scope of activities used
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Figure 5.1: Photograph of the Medipix2, a hybrid, pixelated detector with 256 x 256
individual pixels of pitch 55 pm x 55 pm.
in plaque brachytherapy. Additionally, the Medipix 2 detector is very radiation hard,
capable of operation at up to 300krad (3.00 k G y )[142]. Whilst the Medipix2 uses count
mode with a windowed discriminator, the Timepix builds on this and includes the
capability of effectively measuring charge using a time-over-threshold (TO T) mode.
This form of spectroscopic dosimetry can provide excellent outcomes, however it is
relatively more complex and costly, if otherwise avoidable when count mode could be
used.
This chapter investigates the feasibility of using pixelated detectors, through the
Medipix2 and Timepix, for the purposes of establishing the feasibility of two separate
design concepts for a volumetric detector for plaque brachytherapy.

5.2

Design Concepts

Two design concepts were considered to support the development of a volumetric
dosimetry tool for plaque brachytherapy; the first used a rectangular, pixelated detector
used in a similar, but inverted, fashion to the single detector concept (see Chapter 4 ),
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the second comprised a semicircular, planar pixelated detector to produce a volumetric
dose map in a solid phantom. Both concepts use motors to create controlled, accurate
and repeatable positioning between the detector and the plaque.
The dose volume created would be used for clinical preoperative treatment verifica
tion by extracting information in regions of interest, as one dimensional (depth-dose),
two dimensional (planar slices), or three dimensional (dose volume) data sets. These
dosimetric results could be directly compared to existing treatment plans in real-time
to provide valuable dose verification to plaque brachytherapy.

5.2.1

Translation Concept

A primitive version of the translation concept was seen as the single detector concept
in Section 4.1, and is adapted in this chapter for use with a pixelated detector. The
concept essentially involves incrementally lowering a brachytherapy plaque to the
bottom of a water filled vessel. At each stationary point along the way, the pixelated
detector acquires dosimetric data in conjunction with the current position and stores
it. The series of recorded measurements can be used to reconstruct volumetric dose
distributions, as shown in Figure 5.2b. These distributions provide detailed information
for comparison to patient treatment plans. The general hardware configuration of the
concept is depicted in Figure 5.2a, where the Virtual eye represents the location of a
patient eye during treatment. This concept is investigated experimentally with the
Medipix2 detector in Section 5.3.1.1.

5.2.2

Rotation Concept

The rotation concept uses a semicircular detector, designed to fit closely against the
inner surface of an ophthalmic plaque. A tissue equivalent phantom is used to occupy
the volume surrounding the detector in a shape and position which corresponds to the
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(a) Plaque translation concept

(b) Dose volume construction

Figure 5.2: A rectangular pixel detector array, embedded in a tissue equivalent phantom,
is positioned below a water filled vessel, where the brachytherapy plaque is lowered
towards it in discrete intervals for providing a volumetric set of data.

(a) Plaque rotation concept

(b) Dose volume construction

Figure 5.3: The ophthalmic plaque is rotated about its central, vertical axis while a
semicircular pixel detector array, embedded in a tissue equivalent phantom, remains
stationary to provide a volumetric sweep of measurements. Single planar measurements
are made for multiple plaque-detector angles and superimposed to create a dose volume.
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eye ball in a treatment, as shown in Figure 5.3a. This geometry allows for a planar
dose map to be created for a cross-section of the eye that passes through the central
axis of the plaque. If the plaque is rotated about this axis, different cross-sectional dose
maps can be measured, corresponding to the angle of rotation. When a set of these
maps is reconstructed as a whole, a dose volume from the plaque can be produced, as
depicted in Figure 5.3b. This concept is investigated experimentally with the Medipix2
detector in Section 5.3.1.2.

5.3

Proof of Concept

In order to evaluate and demonstrate the working principles of the pixel array design,
several tests were conducted. This involved using proven silicon pixel detector arrays
designed by the Medipix Collaboration, namely the Medipix2[142] and the Timepix
detectors[143]. The high resolution capabilities of this family of detectors provided
an ideal foundation for determining the system requirements for this study, allowing
for volumetric dose reconstruction prototyping, comparison between count and charge
modes of operation, detailed seed dosimetry and detector resolution investigation.
The detectors were also used to evaluate specifics of preliminary phantom design and
effectiveness of measuring beta-emitting plaques.

5.3.1

Volumetric Dosimetry

Volumetric, or three-dimensional, dosimetry plays a useful role in gaining a good
understanding of the complex and steep dose fields and gradients within the eye during
a plaque brachytherapy treatment. This study looked at two concepts for generating
volumetric dose: translation[141] and rotation [140>1971.
In order to view the differences in dose distributions and the potential for plaque
customisation, two seed configurations were used in the ROPES 15 mm plaque during
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(a) Asymmetrically loaded (5 seeds)
Figure 5.4: The ROPES 15 mm eye plaque loaded with 125I seeds, as indicated by
shading. The annotated arrows indicate the direction used for orientation.

the concept evaluations. They comprised an asymmetric configuration of five seeds
(Figure 5.4a) and a fully loaded configuration with ten seeds (Figure 5.4b). The seeds
used were Oncura model 6711 125I with an activity of 239 pCi each.

5.3.1.1

Translation Concept Evaluation

If the detector array is structured as a regular grid, converting to a three-dimensional
array is trivial. Using the data in this form, it is possible to interpolate between points
in 3D space when appropriate. This concept was investigated experimentally with the
Medipix2 detector and a layered phantom. The method detailed below was used as
the original proof of concept, prior to the revised design in Figure 5.2a which was used
from Section 5.3.2 onward.
The layered phantom consisted of a 0 40 mm, paraffin wax hemisphere cut into
5 x 4 mm slices, as seen in Figure 5.5. Historically, paraffin wax was commonly used
as a tissue substitute and, whilst would not be used in a final design, is more than
sufficient for prototyping use[198].
The slices were stacked concentrically atop one another with the plaque positioned
at the apex. The plaque was oriented with the insert aligned towards one corner of
the detector. The Medipix2 detector had a 4 mm polypropylene protective shroud
around it, a polypropylene insert to protect the detector, and a

20

mm slab of tissue

equivalent Plastic Water® L R [180] below it. Removing one slice at a time, the detector
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(a) Exploded view
Figure 5.5: Paraffin wax, layered phantom for testing the translation concept. In the
exploded view, the Medipix2 detector is seen below four of the wax phantom slices
and the eye plaque.

was used to take a measurement in place of each removed slice. Each measurement
corresponded to a different depth within the eye and consisted of the integrated total
of 500 x 1.0 s acquisitions. The method produced five planar measurements for each
plaque configuration set, as seen in Figure 5.6a and Figure 5.7a.
These Medipix acquisition parameters were selected to establish consistancy be
tween measurements conducted in this study and future measurements and to allow
for visual feedback at each frame. Event pile-up was not a concern, with the maximum
count rate of the Medipix2 at 1 MHz, however, its 13 bit counter depth (allowing up to
8191 events per frame) necessitated multiple frames per acquisition. The 500 s total
duration gave a mean event rate of ^ = 1716 events per pixel at the lowest intensi
ties (using five seeds with the detector at the farthest layer from the plaque) and a
corresponding measurement uncertainty of a/^ = 1 /^ ^ = 2.41 %, demonstrating the
statistical suitability of the data. The sampling parameters for the highest intensity
measurement are provided in Table 5.1.
The data was stored in a 3D matrix using computational software (Mathworks

5.3.

(a) Stacked Layers
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(b) Isosurfaces

Figure 5.6: Translation concept volumetric dosimetry verification with ten seeds in
ROPES 15 mm plaque. The vertical axis shows the distance of the detector from the
source in millimetres, and colours depict the number of events counted. The left image
illustrates the raw data, and the right image shows an isosurface representation of the
interpolated 3D dose volume.

(a) Stacked Layers

(b) Isosurfaces

Figure 5.7: Translation concept volumetric dosimetry verification with five seeds in
ROPES 15 mm plaque. The vertical axis shows the distance of the detector from the
source in millimetres, and colours depict the number of events counted. The left image
illustrates the raw data, and the right image shows an isosurface representation of the
interpolated 3D dose volume.
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Table 5.1: Sampling parameters of the Medipix and Timepix. The measured event rates
correspond to the count mode highest intensities where the detector was positioned
proximate to the plaque for 1 0 x 125I seeds configuration. The parameters above the
division are generic device specifications, and those below are measurement specific.
Source: Llopart et al.[142].
Parameter
Acquisition frame time
Bias voltage
Max pixel count rate
Pixel counter depth
Electronic pixel noise rms (adjusted)
Timepix clock
T O T frame time
Mean measured event rate
Max measured event rate

(a) Asymmetrically
loaded ( 1 0 seeds)

Value
1 .0 s
100 V
1 MHz
13 bits/pixel
140 e10 MHz

498.8 ps
48. 3 events /pixel /frame
62.0 events /pixel /frame

(b) Fully loaded (5 seeds)

Figure 5.8: The approximate ROPES 15 mm plaque orientations for the measurement
at the topmost layer of the paraffin wax translation phantom for both 10 and 5 seed
configurations. The darkened seed slots indicate the presence of seeds, and the faded
slots indicate their absence.

5.3. PROOF OF CONCEPT | 111

Matlab 2012a[199]). It was then interpolated using the cubic spline m ethod[200] to
improve the resolution between slices as needed for volumetric visualisation.

The

results for this set of experiments are presented in Figure 5.6 and Figure 5.7. The
left hand image of each of these Figures shows the Medipix images stacked atop each
other, covering the 25 mm vertical span of the measurement, with the plaque located
closest to the top layer. The approximate orientation of the plaque with respect to the
Medipix detector is depicted for both seed configurations in Figure 5.8.
The corresponding image on the right hand side shows an isosurface plot of the
interpolated data. Each isosurface shell represents a dose surface of a constant value,
as indicated in their respective legends.
The asymmetric distribution of the five seed results of Figure 5.7 is visible for the
shortest plaque distance, but becomes less obvious with increasing distance. The ten
seed configuration of Figure 5.6 shows a mostly symmetric result by comparison. It
also shows a notch feature present towards the centre of the dose distribution in the
topmost layer.

5.3.1.2

Rotation Concept Evaluation

In contrast to creating a stack of parallel dosimetric images, the rotation concept
aimed to generate a set of overlaid dose images, rotated about an axis, that form a
three-dimensional dose volume. The process involved taking planar dose measurements
whilst controlling the angle between the detector plane and the central axis of the
brachytherapy plaque. To evaluate feasibility of this concept, the Medipix2 detector
was used in conjunction with a hemispherical, a paraffin wax phantom and a ROPES
15 mm brachytherapy plaque with Oncura model 6711, 125I seeds. The activity of the
seeds were 238 pCi each.
The plaque was located centrally upon the

40 mm phantom and moved to four

different positions in a trajectory across the surface of the phantom, as per Figure
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Figure 5.9: The experimental operation of the rotation concept.
different angles used in the trajectory of the plaque.

There were four

5.9b. The four plaque-detector angles used in the measurements were: 90°, 75°, 45°
and 22°, where the plaque axis is defined as 90° and the detector plane is 0°. The
orientations and angles are illustrated schematically in Figure 5.9a. Each position was
measured as the integrated total of 500 x 1.0 s acquisitions. Two sets of measurements
were conducted: one using an asymmetrically loaded five seeds and the second fully
loaded with ten seeds, see Figure 5.4.
The individual measurements taken with the ten seed configuration are shown in
Figure 5.10. The plaque source was closest to the detector at the 22° measurement
and furthest at the 90° measurement. The dose rate of these images was normalised at
100% to the maximum of the set. The separate layers were spatially reconstructed by
converting them to a 3D coordinate system and superimposing them, where a sparse
dose volume was created, as seen in Figure 5.11.
The spatial reconstruction of the five seed configuration measurements is shown
in Figure 5.12. Here, the dose rate values were normalised to the ten seed data for
comparison, however, the colour bar is scaled to its local maximum to provide greater
contrast. The five seeds were arranged asymmetrically, as shown in Figure 5.4a, and
aligned normal to the plaque trajectory. This asymmetry is unclear in the data as the
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Figure 5.10: Measurements taken using the Medipix2 detector for angular concept
verification with 1 0 x 1251 seeds (Oncoseed model 6711) in the ROPES 15mm plaque.
From left to right, top to bottom, the angles used are 22°, 45°, 75° and 90°.

Figure 5.11: Reconstructed volume of the four dosimetric images taken with the
Medipix2 with the ROPES 15 mm plaque fully loaded with 1 0 x 1251 seeds (Oncoseed
model 6711). Note: plaque and eye phantom not to scale.
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Figure 5.12: Reconstructed volume of the four dosimetric images taken with the
Medipix2 with the ROPES 15 mm plaque partially loaded with 5 x 125I seeds (Oncoseed
model 6711). Note: plaque and eye phantom not to scale.

minimum plaque-detector distance was inhibited by the phantom size and the inability
to measure angles less than

5.3.2

22°

due to detector geometry.

Spectroscopic and Counting Operation

Following the proof of volumetric dosimetry, the next aim was to determine whether
the event counting operation of the Medipix2 is significantly similar to the timeover-threshold (TO T) (spectroscopy) mode of the Timepix for 125I dosimetry. For
verification of the principle, the event mode results are compared to calculations from
the TG-43U1 formalism. By providing the equivalent of the total integrated charge
generated in each pixel, the operation of the Timepix in T O T mode could be considered
to measure charge from the detector in an integral mode by current integration.
Previously, it was established that event counting is sufficient for spectroscopic
dosimetry for 1251 seed dosimetry in prostate brachytherapy[159]. Due to the 125I
spectrum resulting from low energy photons with a relatively narrow energy spread,
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radiation hardening 1 effects are not significant across the three major photo peaks, as
they undergo similar levels of attenuation. Considering this, a dosimetry system based
on an event counting design is feasible and could be developed at a lower cost than
would otherwise be possible with a more complex charge measurement (spectroscopy)
system.
There was no tissue equivalent material placed below the detector in the first part
of this experiment in order to observe the effect of a change in the scattering material
present for different orientations of the plaque during a treatment. Placement of the
plaque on the eye ball depends on the location of the tumour, for example, posterior
or temporal placement. This will result in a relative change in the location and, hence,
the effect of the air-eye interface between patient cases. However, tissue equivalent
material is used as backing, below the detector, during TG-43U1 comparison.
The translation phantom used in this study improves on the previous, layered
design used in Section 5.3.1.1 to result in a design similar to the original concept shown
in Figure 5.2a. This improvement gave greater flexibility in plaque-detector distances,
rather than being defined by the wax layers, in addition to better tissues equivalence
due to the presence of water rather than paraffin wax. Here, the brachytherapy plaque
was positioned within a water phantom, with the Medipix detector measuring from
below as seen in Figure 5.13. This system used a PMMA column to move the eye
plaque through a small, cylindrical water phantom, 100 mm x 0 29.5 mm in size. In
contrast to the previously investigated method, this system consisted of a stationary
detector and a positionable plaque. This allowed the plaque to be surrounded by water
for a tissue equivalent environment, whilst keeping the detector and electronics dry and
safe. The plaque used was a 15 mm ROPES model fully loaded with 10 x 390 pCi125I
seeds (Oncoseed Model 67111187!).
1Radiation hardening, or beam hardening, is the process of increasing the mean photon energy of
a polyenergic radiation field through the earlier attenuation o f the lower energy photons relative to
those with higher energies.
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Figure 5.13: A schematic representation of the apparatus configuration including the
Timepix detector placement below a water filled vessel.
Fixing the plaque to a linear positioner enabled fine control over the placement
of the plaque relative to the detector. It was translated along a vertical axis which
was both normal and central to the detector surface. The phantom, a water filled
vessel, was placed as close as safely possible to the surface of the detector.

The

plaque was immersed within the phantom and measurements were taken at discrete
intervals between the beginning and final position of the plaque, during which the water
volume remained constant. Initially, the plaque was zeroed and aligned at the closest
possible point to the detector from within the phantom. Event counting and TO T
measurements were taken subsequently at each position using the Timepix, minimising
any geometric error between them.
The data collected from the detectors consisted of a 256 x 256 square array of
values for each distance and mode. Each acquisition was taken over a period of 500 s,
which was composed of the integration of 500 x 1.0 s acquisitions. This was sufficient
to prevent counter overflow for the given source activity and provided low counting
uncertainties (less than ~

1 %).
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Figure 5.14: Spectrum of 10 x 125 I seeds in ROPES plaque taken with Timepix in
TO T mode. The phantom included the presence of backing material and the detector
was located 2.4mm from the source. The fitted curve is gaussian and represents the
combined peaks of the 125I spectrum.

Since total energy deposition was measured in T O T mode, pile-up events had no
detrimental effect on the outcome. Whether a measured charge pulse event originates
from a single or multiple incident photons (pile-up) does not effect the integrated TOT
value[201]. The source activity gave a count rate of 121 events/pixel/second, which
falls far below the maximum count rate (1MHz) or count depth (2 13 — 1 = 8191) of
the Medipix2, and thus neither pile-up nor overflow effects were present in event count
mode.
Prior to conducting the measurements, the Medipix detector was calibrated to
significantly reduce noise and equalise pixel response. Through the Pixelman software
(v1.9.2 working, b.2008-04-03)[202], the dedicated
and the

3

8

bit global threshold for all pixels

bit fine tuning threshold for individual pixels were adjusted down to the noise

floor[203]. Figure 5.14 shows an example of the 125I plaque spectrum measured within
the phantom that used backing material. It was measured using the Timepix in T O T
mode and illustrates the lack of a significant presence of low energy noise due to the
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threshold equalisation process. The individual spectral peaks of the 125I spectrum in
Figure 5.14 have been lost by scattering though the phantom. The sampling parameters
for Medipix and Timepix are presented in Table 5.1.
To generate the depth-dose curve for analysis, a 10 x 10 sample was taken from
the centre of each of the matrices and the values were averaged. Each pixel had a
square pitch of 55 pm, giving the sample region an area of 550 pm x 550 pm. The
two sets of points were then plotted against their corresponding depths to generate
the depth-dose curves presented in Figure 5.15. The percentage difference of the two
curves is presented in the bar graph below with corresponding error to two standard
deviations.
The error associated with the event counting data set ranges from 0.45 % up to
1.33%, though the error bars cannot be distinguished on the plot. The results show
that, for the full range of distances measured (2.4mm - 15.9mm), event counting
and charge mode (TO T) agree to within less than ±0.45% error. This error linearly
decreases in value with increasing distance with an R 2 value of

0 .8 6 6 8

.

To allow comparison between event counting mode and the TG-43U1 formalism, a
water equivalent environment surrounding the detector and plaque was needed. This
was achieved by placing a tissue equivalent block of Plastic Water® below the detector,
as per Figure 5.2a. The resulting set of data is plotted against the TG-43U1 formalism
calculations in Figure 5.16. This calculation was performed using a software process
with superpositioned dose rates along the central plaque axis taken from the individual
seeds of the ROPES plaque. Agreement between the curves falls between +25 % and
- 5 % for all distances. This error increases most substantially for decreasing distances
approaching the plaque, less than around 7mm.
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Figure 5.15: The depth-dose curve of both number of events and the total energy of
events over 500 s intervals using the Timepix is presented in the top plot. The bar plot
at the bottom shows the percentage difference of the event mode / T O T mode and the
associated error (2a). The source was a 15mm ROPES eye plaque with ten 125I seeds.
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Figure 5.16: The depth-dose curve of event counting mode measurements are compared
to the TG-43U1 formalism. The source was a 15 mm ROPES eye plaque with ten 125I
seeds. The associated error has a confidence interval of 95% (2a).

5.3. PROOF OF CONCEPT | 121

5.3.3

Seed Variation and Resolution

The next stage of the investigation was to observe the spatial variation in the activity
distribution of 125I brachytherapy seeds with the Timepix detector directly. This was
conducted to assess the activity variation of seeds between and within two manufacturer
seed batches in order to quantify potential uncertainties that may be addressable
through a dose verification tool. This study was also used to demonstrate the resolution
of the detector to determine its suitability for such a tool.
The seeds were placed on a thin plastic sheet (40 pm thick) on the surface of the
Timepix. In order to preserve the anonymity of the manufacturers, they will hence
forth be referred to as Manufacturer 1 (M1) and Manufacturer 2 (M2). The sets of
measurements consisted of measuring four different seeds for M1 and five different
seeds for M2. The seeds were placed on the detector in an approximately vertical
alignment, as per Figure 5.17.
The measurements for each seed were conducted in integrating count mode for
500 x 1.0 s acquisitions. Through image processing in MathWorks Matlab 2012a[199],
the seed data was oriented and translated to a common position, vertical and centred.
This was achieved through an iterative combination of matrix transformation processes
and cross correlation template matching, until an optimal transformation was reached.
Once each seed had been reoriented, mean values and standard deviations across the
samples were determined for each manufacturer set.
The batch activity of the seeds was 382 pCi for M1 and 215 pCi for M2.

The

variation in the total activity between seeds was eliminated through the normalisation
of the data sets. Given that the average number of counts in the areas of interest
was in the order of 250 x 103, the corresponding error is approximately ±500 counts
or ± 0 .2 0 % whilst the mean error in counting across all pixels and measurements was
0.74%.
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Figure 5.17: A single 125I seed was placed on a thin protective plastic sheet atop the
surface of the Timepix detector to measure the dose distribution in count mode.
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Figure 5.18: Combined data from four seeds for Manufacturer 1
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It can be seen from the plots in Figure 5.18 that the sample of seeds tested from M1
does not yield a uniform activity distribution. The bottom end of the seed (~ #160 on
vertical channels) in the mean activities map for M 1 has a significantly higher activity
to the top end (~ #100 on the vertical channels), with a difference of 12.5%. The
section of seed between these points has a relatively lower mean activity. The per
pixel standard deviation associated with this sample set indicates a large variation of
activity between the seeds, with the greatest discrepancies occurring at the ends of the
seed at around 14 %.
The count data measured from M2 in Figure 5.19 on the other hand demonstrates
a considerably more uniform seed activity model. There are a lack of obvious activity
hot spots or cold spots occurring anywhere on the mean activities map and the expected
anisotropic function is clearly visible. The per pixel standard deviation plot for M2
demonstrates that it features the greatest amount of inter-sample error present at the
ends of the seed, and that the sample set overall has a lower error than that of M1 at
around 9 %.
The data shown in Figure 5.20 consists of a combination of both manufacturer data
sets, giving a total of nine seeds. In the standard deviation map of this data, displayed
on the right, it can be seen that the greatest deviations occur at the ends of the seeds
at around 21 %. This plot demonstrated the differences in dose distribution that occur
between seeds of the same batch and those of different styles. It also demonstrated the
potential of high resolution pixelated detectors in dosimetry for plaque brachytherapy.

5.3.4

Resolution Requirements

In terms of retrieving detail from an image, higher resolution generally is preferable.
However, image processing complexity, data storage, design complexity and feasibility
are less demanding at lower resolutions.

Whilst processing power and storage in
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Figure 5.19: Combined data from five seeds for Manufacturer 2.
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Figure 5.20: Combined d a t a from nine seeds for both Manufacturers.
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current computing technologies are negligible issues for most tasks, limitations can
arise regarding design complexity and feasibility. The aim of this study was to estimate
and demonstrate the minimum required resolution for use in a dose verification tool
for eye plaque brachytherapy.
In this study, a priority of proof of concept and reliability outweigh the need for
optimisation and high end system performance. As such, the pixel resolution of the
detector need only be adequate enough to resolve the finest details of interest, i.e.
dose at the optic nerve (~ 0 1.6 mm). According to the Nyquist-Shannon sampling
theorem[204], in order to resolve this level of detail a pixel half this size is needed (i.e.
800pm). This value was selected as an initial design specification and may be refined
in later designs.
Data taken from the top and most proximate layer to the plaque in Figure 5.7a was
used as an example in Figure 5.21 to indicate the level of detail loss that would occur
for a given pixel size. The Medipix2 consisted of 256 x 256 pixels of 55 pm x 55 pm
pitch which, considering the sampling theorem, allows resolution of details that are
110

pm in size. As this resolution exceeds the requirements of the system to be designed,

downsampling of the image was used to simulate the effect of a lower resolution detector.
Downsampling was achieved by averaging groups of pixels by factors of

8

, 16 and

32 to give a new pixel size of 440 pm, 880 pm and 1760 pm, as per Figures 5.21b, 5.21e
and 5.21h, respectively. Downsampling an image by a factor of n involved calculating
the means of groups of n x n pixels, at a pitch of n x n.
Table 5.2: Summary of statistics for difference maps generated downsampling with
three sampling factors and interpolating back to original size.
Sampling factor

Pixel size (pm)

N

x8
x16
x32

440
880
1760

1.29%
2.59%
5.03%

a %
1 .0 2

%
1.87%
3.66%

|max|
9.30%
12.85%
19.37%
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Figure 5.21: Demonstration of the effect of image resampling on a normalised mea
surement of five 125I seeds. Averaging of pixel groups with three different sampling
factors ( 8 , 16 and 32) was used in downsampling and the bicubic method[205] was used
for interpolation.
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In order to gain some idea of the extent and location of loss of detail from this
process, the downsampled images were then interpolated back to original size using
the bicubic interpolation m ethod[205] and the differences were shown by subtraction
of these from the original image. The interpolated images are shown in Figures 5.21c,
5.21f and 5.21i and their corresponding difference maps are shown in Figures 5.21d,
5.21g and 5.21j, respectively.
Errors between the interpolated and original images are up to approximately 9 %,
13% and 19% in localised regions for factors of

8

, 16 and 32, respectively. This is

particularly prominent in high dose gradient regions around the edge of the images
where the interpolation process is less accurate. The mean magnitude of the errors
between the images is 1.29%, 2.59% and 5.03% for all pixels, whilst the standard
deviation is 1.02 %, 1.89 % and 3.66 % for sampling factors of 8 , 16 and 32, respectively.
These statistical findings are summarised in Table 5.2.

5.3.5

Backscatter and Phantom Design

The aim of this study was to investigate the effect of backscattering from the material
downstream of the detector to better understand the phantom design requirements for
thed o s e verification system beingdeveloped as the overall aim of this thesis.
Two sets of measurements were taken with different scattering conditions to de
termine the effect of eye tissue between the eye-air interface and detector. This was
performed using the translation water phantom, the Medipix 2 detector, a block of
tissue equivalent material and a ROPES 15 mm plaque loaded with ten 125I seeds of
activity, 60pCi each. The apparatus is depicted in Figure 5.22, where the Virtual eye
represents the equivalent location of the patient’s eye during treatment.
Scattering conditions were controlled through the presence of the tissue equivalent
material below the detector, labelled TE backing in Figure 5.22. The material used was
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Figure 5.22: A schematic representation of the apparatus configuration for testing the
effects of backscattering. The detector is placed below a water filled vessel and above
a tissue equivalent (TE) material slab[180].
a 50 mm x 100 mm x 100 mm block of Plastic Water® L R ,[180]. A series of measure
ments were taken for each configuration for plaque-detector distances in the range of
2 mm - 16 mm. Each measurement was the integrated total of 500 x 1.0 s acquisitions.
As per the method used in Section 5.3.2, the central

10

x

10

pixels were averaged

for each measured distance and subsequently plotted against their respective distances.
This process was performed for both backscatter configurations and the results are
displayed in Figure 5.23. In addition to these data series, the percentage increase
in counts with the addition of the tissue equivalent material was plotted against the
secondary axis in Figure 5.23 for comparison.
Errors in the event count datasets are ±300 pm in distance and range from 0.49 % 1.29% and 0.50% - 1.30% for configurations with and without backing material,
respectively. The addition of backing material caused overall dose enhancement, as
expected due to increased backscattering. This enhancement was approximately 3.5 %
at 3.5 mm and increased to a maximum of 6.71 % at 5.19 mm. The dose enhancement
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Figure 5.23: The depth-dose response of a 15 mm ROPES eye plaque with and without
the presence of a 50 mm tissue equivalent block of Plastic Water® below the detec
tor. The central 10 pixels x 10 pixels of the Medipix2 were averaged for each depth
measured.

tapered off towards zero for distances beyond the peak.

5.3.6

Beta Source Evaluation

Ideally, a robust dosimeter for plaque brachytherapy should be able to measure dose
from most, if not all, of the different radionuclide sources used in the treatment. Whilst
the radionuclide of focus in this study is the low energy gamma emitter,

125 I,

it was also

beneficial to determine the potential and limitations of silicon pixelated detectors for
dosimetry of other radionuclides. Therefore, the aim of this study was to measure the
accuracy of dose measurement of beta sources using such detectors. The beta emitting
plaques from BEBIG[56] are a different style to the ROPES models previously tested,
and better suited to small tumours. They consist a of thin layer of

106 Ru,

electrically

deposited on silver foil and encapsulated by a silver backing.
The parent radionuclide, 106Ru has a half-life of 374 d and disintegrates to the
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daughter product,

106 Rh,

via a beta decay (Q value = 39.4keV). The majority of the

therapeutic dose is delivered from the unstable

106 Rh,

which has a maximum energy

of 3.54 MeV and a half life of about 30 s.
Using the translation water phantom, described in Sections 5.3.2 and 5.3.5, with
Plastic W ater[180] placed below the detector as backing material, dose distributions
were measured for two types of BEBIG plaques, type CCA and type COB. The CCAtype plaque is circular in shape, with a diameter of 13.5 mm, as depicted in Figure
5.24a. The COB-type plaque is larger at 19.8 mm diameter and has a notch shaped
into it, seen in Figure 5.24b.
The measurements involved aligning the plaque normal to the detector plane by,
first, resting it on a flat block with the suture eyelets overhanging the corner so as
not to impede its orientation. The plaque was then fixed to a vertical PMMA tube
using the suction of a vacuum pump to seal against its smooth outer surface. A linear
positioner with micrometre precision was used to support the tube over the phantom
and detector.
Lateral orientation was achieved by positioning the plaque over the detector as close
as the plaque’s suture eyelets would allow from within the phantom. With the Medipix
detector sampling at a frame rate of about one frame/second the lateral position was

(a) CCA (,015.3 mm)
Figure 5.24: Geometric shape of BEBIG plaques which have a thin film of 106Ru
deposited onto a silver backing. The radioactive area is marked in colour. Adapted
from Eckert & Ziegler BEBIG GmbH[56].
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adjusted accordingly, until centralised.
The Medipix detector was used to take the integral of 500 x 1.0 s acquisitions at
incrementally increasing depths from within the water phantom. This ensured that
enough statistics were taken to obtain uncertainties of less than ~ 1.5% for regions of
interest. There were a total of 17 measurements with absolute distances ranging from
3.0 mm - 28.2 mm (±500 pm for the group, ±500 nm between individual measurements).
After zeroing to the minimum range, the positioner was used to adjust the distance.
Figures 5.25a and 5.26a show the dosimetric images at the closest position for CCA
and COB type plaques, respectively. The images were normalised to their respective
dose maximums.
For comparison, the Plaque Simulator 5.0.0 software by BEBIG [22] was used to
generate dosimetric images of both plaque types at a distance of 3 mm. These images
are displayed in Figures 5.25b and 5.26b for plaques types CCA and COB, respectively.
The image from the CCA plaque in Figure 5.25a shows that the plaque was centrally
aligned to the detector and that the dose distribution increased to a maximum in the
centre. In comparison, the dose map produced by the software shows a much more
uniform distribution in the central region, with a drop off occurring at around 4 mm 5 mm.
In Figure 5.26a the dose distribution from the COB type plaque is non-uniform
with maximums at two hot spots located symmetrically on either side of the notch.
The area between is approximately 70 % - 80 % of the maximum dose. The dose map
from the corresponding Plaque Simulator COB-type plaque output is shown in Figure
5.26b. It has a much more uniform coverage in a crescent moon shape (“ ^ ”).
At locations centred through the points of interest annotated in Figure 5.25a and
Figure 5.26a, the mean value of 10 pixels x 10 pixels were calculated for each depth.
Depth-dose plots were generated for the CCA-type plaque and the COB-type plaque,
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Figure 5.25: Dosimetric images taken at 3 mm for measured and calculated BEBIG
CCA-type plaque, with distances in millimetres. The black cross on the measured
image indicate the points of interest taken for the depth-dose curve.
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Figure 5.26: Dosimetric images taken at 3 mm for measured and calculated BEBIG
COB-type plaque, with distances in millimetres. The measured COB-type plaque
shows two hot spots (red) instead of the expected “ ^ ” shape, resulting from non
uniform deposition of the radionuclide. The black crosses on the measured image
indicate the points of interest taken for the depth-dose curve.
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respectively.

Two depth-dose curves are displayed for the COB type plaque, one

through the geometric centre of the plaque and the other through one of the hot
spots. Depth-dose curves for each plaque were also generated using Plaque Simulator
5.0.0. The curves were taken through the central axes of each of the two plaques, and
were plotted on the same graphs as their corresponding measured plaque types. The
manufacturer uncertainty of 20% (2 a )[206] has also been plotted for each point. The
curves were normalised to 100 % at 7.7 mm for the central axes.
Figure 5.27 shows that there is excellent agreement between the measured and
calculated CCA-type plaque, within the manufacturer range of error. The overlapping
distances between the methods covered the range of 6.5mm - 12.0 mm, with 12 mm
being the centre of the eye.
The divergences are larger between the measured and calculated COB-type plaques,
as displayed in Figure 5.28. Here, the difference between the plots exceeds the un
certainties for the data and the curves exhibit dissimilar dose rate gradients. The
measured difference between the maximum value of the hot spot recorded and that of
the centre of theplaque is approximately

5.4

20

%.

Discussion

The feasibility of using a pixelated silicon detector for plaque brachytherapy dosimetry
was tested using the Medipix family of detectors. This was done by evaluating two
potential designs, the translation concept and the rotation concept. In addition to
this, a number of investigations were undertaken; the suitability of event counting for
125I dosimetry; variation in seed dose distributions; resolution observations; the effect
of backing scatter in a phantom; and finally, the dosimetry of beta-emitting plaques.
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Adjusted depth [mm]
Figure 5.27: Depth-dose curves for measured and calculated CCA-type plaques. The
curves are taken through the points of interest marked in Figure 5.25. Distances are
measured from the central axis of the inner surface of the plaque.

Adjusted depth [mm]
Figure 5.28: Depth-dose curves for measured and calculated COB-type plaques. The
curves are taken through the points of interest marked in Figure 5.26. Distances are
measured from the central axis of the inner surface of the plaque.
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5.4.1

Translation Concept

The translation concept study attempted to determine the suitability of a pixelated
detector in generating a dose volume from a collection of planar dose slices with enough
resolution and timeliness for practical clinical use.
Pixelated detectors proved to be well suited to volumetric dosimetry. The dose
volumes produced were intended as demonstrations of the concept and clearly showed
a high level of detail in the detector plane. Beyond simple recognition of asymmetric
differences between the two plaque configurations tested, the resolution would enable
finer features to be resolved. The phantom only allowed for five measurements, though
isosurfaces were generated by interpolating the results. These results indicated that
the concept could act as a platform from which a preoperative dose verification system
can be designed. Ideally, this three dimensional data would be directly compared to
the treatment plan from within a treatment planning system such as BEBIG’s Plaque
Simulator.
The layered translation phantom required the manual placement of the detector
at a specific distance within the phantom layers. This process was labour intensive
and as a result was time-consuming and prone to human error. The layered design
also limited the plaque-detector distances to discreet values and inherently limited the
vertical resolution of the system. In such a system, the number of phantom layers
used is proportional to procedural time and increases the likelihood of introducing
inter-layer displacement error.
From this early design, it was suggested that future translation phantoms use a
water bath and a method of controlling the plaque-detector distance such as that
depicted in the original concept in Figure 5.2a. Submersion of the plaque in water,
whilst offering excellent tissue equivalence, may be a clinical concern for contamination.
Modified sterilisation procedures would need to be adopted as the result of such a design.

5.4. DISCUSSION | 136

Whilst the translation water phantom approach to dosimetry offers a geometrically
simple solution, it cannot easily measure critical surface doses of the plaque itself
without a significant detector redesign.

5.4.2

Rotation Concept

Images generated from the Medipix detector in the rotation phantom were used to pro
duce a simple dose volume. Whilst the number and orientations of measurements were
strictly limited, the overall outcome showed the rotation based volumetric dosimetry of
eye plaques is viable. Section 5.3.1.2 also showed that conventional pixelated detector
geometry would need to be significantly modified to accommodate the shape of the
plaque, as the square Medipix designed used prevented both surface measurements
and acceptable coverage.
In some ways, the concept of the rotation phantom, is advantageous over the
translation phantom for volumetric plaque dosimetry, despite the limitations of the
investigation. The major foreseeable concern with the translation phantom concept
is that it lacks the ability to measure dose at the inner surface of the plaque. This is
a region of interest for clinicians and the TG-43U1 formalism[20] does not effectively
handle it. Additionally, the dose rates closest to the source are those which are both
the greatest and have the steepest dose gradients. It is essential to understand the
dose to this region of the eye as the outer scleral dose can be many times greater than
the prescription dose[207].
The ideal detector design would neatly sweep across the inner surface of the plaque,
providing surface dosimetry of the plaque. Further improvements to this rotary phan
tom design would include a reduced and adjustable plaque-detector angle increment
in addition to automated positioning.
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5.4.3

Spectroscopic and Event Counting Dosimetry

The T O T and count mode data depicted in Figure 5.16 demonstrate very strong
similarities to each other but strongly disagree with the TG-43 protocol for distances
less than 5mm, as expected. The development of a dosimetry system based on the
Medipix2’s event counting mode would be a cheaper and simpler alternative to one
based on the spectroscopic capabilities of Timepix. This is possible because the spectra
of 125I does not change considerably with depth.
The discrepancies between the measured data and the TG-43U1 formalism curve
can be explained due to the limitations of the TG-43U1 formalism. This is primarily
due to its inability to account for material heterogeneities, most significantly, the
metal plaque backing. In this case, the backing causes a dose reduction due to its
absorption of the otherwise backscattered radiation. This outcome has been reported
in the literature I70,84,108-114,149! with mixed results.

5.4.4

Seed Activity Variation and Dosimetry

From this study of the dose distribution of seeds between and within the same manu
facturers, it can be seen that the standard deviation of the ends of the seeds is much
greater than other areas. Standard deviation was also greater in the seeds from M1 in
comparison to those of M2. This could in part be due to the lower numbers of seeds
measured or a product of the manufacturing and certification processes.
This study was aimed at illustrating the potential for seed-to-seed variation, both
between manufacturers and within manufacturer batches. Whilst the number of seeds
measured in this study limits its overall significance, the results of the study show
that dose distributions vary within seed batches and between manufacturers; an effect
that cannot be accounted for in the TG-43U1 formalism. It stresses that a reliable
preoperative dose verification tool capable of measuring close to the plaque surface is
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required to reduce these types of uncertainties and ensure better treatment practises.

5.4.5

Resolution Requirements

The Medipix2 detector is a high resolution instrument capable of resolving details down
to 110 pm. For the development of a preoperative dose verification system prototype,
however, this level of resolution would be superfluous for a new detector design.
Three sampling factors were assessed, namely

8

, 16 and 32, and resulted in recon

struction that produced differing levels of recoverable detail. From the summary in
Table 5.2, higher factors for sampling led to a greater level of loss in recoverable detail,
as expected. The sampling factor that corresponded to pixels of 880 pm (sampling
factor 16) was the most clinically achievable considering the trade off between technical
challenges, cost and required resolution.
Interpolation was used to restore downsampled images back to their original reso
lution, albeit at the loss of detail. Figure 5.21g illustrates that for a sample factor of
16 the worse discrepancies (~ 12.9%) in reconstruction occurred at the image edges,
where the interpolation boundary points were missing. The mean of the discrepancy
magnitudes for this sample factor was relatively low at 2.59 % in comparison to other
errors in the treatment process, including seed variation (up to around 9% - 14% at
1

a) and planning calculation limitations, meaning that interpolation could be used if

needed. These values are strongly dependant on the level of recoverable detail required.
The proposed detector design should have a resolution of around 1 mm and, whilst
interpolation of data is possible, there are inherent risks of misrepresentation of data.
For the volumetric dosimeter concepts presented in this chapter, resolution would be
adjustable in the direction of motion.
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5.4.6

Backscatter and Phantom Design

From the similarities observed in the depth-dose responses of the backing investigation,
it can be seen that additional material placed below the detector influences the dose
received in the detector for small plaque-detector distances. This had maximum effect
at a distance of around 5 mm with a difference of close to 7%.
Due to the likely dominance of pre-existing backscattering through the silicon
detector and PCB, differences at close distances are not as large. The data points
monotonically decrease for distances greater than 5.19 mm due to the short range
of backscattered radiation from the 125I source. In practical dosimetry, the detector
should be used in conjunction with a tissue equivalent material to account for the
backscatter.
Further study into the geometry of the vessel used for the water phantom should
also be undertaken to investigate side scatter. Ideally, the phantom shape in general
should be adapted to suit a given tumour location, as the distance and orientation
of the eye-air interface will vary between cases. This is a complex problem, however,
and Monte Carlo simulation for optimisation and a modifiable or modular design of
the phantom for such a dosimetry system would be useful. This is another reason for
the discrepancy from the TG-43U1 formalism with experimental measurement because
TG-43U1 assumes an infinite water environment, which is clearly not the case during
the brachytherapy treatment.
The dose verification system designed as the main aim of this thesis should incor
porate tissue equivalent material around the detector in a manner that permits further
investigation into backscattering, accounting for the eye-air interface where possible.
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5.4.7

Dosimetry of Beta-Emitting Plaques

Beta-emitting plaques are generally the preferred plaque brachytherapy method for
treating shallow tumours. The two styles tested in this investigation were the CCAtype and COB-type BEBIG plaques. Dose distributions of the CCA-type plaque, which
is circular in shape, are relatively simple in comparison to the COB-type plaque which
features a notch enabling it to be used for tumours that are close to the optic nerve.
The CCA-type plaque calculations from Plaque Simulator 5.0.0 correlated well with
the measured dose planes. The depth-dose curve matched to within the manufacturers
indicated level of uncertainty (20 % 2a) for all distances measured. The calculated dose
plane depicted a dose profile with a much flatter top than that measured, illustrating
differences in the dose distributions.
The measured dose map for the notched COB-type plaque showed two distinct
hot spots in contrast to simulations from the literature[206] and the dose plane pro
duced using Plaque Simulator, where crescent moon shaped distributions were evident.
Measurements by the manufacturer also showed that the dose distribution on the
surface of the COB-type plaque was non-uniform[206]. It is likely that this is due to
the non-uniform deposition of the radionuclide on the plaque.
The design of plaques require that they feature suture eyelets, making them poorly
suited for close measurements with planar detectors. These suture eyelets prevent the
detector from being placed normal to the plaque central axis closer than distances of
about

6

mm to the central surface. Given that the majority of tumours treated with

the 106Ru plaques are less than 5 mm in thickness, the device offers little practical use
for them. A refined detector design is needed for the measurement of dose close to the
plaque surface, such as that proposed in the rotation concept.
The uncertainty in dose distribution demonstrated in this beta-emitting plaque
study show that there is significant benefit to gain from the use of a preoperative dose
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verification system that is capable of mapping near surface doses.

5.5

Conclusion

Two concepts were investigated for using pixelated silicon detectors for volumetric
dose verification in plaque brachytherapy, the translation and the rotation concepts.
Several other aspects were also studied to provide additional design specifications for
the ultimate development of aplaque dosimetry tool.
The concept studies demonstrated the feasibility of their physical development and
general operation. The translation concept consisted of translating a two-dimensional
detector plane normal to its surface to create three-dimensional dose distributions
of a plaque. The rotation concept, in contrast, involved the rotation of a detector
plane about itself to create three-dimensional dose distributions of a plaque. Both
the experimental procedures required a significant amount of handling and their dosi
metric coverage was spatially limited in design. Whilst results were promising, both
phantom solutions were suboptimal. A water phantom modification was suggested and
implemented for further translation based volumetric dosimetry. The rotation based
phantom needed to be optimised through the redesign of the detector shape.
Using the modified translation water phantom, the event counting mode of the
Timepix detector was compared to its time-over-threshold (charge) mode for the mea
surement of 125I plaque dosimetry. The depth-dose results showed excellent agreement
between the two methods. Event counting mode was used with tissue equivalent back
ing material and the water phantom and compared to the TG-43U1 dose calculations
for a 15 mm ROPES plaque fully loaded with 125I seeds. Dose enhancement occurred
at distances close to the plaque due to TG-43U1 not accounting for heterogeneities
including the metalplaque backing.
Two batches of seeds from unnamed manufacturers were tested using the Medipix2
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detector for the investigation of intra-batch and inter-batch variations.

The dose

images from the Medipix clearly depicted the anisotropic dose functions of the seeds.
The maximum standard deviation of one set of seeds (M1) was about 14% while the
other was about 9% (M2), and the maximum discrepancies in the seeds occurred at
their tips. This study illustrated that benefits could be gained from preoperative dose
verification by minimising source uncertainty.
The Medipix family of detectors used in this concept study had very high resolu
tion, and while it could be of great benefit in plaque dosimetry, their design inherently
inhibits their use in the rotation concept by preventing scleral measurements at the
surface of the plaque. By downsampling, bicubic interpolating and comparing a mea
surement taken using the Medipix2 to its original, for several sampling factors the loss
detail was examined. When optimised by Nyquist theory for resolving dose to the finest
features in plaque brachytherapy (~

1 .6

mm), 800 pm was considered an acceptable

initial resolution for detector design. Though it is image dependant, the mean error
in reconstruction for pixels downsampled to a resolution of 880pm was 2.59%, and
showed that lower resolutions would still be useful.
The effect of the presence of tissue equivalent material below the detector was
investigated and shown to strongly effect dose. A block of Plastic Water® increased
dose by up to nearly 7 % at around 5 mm from the plaque. This supports the need for
the development of reliable dose verification tools for eye plaque brachytherapy, which
could measure such discrepancies if plans are incorrect.
Two types of BEBIG, beta-emitting plaques were tested to observe the effectiveness
of dosimetry using silicon pixelated detectors. The CCA-type plaque showed agree
ment within manufacturer uncertainty to the depth-dose curve generated using Plaque
Simulator. The COB-type showed an unexpected dose distribution featuring two hot
spots and a depth-dose curve that did not correlate well to calculated values. Dose
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verification close to the plaque surface would be useful for overcoming the fabrication
induced activity uncertainties and non-uniformities.
By incorporating the outcomes of this concept study, the development of a fast,
three-dimensional, preoperative dose verification system for plaque brachytherapy is
feasible. Details of the design and further development of such a system, called the
Panoptes,

are presented in the following chapter.

Part III
The P a n o p t e s

144

Chapter 6
Design and Development
The previous part of this thesis consisted of two chapters which were used as proof
of concept studies for the development of a preoperative dose verification system for
plaque brachytherapy. The chapters showed that single silicon p-i-n diode detectors
were well suited to point based dosimetry and that the further developed concept of
pixelated silicon detectors offers much in the way of volumetric dosimetry. In this final
part (Part III) of the thesis, the design, development and evaluation of a pixel array
detector system, called the P a n o p t e s (Pixelated, Automated Nuclear Ophthalmic
Plaque Treatment Evaluation System) is presented.
The translation and rotation dosimetry concepts investigated in the previous chapter
were used as a basis for the P a n o p t e s design. This chapter details the design and
development of the custom pixelated detectors, electronics, phantoms and graphical
software interfacing for the P a n o p t e s . A photograph of the assembled hardware is
shown in Figure 6.1. A diagram of the system components and their relationships is
provided in Figure 6.2.
The detector design and fabrication was critical for the overall success of the project.
It was carried out after the readout electronics had been selected, and prior to the
design and development of complementary systems. Specifically, the detector design
145
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Figure 6.1: Photograph of the P a n o p t e s showing the detector board fixed within the
positioning system (left) and the main electronics enclosure (right) which contains the
power supply and interface boards.

Figure 6.2: Overview of the P a n o p t e s subsystems
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for the P a n o p t e s was investigated for both of the volumetric acquisition concepts
considered in Section 5.2. However, the rotation based concept was pursued exclusively
as it demonstrated greater potential for dose volume coverage near the plaque surface.
Design of the electronic systems followed the detector and included the detector
board, interfacing board and power supply board. The detector board featured multi
ple front-end mixed-signal readout ASICs and provided power and signal routing to
them. The detector board was interfaced to a central control board which used a field
programming gate array (FPGA) for control processing. It managed data handling
and controlling acquisitions on the detector board, routed information to and from the
software interface and controlled a stepper motor positioning system.
Concurrent to the development of the electronic systems was the phantom design.
It consisted of a single piece of 3D printed material shaped as a hemisphere and, beyond
its dosimetric purpose, filled the secondary role of protecting the sensitive electronics.
The software interface was written to provide a means for the operator to control all
acquisition parameters and take measurements. It allowed for tasks such as controlling
sets of automated measurements, single channel analysis of sources and visualisation
of measured data.

6.1

Detector Design

The P a n o p t e s project involved the investigation of two approaches for dose volume
acquisition and this required two individual designs of pixelated silicon detectors. The
first was designed for the translation based concept and was rectangular in shape and
bore 127 pixels. The second was designed to suit the rotation based concept, was
semicircular in shape and consisted of 64 pixels comprised of two different sizes. A
photograph of the two detector designs is presented in Figure 6.3.
The detector wafer consisted of 300 pm thick, bulk n-type silicon. The detector
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Figure 6.3: Photograph of the silicon pixelated detectors, showing the rotation based
design on the left and the translation based on the right. Ruler units are in millimetres.

Al (1.1pm)
SiO2 (0.8pm)
n + (82.2nm)
p + (112.2nm)
n
n + (82.2nm)
Al (1.1pm)

Figure 6.4: Cross-section of a single diode of the detectors

6.1. DETECTOR DESIGN | 149

geometry and implantation parameters were designed at the CMRP, University of
Wollongong and the masks were produced and the detector fabricated at the CMRP
microelectronics foundry, SPA BIT. All of the detectors in both designs were of p-i-n
diode structure, as depicted by the cross sectional view in Figure 6.4.
The pixels featured p+-type silicon implanted with boron at E = 30 keV and a dose
of 5 x 1015 ions/cm 2, which gave an ionisation depth of

1 1 2 .2

nm [208]. An n+-type

silicon layer was present in all other regions on the top and bottom detector surfaces.
It was implanted with phosphorus at E = 60 keV and a dose of 50 x 1015 ions/cm2,
giving a depth of 82.2 nm [208]. The aluminium metallisation layer had a thickness of
1.1 pm and the silicon oxide, 800 nm. In all cases projection masks were used, and the
fabrication processes used

1

pm technology.

Aluminium contacts were used to route the signals to groups of bonding pads at
the edge of the detector. The output bonding pads were designed to match the 32
input pads of the front-end mixed-signal ASIC, as discussed later in Section

6 .2 . 1 . 1 .

Multiple ASICs were needed to accommodate the number of pixels on each of the
detectors; four for the translating detector and two for the rotating detector.
The detectors both featured bonding pads on the top to connect to the aluminium
surface, and hence the underlying n+-type region, for applying a bias voltage. Similarly,
the bottom of the detectors had an aluminium layer, connected to the other n+-type
silicon region. The bias voltage could be applied through this layer via a conductive
glue to a printed circuit board pad.

6.1.1

Rotation Based Detector

The rotation based concept required that the detector be designed with a semicircular
shape to allow it to fit closely within the inner radius of an eye plaque, as seen earlier
in Figure 5.3a. The silicon detector was cut multiple times from an originally square
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Figure 6.5: Semicircular detector with 64 pixels, designed for the rotating phantom
concept. The curvature of the detector was based on the radius of the human eye.
The numerical indexing on the pixels was derived from the horizontal placement of the
output bonding pads.

shape to form the resulting semicircle. The detector was 24.05 mm wide by 15 mm high
and the semicircle had a radius of curvature of

12

mm. Some samples of the fabrication

masks used in making the detector are presented in Figures D.1 - D.3 of Appendix D .
The detector featured two sizes of pixels: 32 small pixels measuring 300 pm x 300 pm,
and 32 large pixels measuring 1.00 mm x 1.00 mm, shown in the schematic of Figure
6.5. The variation in pixel size allowed a more efficient coverage of the detector plane,
by using small pixels to provide a higher resolution at the sclera and around the plaque,
and by using large pixels for better signal statistics at larger distances. The large pixel
size was also intended to maximise the statistics measured in areas of relatively lower
dose.
The numerical indexing of the pixels, shown in Figure 6.5, was based upon the
vertical track routing to the bonding pads as they occur from left to right. Pixels
ranging from 1 - 3 2 are routed through the left hand ASIC and the pixels from 32 64 are routed to the right hand ASIC.
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6.1.2

Translation Based Detector

The rectangular detector was designed to be used with the translation based phantom
detailed in Section 5.2.1. It had a width of 24.00 mm and a height of 27.00 mm,
large enough to cover the entire diameter of the average human eye. A schematic
representation of the detector is provided in Figure

6 .6

.

The p-i-n diode topology of the square detector was the same as that of the
semicircular detector, except that all of the 127 diodes are 500 pm x 500 pm in size.
The pitch between pixels was 2.00mm in the horizontal and vertical directions.
The detector was arranged in alternating columns of six and five pixels and the
signal outputs from the pixels were routed to four groups of bonding pads for interfacing
with the front-end readout ASICs. Some samples of the fabrication masks used in
making this detector are presented in Figures D.4 - D.5 of Appendix D .
To best achieve the aims of this study, a single concept needed to be selected for
investigation in the P a n o p te s . The rotation concept was deemed most appropriate
as it allowed measurements closer to the surface of the plaque with relatively lower
electronics complexity, compared to the translation concept.

6.2

Electrical Design

The electrical hardware consisted of four main components: the detector board, power
supply, the interface board and the stepper motor. The detector board bore the detector
and front-end electronics in a low noise environment. The interface board featured a
field programmable gate array for logical processing and was used for communication
to and from the other electrical components and the user. The power supply was used
to provide standard voltage rails for the electronics, in addition to the detector high
voltage bias and the stepper motor power rails. The stepper motor was controlled
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Figure 6 .6 : Rectangular detector with 127 diodes, designed for the plunge phantom
and the channel numbers on the detectors are derived from the horizontal placement
of the bonding pads.
using signals from the interface board via a driver circuit. The interconnections of the
electrical systems are depicted in a system diagram shown in Figure 6.7.

6.2.1

Detector Board

The detector board was designed with the primary considerations of providing a
platform for detector and phantom mounting and also a low-noise environment for the
front-end, readout electronics. The board featured the pixelated detector at one end
and the electrical interface at the other. The interface provided the bias voltage along
with separate digital and analogue + 5 V voltage rails, the serial peripheral interface
bus, and various control lines. Figure

6 .8

shows a photograph of the detector mounted

onto the PCB with, and bonded to, the two readout ASICs.
The board used a four layer design, featuring both a multi-net power and a multinet ground plane as the central two layers. The board was separated into two main
regions, digital and analogue, to limit the noise transmitted through to the ASIC.
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Figure 6.7: Block diagram of the P a n o p t e s electrical interfaces showing electrical
hardware in blue, and the control systems, in orange.

Figure 6 .8 : The semicircular detector sample N3 was mounted to the detector board
(top half shown). Wire bonding joined the detector to the ASIC, and the ASIC to the
board.
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Several low-noise +3.3 V voltage regulators were used with + 5 V inputs to provide
stable power rails to the ASIC. The bias voltage supplied to the detector was current
limited using a 1 MQ resistor and stabilised using ceramic capacitors. Operational
amplifiers were used to create four voltage followers for reliably routing output signals
from the ASICs to the interface board. The detector board was connected to the
interface board via a 34 pin header and shielded cable, the connection scheme for
which is provided in Table C .1 in Appendix C .
The circuit schematics of the detector board are presented in Figures C.1 to C.3 of
Appendix C and the printed circuit board layouts are presented in Figure C.4.

6.2.1.1

Front-End Electronics

The readout ASIC used for the P a n o p t e s was the HERMES4[209] and was designed
at the Instrumentation Division of Brookhaven National Laboratory. It was selected
primarily due to its high-rate, high-resolution, moderate complexity, and suitability
for 125I dosimetry as used in plaque brachytherapy. This family of ASICs has been
used in a number of low-noise applications in the past I210-213!.
HERMES4 is a mixed-signal, front-end ASIC fabricated in 350 nm CMOS, dual
poly, four-metal 3.3 V technology. It has 32 analogue input channels, each of which
comprises a low-noise preamplifier with continuous reset[214], a high-order shaper with
baseline holder (B LH )[175], a single low-level discriminator (Window 0), two window
discriminators (Windows 1 - 2 ) with fine adjustment digital-to-analogue converters
(DACs) and one 24-bit counter, as annotated in the photograph in Figure 6.9. Each
of the four window thresholds for each channel is individually adjustable with a 6 -bit
DAC. The power consumption for each channel is reported to be ~

8

mW, of which

3 mW is dissipated by the preamplifier. There is no timing information available from
the ASIC.
Communication with the HERMES chip was conducted using the serial peripheral
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Preamplifier

3mW

Shaper/BLH

Discriminators/DACs

Counters

5mW

Figure 6.9: Photograph of the HERMES4 A SIC [209] showing various sections of each
channel. Each channel counts the number charge pulses that fall within three separate
adjustable energy windows and can be subsequently read out digitally.

Figure 6.10: Simplified schematic of a single channel of the HERMES4 mixed-signal
front-end ASIC[209] and its connections with the FPGA via the serial peripheral inter
face bus
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interface (SPI) bus. The serial data input (SDI) line allowed for some of the analogue
processing chain’s parameters to be configured, viz. gain [0.75 mV fC-1 , 1.50mVfC-1]
and shaper peaking time [0.5ps, 1.0ps, 2.0ps and 4.0ps]. Upon request from the
FPGA processor, the serial data output (SDO) line from the device clocked out the
three

2 4 -bit

counter values sequentially for each of the

32

channels, totalling the

2304

bits of a data frame. Figure 6.10 shows a simplified diagram of a single channel of the
ASIC and its relationship to the interface board through the SPI bus.

6.2.2

Electrical Enclosure

The main electrical enclosure, shown earlier in Figure 6.1, housed the power supply
board and the interface board, seen in Figure 6.11. Its steel casing was earthed to the
mains supply (240 VAC) through a fused IEC[215] socket and provided electromagnetic
shielding. The boards were electrically isolated from the enclosure and the interface
board was further protected from power supply interference with a dedicated elec
tromagnetic interference (EMI) shield. The front and back panels of the enclosure
were both used as connection and control interfaces, images of which are provided in
Appendix B as Figures B.5a and B.5b, respectively.
The front panel featured a power indication LED and sockets for the stepper motor
control and power lines, in addition to the interface connection to the detector board.
The later used a shielded multi-core cable for all power and control signals. The back
panel provided access for power and a USB type-B connection for communication to
and from the host computer to the FPGA module. Control of the high voltage biasing
system was provided through an enable override switch, manual-remote switch and a
voltage adjustment dial.
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Power supply
board

Interface board
(with attached
F P G A m odule)

Figure 6.11: The internal circuit boards of the P a n o p t e s included both the power
supply board (top) and the interface board (bottom) which featured a socketed FPGA
module (all highlighted in orange). When fully enclosed, the interface board was
electromagnetically shielded from the power supply board with a dedicated metal
enclosure (not shown).

6.2. ELECTRICAL DESIGN | 158

6.2.3

Power Supply

The power supply system provided rails for + 5 V D , +5V A , and +15 V for various
systems including the FPGA, detector board and stepper motor. It also provided
an adjustable high voltage (0 V - 200 V) signal with positive polarity to be used for
biasing the detector. A series of mechanical relays was used for fail-safe switching of
power signals and lines. Circuit schematics and printed circuit board layouts for the
power supply are provided in Appendix C as Figures C.5, C . 6 and C.7, respectively.
A toroidal step-down transformer with dual secondary windings and a bridge recti
fier circuit was used to rectify the input power and provide ± ~ 25 VDC. These lines
were then regulated into ± 5 VA (DC for analogue line), +5 VD (DC digital line), ±12 V
and 15 V using the 78xx and 79xx series linear regulators. The analogue and digital
power nets were separated to reduce system noise, though they shared a common
ground via a ground-star style filter. The primary side of the transformer featured an
in-rush protection circuit consisting of an RC-timed relay and a shunt resistor.
The high voltage bias supply was provided by the very low noise EMCO CA-02TP [216], which was capable of providing from 0 V - 200 V with a maximum output current
of 5 mA. The high voltage adjustment could be set manually using a potentiometer,
or through the software interface and a digital-analogue converter. The voltage ripple
in the high voltage bias was measured to be ~ 5mV at the operational voltage (50 V).
The board supplied the +5 VD and +15 V rails to the stepper motor driver via the
central acquisition board for logic control and powering the motor coils, respectively.

6.2.4

Interface Board

The interface board was responsible for the logical operation of signals and interfacing
to and from the host computer and the detector board, along with the control of the
high voltage bias and the motor control for plaque positioning. The power supply and

6.2. ELECTRICAL DESIGN | 159

interface boards comprised the internal circuits of the main P a n o p t e s electronics box,
as shown in Figure 6.11. Circuit schematics for the interface board are provided in
Appendix C as Figures C .8 - C.12, and the printed circuit layout in Figure C.13.
The +3.3 VDC voltage rail required for the FPGA module was generated on the
interface board using a LD1086 linear voltage regulator.
separate

34

The board featured two

pin headers for routing voltage rails from the power supply board and to

the detector board. The interface board also forwarded the power rails to the stepper
motor driver and all power rails to the detector board. Through the FPGA module,
the interface board could set a DAC, which was used for setting the input value of
the high voltage bias. The SPI signals and CS, EN, W R and RST control lines of the
readout ASIC on the detector board were buffered to and from the FPGA module.

6.2.5

Field Programmable Gate Array (FPGA) Firmware

The interface board used a drop-in prototyping module, the Opal Kelly XEM6001[217],
for managing communication, clocks and power for the Spartan-6 , high gate-count
FPGA (XC6SLX16-2FTG256C) t218l The FPGA was used in the P a n o p t e s for all
logical processing that required time critical hardware interfacing.

It acted as an

immediate controller between the host computer and the other electric systems, as
seen in Figure 6.2.
The XEM6001 featured on-board serial flash memory storage and, upon powering,
booted the stored configuration file for immediate operation. It used hardware de
scriptor language (HDL) libraries on the FPGA side to interface with software using
the corresponding application programming interface (API) on the host computer side.
This communication used a host interface clock of 48 MHz on the Universal Serial
Bus (USB) protocol v2.0[219]. The flexible XEM6001 clocks were generated with an
on-board phase-locked loop (PLL).
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Figure 6.12: The main schematic module of the FPGA firmware showing several of
the interconnected sub-modules.
The main FPGA module was responsible for the logical handling and coordination
of a collection of sub-modules at the clock cycle timing level and is shown in Figure
6.12. The sub-modules focused on controlling Serial Data In (SDI) and Serial Data
Out (SDO) lines, acquisitions, the high voltage bias driver, motor positioning and
HERMES chip selection.
The FPGA modules communicated with the two HERMES chips individually, by
selecting them via their respective chip select CS lines. The chips were only selected
during a transfer process either to or from the HERMES. The host computer was
used to coordinate the macro level timing of the chip selection process. The schematic
module that handled the chip selection of the two HERMES devices is presented in
Figure E.2 of Appendix E.

6.2. ELECTRICAL DESIGN | 161

The front end readout chips were configured with parameters sent from the host
computer via the FPGA module. The FPGA module used the SPI interface to send
configuration data for gain, peaking time, DAC values for global window thresholds for
Windows

0

-

2

, individual DAC values for Windows

1

-

2

for each channel, along with

some other configuration parameters. The total communication chain was fast enough
to permit pre-acquisition configuration for every set of acquisitions, which allowed
parameter changes to be made easily. The schematic firmware module that handled
the SDI line for configuration to the HERMES is presented in Figure E.3 in Appendix
E.
Once the HERMES ASICs had been correctly configured, an acquisition time
had been set and the starting trigger had been received from the user interface, the
acquisition process was initiated on the FPGA module. The acquisition time variable
was 16-bit and represented the time, in clock cycles, that the input event counters were
enabled on the HERMES chips, via the EN signal. Given that the clock period was
100 ms, the range of acquisition was from 0.1 s - 6553.5 s, which was sufficiently precise
yet large enough for acquisitions of brachytherapy plaque sources. The enable signals
for the counter inputs were set and reset simultaneously on both ASICs, ensuring that
equal and concurrent acquisitions could occur. When the acquisition time had elapsed,
the FPGA module flagged a completion trigger and, upon acknowledgement from the
host computer, the data from each HERMES chip was clocked out consecutively and
forwarded to the host computer for processing. The schematic firmware module that
handled the SDO line from the HERMES is presented in Figure E.4 and the Verilog
module of the acquisition handler is provided as Listing E.1 in Appendix E.
The EMCO high voltage bias supply was set through a digital-analogue converter
that received a value sent serially from the host computer via the FPGA on a SPI
bus. The output from this device was monitored using an analogue-digital converter,
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which was in turn sent back to the host computer via the FPGA. Additionally, the
FPGA and host computer could control the connection of the high voltage supply
to the detector circuitry through mechanical relays on the power supply board. The
firmware schematics are presented in Figures E.5 to E.7 in Appendix E.
The orientation of the plaque relative to the detector was controlled using a stepper
motor, the S A N M O T IO N - 103H7126-0140[220]. The position of motor was handled
using three FPGA signals: STEP, DIR and DISABLE for position incrementing,
direction, and disabling, respectively. The host computer was used to initiate FPGA
signalling for motor movement through the use of three variables to provide information
regarding the number of steps, the rotation direction and the step frequency. The
stepping resolution was determined from the motor specifications ( 1 . 8 °/step) and the
motor driver interface[221] (10 microsteps/steps) giving 0.18 °/microstep. The motor
coils were powered by the 15VDC digital rails supplied by the power supply board.
The Verilog module of the motor controller isprovided as Listing E . 2 in Appendix E.

6.3

Phantom and Positioning System

An eye phantom was designed and fabricated to provide tissue equivalence required for
accurate dosimetry. It also provided mechanical protection for the sensitive detector
and ASICs. For the P a n o p t e s , the term phantom can be considered in two ways: the
first includes the material that is used for radiation attenuation, while the second is the
entire hardware system needed for measurement. For the purposes of this study, the
term phantom refers to the tissue-equivalent material object, and the term positioning
system refers to the remaining hardware, including the stepper motor, shaft, box etc.
The phantom was 3D printed as a single piece of material called VisiJet® Crystal
made by 3D Systems[222]. This printing process allowed for the phantom to be produced
with much better tolerances (16 pm) than traditional fabrication methods would allow,
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Figure 6.13: Photograph of the fully assembled P a n o p t e s detector board with phan
tom fixed in place

given the production time and cost.
The use of 3D printing also eliminated otherwise difficult to avoid air gaps, and
offered greater flexibility for design modification. The distance between the plaque
and the edge of the detector was 500 pm to enhance the capabilities of near-surface
dosimetry.

A photograph of the detector board with the phantom mounted over

the detector is shown in Figure 6.13 and dimensioned drawings for the phantom are
provided as Figure B.2 in Appendix B .
Unfortunately, due to the proprietary nature of the available printer material, its
exact fractional composition could not be obtained. The material safety data sheet
indicated that the composition comprised three main constituents with a range of
percentages, as detailed in Table 6.1. This information was not sufficient to perform
accurate simulations and it is recommended that future studies investigate the radiation
response of this material or seek alternative printable materials.
The positioning system was designed with the aim of providing mechanical position
control over the plaque whilst limiting disruption to normal clinical procedure. It
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Table 6.1: Composition information for the phantom printed in 3D Systems’ VisiJet®
Crystal[222] material.
Component

Percent

Urethane acrylate oligomers
Ethoxylated bisphenol A diacrylate
Tripropyleneglycol diacrylate

20 % - 40 %
15% - 35%
1.5% - 3%

allowed the plaque to be assembled directly on the phantom where it could be measured
and verified without double-handling.

The position system consisted of a PMMA

(poly(methyl methacrylate)) box, stepper motor, lock-down shaft and board holder. A
photograph of the positioning system prior to painting is provided in Figure 6.14 and
dimensioned drawings of the box and lock-down shaft are provided in Appendix B in
Figures B.3 and B.4, respectively.
After assembly of the plaque, the lock-down shaft was used to hold it in place
centrally onto the phantom, using a plaque specific seat. The shaft was a telescopic,
three part mechanism that could be retracted out of the way during loading and locked
down onto the plaque with a spring during operation. The bottommost end of the
shaft featured a detachable plaque holder designed to securely fit around the plaque,
as shown in Figure 6.15. This feature allows many styles of plaques to be used with
limited handling whilst ensuring measurement accuracy. The stepper motor, coupled
to the other end of the shaft, acted to rotate the plaque about its axis when changing
the plaque-detector angle during acquisition. The board holder was used to orient the
detector board vertically, aligning the detector to the axis of the shaft.
The box frame was coated in a conductive nickel based paint that was used to
inhibit light and shield the sensitive internal electronics from external EMI. Prior
to operation, a panel was magnetically locked into place at the front of the box to
complete the shielding.
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Stepper motor

Lock-down bolt

Plaque in holder

Detector board

J
Figure 6.14: Photograph of the entire phantom and positioning system, prior to
shielding with metallic paint. The detector board was fixed vertically in the centre
and a guide bolt applied a gentle force to the plaque yet allowing it to rotate with
the stepper motor whilst the detector took incremental measurements. Within the
phantom, the top surface of the detector faced towards the back of the positioning
system box.
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Figure 6.15: The positioning system could accommodate many styles of plaques by
using a detachable plaque holder, illustrated above, which was used to position the
plaque in a secure manner and provide control over its orientation.

6.4

Software Interface

The software interface for the P a n o p t e s , called Panopticon, was designed to provide
user control over the system. It was also used to provide fast, visual feedback and data
storage from measurements. The interface was written using C + + [188] and Digia’s Qt
interface libraries[189], with the consideration that it should be portable to multiple
platforms, namely Windows, Unix and MacOS (on which Plaque Simulator[22] oper
ates). The interface was responsible for handling the communication to and from the
XEM6001 FPGA module via the Opal Kelly FrontPanel A P I[223].
The Panopticon software used the FrontPanel programmer's interface, an Opal Kelly
C + + API, to communicate via USB 2.0 with the Opal Kelly XEM6001. The XEM6001
is a prototyping board featuring a SPARTAN - 6 FPGA which communicated through
a combination of triggers, signals and data pipes to the host interface, Panopticon.
When the plaque, phantom, electronics and software configuration details were
prepared, an acquisition process would be ready for initiation. Whilst the interface was
in an idle state, an intermittent handshaking signal was used to maintain contact to the
FPGA. An acquisition involved first disabling this handshaking to reduce noise, then
sending the configuration details to the FPGA, followed by an acknowledged trigger
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signal. The user interface then waited for the acquisition time to expire and polled
the return triggers to check if the data acquisition was complete. If successful, then
data was transferred to the interface and to file if desired. Once the data had been
processed, another acquisition may follow or the motor may be repositioned, depending
on the acquisition type and status. A screenshot of the main interface of Panopticon
is provided in Figure 6.16.
With each measurement taken, the software stored the count data and acquisition
details in a P a n o p t e s data file (*.pdat), as ASCII text to ensure maximum accessi
bility to the information. Additional details that were stored included any modifiable
parameters or notes, such as time and duration of acquisition, bias voltage, front end
electronics configuration, motor details, etc. An example output is provided in Listing
F.1 in Appendix F.
Once the measured data had been decoded, the 64 data channels were stored in
the random access memory. This data was processed further to determine the range
of values present, after which it was represented diagrammatically on a detector map
graphic where colour was used to indicate count values. The detector map was a
schematic representation of the detector’ s layout and interactively allowed the user to
mouse-over pixels of interest and reveal their numeric value in a pop-up overlay, as
seen in Figures 6.17a and 6.17b.
Adjacent to the detector map, a histogram chart plotted counts per channel, sep
arated chromatically by large and small diodes. It had been included to allow users
to easily assess the dose distribution across the dataset. The histogram offered a customisable number of event bins and the lower and upper trims could be set manually.
The colour scaling of the detector map could be used to represent the adjusted values
of a trimmed histogram.
Object perceptibility in an imaging system can be enhanced through the improve-
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Figure 6.16: Screenshot of the main interface of Panopticon

ment of its signal-to-noise ratio via reducing image noise. The two major contributions
of image noise in a system, such as the P a n o p t e s , are fluctuations in the number of
photon events per unit area (entirely stochastic), and those imposed by the imaging
system, which can be both stochastic and non-stochastic. Non-stochastic imaging sys
tem noise contributions, or fixed-pattern noise, arise from the sensor and the readout
electronics.
The origin of noise in the sensor can be attributed to material inhomogeneities
which causes non-uniform field distributions, local variations in leakage current and
localised reductions in charge collection efficiency. In the readout electronics, the main
source of readout-related sensitivity variations are contributed to transistor mismatches
introduced during chip production.[224]
To compensate for these inter-pixel variations caused by fixed pattern noise, a
so-called flat-field calibration is conducted. This involves taking measurements of a
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(a) Uncalibrated data

(b) Calibrated data
Figure 6.17: Data could be viewed where count values were colour mapped to the
pixels and a histogram of the count distribution provided quick statistical information.
The number displayed on the detector map shown is a mouse-over of the value for Pixel
#32, see Figure 6.5. Data calibration could be applied using a file generated from a
flat field acquisition. The above screenshots show measured data with and without
calibration.
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uniform field and normalising individual pixel response against the mean of the whole
sensitive volume, or some specific pixel. The coefficients generated during this process
constitute the flat-field calibration map.
Calibration files could be generated within Panopticon using measured flat-field
data and could be applied to any data set. Applying pixel calibration caused the
individual calibration factors to scale each pixel value. The factors could be calculated
in the software immediately after the system had acquired a flat-field measurement or
retroactively, using an existing flat-field measurement. The data values were normalised
and the resulting calibration factors were saved to disk in a single calibration file, which
could be loaded later. Figure 6.17a shows dose measurement data where the pixels
are uncalibrated, in comparison Figure 6.17b shows the same data with calibration
applied.
Another useful feature for testing and commissioning of the device was the single
channel analyser function (screenshot in Figure 6.18). This tool was used to measure
the spectrum of a radiation source by taking multiple measurements and adjusting the
three threshold windows, from minimum to maximum. The acquisition time for each
energy bin could be adjusted, as could the width of the energy bin. Figure 6.18 shows
the results of a scan with the energy bin set to minimum, that is, the lower and upper
threshold values were set one increment apart.
During dosimetric measurement only a single threshold is required when ignoring
the noise-floor, however utilisation of multiple windows could be used to provide more
accurate dosimetry by separating spectral peaks, or reducing electronic noise through
taking the mean response. Although they are infrequently used in practice, the spectra
of bi-nuclide plaques[132] could be divided into constituent parts for greater dosimetric
accuracy when dealing with a range of energies.
An energy threshold histogram could be plotted in real-time and the histogram for
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Figure 6.18: Panopticon interface - Single channel analyser. The vertical axis on the
plot is in log scale and represents the number of counts measured. The horizontal axis
represents the global energy threshold DAC values (0 - 1023) which effectively forms
the energy bins when used as a single channel analyser.

any of the pixels could be displayed. An output file could be created upon completion
with all relevant acquisition details and the measured spectrum for each of the three
energy windows, for all pixels.
The long term aim of Panopticon 6 was for use as a complementary tool for the
Panoptes

in a clinical environment. Whilst the current software allowed the maximum

level of diagnostics and control of the P a n o p t e s , it included a simplified version of
clinical user mode which inhibited unwarranted setting manipulation and included
methods for storing patient data and other clinical information. Further development of
this system, or integration into an existing dosimetry tool, such as Plaque Simulator[22],
would be required prior to clinical implementation.
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6.5

Conclusion

The detector, electrical, phantom, positioning and software systems for the P a n o p t e s
were designed, developed and integrated to produce a functioning radiation detection
system.
Two types of pixelated silicon p-i-n diode detectors were designed and fabricated
for the translation and rotation based concepts, respectively. Only the semicircular
detector for the rotation based concept was chosen for use with the subsequent design
of P a n o p t e s . Its perimeter was cut with a radius curvature of 12 mm, the average
size of a human eye.
Electrical systems were designed, fabricated and assembled for P a n o p te s . These
included a power supply board, FPGA interface board, detector and readout board
and stepper motor circuitry. A mixed-signal, front-end ASIC called HERMES4 was
used to handle detector readout. It communicated to a user interface through the
interface board which utilised an FPGA based on an Opal Kelly XEM6001 module.
The interface board also set the high voltage bias and powered and controlled the
stepper motor for orienting the plaque.
A high resolution 3D printer was used to produce an eye phantom, which fitted
precisely over the detector. The design allowed the detector to be within 500 pm of
the inner surface of a brachytherapy plaque, although the exact composition of the
proprietary material could not be obtained from the manufacturer. The material used
in this study was selected to allow the continued development of the proof of concept.
It is recommended that future studies investigate the radiation response or seek an
alternative material. The positioning system developed consisted of a lock-down shaft
which was driven by the stepper motor to control the position of the plaque. The
detector and phantom were enclosed within an EMI shielded, light-proof box to reduce
unwanted noise in the detector.
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A software interface, called Panopticon, was written for coordinating acquisitions
from the detector. The program could perform a wide variety of functions, such as
running multiple, consecutive measurements, with integrable acquisition times ranging
from

100

ms to ~

110

min, saving data to disk upon completion; automatically con

trolling the plaque position via the stepper motor; visualising measured data with a
detector map and histogram; and measuring the energy spectrum of a source by acting
as a single channel analyser.
The following chapter details the characterisation of both the semicircular detector
in isolation and as an integrated part of the P a n o p t e s .

Chapter 7
Characterisation
In the second part of this thesis, the concept of using a pixelated detector for plaque
brachytherapy dosimetry was shown to be viable. Following on, a semicircular shaped
detector was designed, fabricated and implemented as part of a dosimetry system.
This chapter details the characterisation that was performed on this detector as an
unconnected device and as an integrated part of the P a n o p t e s .
The detector was tested using current-voltage and capacitance-voltage analysis, as
well as alpha spectroscopy and ion beam induced charge collection. This was, in part,
useful for determining the energy resolution and geometry of the sensitive volume of
the detector. Monte Carlo simulation was used to establish individual silicon response
to water dose conversion factors for each pixel in the detector across all angles.
The energy spectra of the pixels was measured by configuring P a n o p t e s as a
single channel analyser. From this, the noise threshold for the pixels was determined
for optimisation of 125I dosimetry. Flat-field calibration was performed using a 250 kV
photon beam to normalise individual sensitivity. The work in this chapter has resulted
in the follow publication:
• M. Weaver, M. Petasecca, D. L. Cutajar, M. L. F. Lerch, G. De Geronimo,
D. Pinelli, A. Cullen, D. Prokopovich, V. Perevertaylo, and A. Rosenfeld, “Panoptes:
174
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Calibration of a dosimetry system for eye brachytherapy,” Radiation Measure
ments, vol. 71, pp. 310-314, Dec. 2014.

7.1

Detector Characterisation

The electrical performance of the detector was evaluated by measuring its currentvoltage and capacitance-voltage characteristics. Charge collection and spectral charac
terisation of the detector were performed through a-spectroscopy and ion beam-induced
charge collection (IBICC) efficiency at the Australian Nuclear Science and Technol
ogy Organisation (ANSTO). All physical test measurements were performed with the
silicon detector bonded and mounted on to a breakout board, presented in Figure
7.1. The detector sample used for characterisation differed from that used later in
the P a n o p t e s performance testing, although it was from the same fabrication batch.
Monte Carlo simulation was used to determine the energy conversion factors for each
pixel of the detector by determining and optimising for angle-dependent silicon-water
dose conversions.

Figure 7.1: Semicircular detector breakout board prior to the mounting and bonding
of the detector.
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7.1.1

Current-Voltage Characterisation

Pixel leakage current was measured as a function of reverse bias voltage from 0 V 50 V in 100 mV increments.

To achieve this, the detector on the breakout board

was placed inside a dark, shielded box which was electrically connected through to a
Keithley Model 230 Programmable Voltage Source for applying reverse bias voltage
and a Keithley Model 614 Electrometer for measuring the leakage current. The voltage
source was controlled through the IEEE-488 interface[184] and a computer running
LabView[185]. The measurements were digitised using a Keithley Model 199 System
DMM/Scanner connected to the electrometer and then sent back to the computer on
the same interface. This process was identical to that described in Section 4.2.1.1; for
a connection diagram see Figure 4.6.
The leakage current-voltage (I-V) curves for 55 pixels were measured, though for
clarity only three pixels are presented in Figure 7.2. The selected pixels are Pixel #01,
a small pixel with a short track, Pixel #26, a small pixel with a long track, and Pixel
# 5 9 , a large pixel with a short track.
The median values for leakage current were 1.94 ± 0.49 nA and 430 ± 72 pA for the
large and small pixels, respectively. As stated, the leakage current is dependant on the
junction geometry and the large and small pixels have areas of 1.00 mm 2 and 0.09mm2,
respectively. These areas differ by a factor of 11, while the median values of leakage
current differ between the large and small pixels by a factor of 3.96. This discrepancy
occurs, because the sensitive volume of the small pixels increased relatively more with
applied bias than the large pixels. The effect is more clearly depicted later in the charge
collection efficiency study of Section 7.1.4. Though not plotted, the breakdown voltage
was measured to occur at around 63 V for Pixel #27. Some of the pixels displayed
higher leakage currents than expected, which could be attributed to non-uniformity in
wafer resistivity, and defects.
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Voltage [V]
Figure 7.2: Leakage current-voltage characteristics of select pixels showing the large
pixel (#59) with a higher current than the small ones (#01 and #26) independent of
track length.

7.1.2

Capacitance-Voltage Characterisation

As stated in Section 3.1.1.4, the p-i-n diode has a wide, near n-type, intrinsic layer that
gives a low capacitance and low leakage current under full depletion. To determine
a suitable operational voltage and gain a quantitative understanding of the pixel
capacitance, the capacitance-voltage (C-V) characteristics of a number of both small
and large pixels was measured.
Using a Boonton 7200 Capacitance Meter[186], a reverse bias voltage was applied to
the detector, via the breakout board, and was incrementally changed from 0 V - 50 V
(below the breakdown voltage) in 100 mV steps. The capacitance was recorded at
each step using National Instruments LabVIEW [185] and the IEEE-488 interface[184].
The electrical connection for the test circuit is identical to that diagrammed earlier in
Figure 4.8, except that the detector was connected through the breakout board.
The unwanted capacitance of the test circuitry was ignored by connecting an
identical, though unpopulated breakout board, zeroing the capacitance meter prior to
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Voltage [V]
Figure 7.3: Capacitance-voltage characteristics of various pixels. Pixels #01 and #26
are small type, with Pixel #01 having a short track and Pixel #26 having a long track.
Pixel #59 is the large and has a short track length.

each pixel measurement and then replacing with the correct, populated breakout board.
The data measured for some pixels on the detector sample indicated pixel damage,
and were therefore omitted. These performance issues included very low breakdown
voltages or unstable and inconsistent response.
A sample of CV curves for both small and large sized pixels are presented in
Figure 7.3. As expected, the large pixel features a greater decrease in capacitance with
increasing voltage in comparison to the small pixels. Additionally, the difference in
capacitance between pixels of differing track lengths is significant with longer tracks
resulting in a large capacitance; small Pixels #01 and #26 are extreme examples.
To further analyse the relationship between apparent pixel capacitance and track
contribution the capacitance at operational voltage (50 V) was plotted for each pixel
against the radial distance from its bonding pad group, see Figure 7.4. Here, a strong
correlation can be drawn between track length and observed capacitance, which can
only be altered through detector design.

7.1. DETECTOR CHARACTERISATION | 1 7 9

20

18
fa

O

x

<§>

O

16
XX

x x

X Large pixels
O Small pixels

O

8

6

3

4

5

7

6

8

9

10

11

12

13

14

15

Approximate track length [mm]
Figure 7.4: Capacitance-track length characteristics of a select number of pixels taken
at a reserve bias voltage of 50 V. Note the trend of increasing capacitance with
approximate track length (distance from appropriate pixel bonding pad group).
7 .1 .3

E n e rg y R e s o lu tio n - A lp h a S p e c tr o s c o p y

Alpha spectroscopy is a very effective method for determining the energy resolution
of silicon diodes. The alpha emitter used for this experiment, americium-241

( 241

Am),

has a spectrum of alpha energies with a weighted mean of 5.468 MeV and a projected
range in silicon of ~ 28 p m [208]. Given the detector thickness is 300 pm, full energy
deposition is expected to occur.
This spectroscopy characterisation aimed to investigate the uniformity of the detec
tor’s n-type silicon substrate by observing the energy resolution across various pixels
and under differing biasing conditions. Greater substrate uniformity results in higher
uniformity in the internal electric field and entrance windows of the pixels and thus
indicates the level of quality of the substrate and its fabrication. High uniformity leads
to more consistent performance between both pixels and detectors, and infers better
energy resolution across all energies which is important for eye plaque dosimetry.
For alpha particles of this energy, the noise contribution from the preamplifier and

7.1. DETECTOR CHARACTERISATION | 180

electronics can be less significant than the inherent energy resolution of the detector[163].
The theoretical limit of the FWHM observed in silicon at a specific energy can be
determined from Equation 7.1, where Fano factor and ionisation energy for silicon are
given as FSi = 0.11 and eSi = 3.62eV, respectively[163].

FWMH|ttm = 2.35 x V F E l

(7.1)

As the incident alpha particle energy, E, is 5.486 MeV in this case, the theoretical limit
is FWMH|ttm = 3.47keV or 0.063%.
Alpha spectroscopy was carried out on three pixels, # 2 4 , # 6 4 and # 5 9 , which
were selected based on their position, low capacitive-voltage characteristics and size as
mapped in Figure 7.5. An

241

Am source and the detector were placed in close proximity

within a vacuum chamber in order to both maximise the count rate, and to eliminate
the interaction of the a-particles with air. A reverse bias voltage of 50.0 V was applied
to the back plane of the detector and, during separate measurements, the pixel of
interest was connected to an Amptek A250 preamplifier[225]. The preamplifier was set
with gain, k = 2, low-level threshold, LLT = 40 (320.5keV), and acquisition time,
t = 600 s. Energy calibration was performed by using a calibrated pulse generator to
inject the preamplifier with pulses, with energies of 3.00 MeV, 4.00 MeV, 5.00 MeV and
6.00 MeV. The locations of these were used to scale the output channel accordingly.
The energy spectra measured with the three selected pixels are presented in Figure
7.6. There was good energy resolution for all three with FWHM of the spectral peaks
measuring 1.3% (70keV), 2.2% (120keV) and 1.9% (100keV) for pixels #59, # 64 and
#24, respectively. These peaks coincide relatively well (within 2.2% of peaks energies)
given the differing track lengths for the pixels presented, though it is expected that
the resolution will worsen with increasing capacitance. Some fine spectral features are
present around the peaks which can be attributed to the presence of the aluminium
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■

.

59 64
Figure 7.5: Location of three of the pixels used in spectral analysis. Pixels of both sizes
and differing track lengths were chosen for comparison. The grey pixels surrounding
Pixel # 2 4 indicate those involved in the charge sharing testing.

and the passivated oxide layers over the sensitive volume. This allows for the same
energy thresholding in the front-end electronics to be used for all pixels.
The term charge sharing describes the process whereby a single particle deposits
its charge across multiple pixels. Charge sharing between pixels degrades the quality
of the measurable signal.

In order to determine whether the P a n o p t e s detector

exhibited charge sharing, the spectrum of a single, centrally located pixel ( # 2 4 ) was
measured in two configurations: with the neighbouring pixels connected to ground;
and with the neighbouring pixels left floating. By grounding the neighbouring pixels,
their collection potential is eliminated and no charge sharing is expected. The floating
pixels, by comparison, permit the collection of charge.
The neighbouring pixels included Pixels # 1 7 - # 19 and #25 - #27, and are
indicated in gray in Figure 7.5. The energy spectra for both configurations of Pixel
#2 4 are shown in Figure 7.7. While sufficiently indicative of performance, the statistics
gathered for these plots were somewhat low due to the limited access to time on facilities
and the relatively low activity of the

241 Am

source used. By fitting first order Gaussian

curves to both measurements of Pixel #24 the peaks occur at 5.349 MeV and 5.338 MeV
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Figure 7.6: Alpha spectroscopy of three select pixels (#24, #59, # 6 4) using
source. Curves have been normalised for comparison.
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Figure 7.7: Alpha spectroscopy using 241Am source for pixel # 2 4 with and without
neighbouring pixels grounded. Curves have been normalised for comparison.
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for floating and grounded neighbour connections, respectively. These peaks align to
within 99.79 % at these energies, showing that neighbouring pixels have a negligible
effect on a given pixel.
More sophisticated methods for measuring the energy response of the detector
can be accomplished through ion beam induced charge collection, where ions are
raster scanned at a detector sample to provide both charge collection and positional
information.

7.1.4

Charge Collection - Ion Beam

Using the heavy ion beam facilities in the ANTARES Accelerator at ANSTO, ion
beam induced charge collection (IBICC) was carried out using a 5.5 MeV He+ 2 ion
source. Similar to the effect which occurs in alpha spectroscopy, explained above in
Section 7.1.3, ion beam measurements are useful in charge response analysis due to
the full energy deposition of the particles in the silicon detector. The helium ion has a
projected ionisation depth of ~ 28 pm [208] in silicon. The preamplifier used for these
sets of experiments was the Amptek A250[225].
The aim of these measurements was to determine the charge collection response of
the pixels, the response of applied bias voltage, and to determine the extent of charge
sharing. Three pixels of interest were selected to illustrate the results, namely, Pixels
#24, Pixel #64 and Pixel #56, see Figure 7.5 for their locations. Median energy maps
and the corresponding energy spectra are shown for large and small pixels in Figure
7.8 and Figure 7.9, respectively. The data was calibrated using input from a pulser
signal of known energies and curve fitting the channel energies accordingly.
The measured energy resolution of the silicon detector was good, having a FWHM
of 20 keV or 0.37% at the main energy peak. Lower energy events lead to splitting
and broadening of the main peak and are more noticeable in the spectra of the small
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diodes, as seen in Figure 7.9. This occurred as a small portion of the alpha particle
energy was deposited in the non-sensitive silicon oxide and aluminium layers and where
ionisation occurred on the edge of the sensitive region causing partial collection, as
seen in Figure 7.10.
Charge collection mapping was conducted as a function of bias voltage for both
sizes of pixel. The bias voltages used for both pixel sizes were 0.0 V, -1 0 .0 V, -2 0 .0 V,
-3 0 .0 V, -4 0 .0 V and -5 0 .0 V and the ion source was 5.5 MeV He+2. The normalised
response was plotted as a function of the bias voltage and presented in Figure 7.11.
The values for this response curve were taken as the average of 20 pixels x 20 pixels
taken at the centroid of the 0.0 V image for each size, respectively.
It can be seen that the charge collection response of both pixel sizes increased
substantially between 0.0 V - 10.0 V, after which the response flattened. Nearly full
depletion occurred for both pixel sizes, reaching about 96% charge collection efficiency.
To determine whether or not charge sharing occurs between neighbouring pixels,
charge collection mapping was conducted for Pixel #24 under two different conditions.
This first involved having Pixel # 2 4 ’s nearest neighbouring pixels connected to the
test circuitry ground, and the second left them disconnected (floating). Connecting
the pixels to ground eliminated any electric field which would act to attract nearby
charge to them; leaving them floating did not prevent this from occurring.
The neighbouring pixels included Pixels # 1 7 - # 19 and #25 - #27, and are
indicated in grey in Figure 7.5. Charge collection maps were produced using a helium
ion source, for neighbours grounded and floating. The resulting energy spectra, nor
malised to their ion source peaks, are presented in Figure 7.12. No significant changes
in spectra occurred due to partial charge collection.
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The measurements were taken with a bias voltage of -5 0 .0 V. Spatial axes are in units
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Figure 7.9: Energy spectrum for Pixels #6 4 and #59, small and large type pixels
respectively. The measurements were taken with a bias voltage of -5 0 .0 V. Three
prominent peaks are visible and have been labelled. Spatially resolved maps which are
thresholded over these peak regions are presented for Pixel # 5 9 in Figure 7.10.
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Figure 7.10: Spatially resolved energy windows of the three peaks shown in Figure 7.9
for Pixel #59 with bias voltage of -5 0 .0 V. Peak # 1 occurs at the aluminium contact
above the p + region, Peak # 2 occurs due to the silicon dioxide layer over the edge of
the sensitive region, and Peak # 3 occurs over the exposed p + region.
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Energy [MeV]
Figure 7.12: Charge sharing comparison of Pixel # 24 (small) at -5 0 .0 V with neigh
bouring pixels left floating (disconnected) and with neighbours connected to the test
circuit ground. The curves are normalised to their respective ion source peaks. Neigh
bour pixels include Pixels # 1 7 - # 19 and #25 - #27.

7.1.5

Monte Carlo Dose Response Simulations

In order to convert the values returned by the detector electronics to dose response
in tissue, the energy response both in tissue and the detector must be quantified.
As described in Section 6.3, the semicircular pixelated detector is located within the
spherical eye phantom, such that the detector central axis aligns with the plaque
central axis. Despite this, there is still an effect of differences in attenuation of the low
energy photons that propagate through the silicon plane compared to water. This effect
depends on the angle of the plaque due to differences in the number of seeds crossing
the silicon detector plane. As the silicon pixelated detector is thin (300 pm) relative
to the size of the eye phantom, the impact of dose conversion factors in spectroscopic
dosimetry for each pixel is expected to be low.
The effects of the perturbation of the radiation field by both the silicon detector
within the PMMA (poly(methyl methacrylate)) eye phantom and the substitution of
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water by PMMA, need to be accounted for. This was performed using conversion
factors to convert the detector’s spectroscopic pixel response to tissue (water) dose
for each pixel. Monte Carlo simulation offers a strong platform for quantifying these
details and enabling the use of P a n o p t e s for dosimetry.
To calculate the conversion factors for P a n o p te s , Monte Carlo simulations were
performed using the Geant4 Toolkit I226 >2271. Here, the full P a n o p t e s detector, PMMA
eye phantom and surrounding air were modelled, below a 15 mm ROPES eye plaque,
loaded with ten 125I seeds. The simulation included modelling the full P a n o p t e s
detector where the sensitive volumes corresponded to the individual pixels.

The

detector was modelled inside a PMMA eye phantom. A 15 mm ROPES eye plaque
containing ten Oncura model 6711 125I seeds was located at the apex of the eye phantom,
and the phantom housed the detector, as shown in Figure 7.13.
The Livermore low energy physics models[228] were used with Geant4 version 9.5
patch 01. The individual physics interactions considered in the simulations were the
photoelectric effect, Compton scattering and coherent scattering for photon interactions
and Bremsstrahlung, ionisation and multiple scattering for electrons, with a 1 pm
minimum range set for the generation of secondary particles. The simulations of the
eye phantom in the detector were performed in two configurations:
1)

the materials used for the detector, phantom and environment were silicon,
PM M A and air, respectively; and

2

) all materials, except the plaque and seeds were modelled as water.
Each of these configurations consisted of a set of measurements with the plaque-

detector angle varying from 0° - 360° in 15° increments. Computational cost was
reduced as only 180° needed to be covered in the simulation due to the symmetry of
the model. The conversion factors for each pixel were calculated as the ratio of dose
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Figure 7.13: Schematic of Monte Carlo model where two material configurations were
compared, treatment equivalent (water) and phantom equivalent (silicon, PMMA, etc.).
For clarity, the seeds are not displayed.

measured in silicon to dose measured in water averaged, across all angles, as seen in
Equation 7.2.

ki = 2244 0=0,15,30,...
£
D
D20i^(9)
lk
DH

(7.2)

Equation 7.3 shows the dose, D wi(9) as a function of plaque angle, 9, where N is
the number of counts per unit area at Pixel # i, and k*(9) is the conversion factor for
this pixel, at plaque angle, 9.

Dwt (9) = Ni x kt(9)

(7.3)

The conversion factors presented in Figure 7.14 show that the positions of the pixel
dictate their energy response; the pixel conversion factors are clustered into groups
corresponding to their layout. The closer a given pixel is to the plaque, the higher the
proportion of its incident particles that will have deposited energy in silicon, giving it a
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more influential conversion factor. These data are tabulated in Table A.2 in Appendix
A.
The deviations of the conversion factors calculated for each pixel across all angles
are presented as error bars in Figure 7.14 and are plotted in Figure 7.15. These data
are tabulated in Table A.2 in Appendix A . The pixels that are positioned closer to the
central plaque axis have less deviation across all angles. The mean deviation across all
pixels is 1.9 %, while around 96 % of the deviations from all pixels and angle fall within
4.0 % and the absolute maximum deviation from all pixels and all angles is 7.4 %, on
Pixel # 2 , one of the farthest from the plaque.
It can be seen from Figure 7.15 and the pixel map in Figure 6.5 that with decreasing
pixel-plaque distance, there is a reduction in angular discrepancy across all angles. This
is ideal for dosimetry as these pixels fall in the region of most interest, near the plaque.

7.2

Integrated Detector Characterisation

The systematic response of the P a n o p t e s was evaluated for calibration and under
standing of performance.

Using a flat radiation field, the P a n o p t e s was used to

measure the spectral response of an 125I source, and the detector-ASIC sensitivity was
normalised.

7.2.1

Energy Resolution and Thresholding

In order to calibrate the readout electronics for energy thresholding, the P a n o p t e s
was configured as a single channel analyser (SCA) and used to measure an 125I source.
Energy thresholding is the process of counting only input energies within a given range.
This was achieved by setting the global threshold DACs on the readout electronics
to compare against input pulse heights (event energies). Only the low-level threshold
required tuning, in order to ignore level energy noise. The upper-threshold was set
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Pixel Number
Figure 7.14: Dose to water conversion factors for all pixels, averaged across all angles.
The conversion factor value is lower for pixels closer to the plaque. The error bars
corresponding to each pixel represent the standard deviation of the conversion factors
of all angles for that pixel.
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Figure 7.15: Angular discrepancies across all angles for simulated conversion factors of
individual pixels. The conversion factor deviation increases with increasing distance
from the plaque central axis.
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fully open as there was no expected presence of high energy noise. Since the peak
energies were known, linear calibration was a simple process. The software interface
that was used to handle the analysis procedure is described in Section 6.4.
The device operated as an SCA by setting a small threshold window width and
taking multiple acquisitions, incrementing the windows along with each acquisition,
from minimum to maximum . This process was carried out for all three windows and
all pixels concurrently. For Window 0, this type of windowing is not possible as it is
only a one sided, low level discriminator.
Whilst all the pixels were measured, Pixels # 27 and #3 4 were selected for presen
tation due to their central location, good statistics and difference in size; i.e. small
and large types, respectively. The selected pixels are highlighted in Figure 7.16, and
were deemed a good representation of the dataset.
For the acquisition shown in Figure 7.17, the bin width was set to the minimum, a
single channel, giving a total of 1023 bins. With a bias voltage of 50 V applied, each
acquisition was set to run for 10 s, totalling an acquisition time of approximately 3 h
and

20

min.

The spectra shown in Figure 7.17 have good resolution and clearly resolvable 125I
peaks.

The FWHM for Pixel # 2 7 and Pixel # 3 4 are 2.5 keV (9.3%) and 3.0 keV

(11.1%), respectively. Low energies, not shown on the plot, are dominated by noise.
Energy thresholding was used to select only the peaks displayed in Figure 7.17, which
improved dosimetric accuracy on the P a n o p te s .

7.2.2

System Equalisation

A detector’s sensitive volume is determined by its geometry and applied bias voltage,
and hence amount of charge collected for a given radiation flux density, see Section
7.1.4. The sensitivity of individual pixels of the same size could differ slightly from
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Figure 7.16: Location of Pixels # 2 7 and #3 4 used in the spectral measurement.

Energy [keV]
Figure 7.17: Spectrum of 1 0 x 125I seeds loaded in ROPES 15mm plaque with phan
tom. Taken by configuring the readout ASIC to perform single channel analysis using
Pixel#27, the location of which is shown in Figure 7.16. The relative emission spec
trum of a Model 6711 brachytherapy seed is overlaid for comparison. Source: Ling
et al.[229], Be et al.[230]
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one another due to the presence of silicon defects and resistivity variations in the
pixel and its coupled readout electronics channel.

Before the P a n o p t e s can be

used for dosimetry, the pixel response must be equalised through this type of flat-field
calibration. The calibration factors determined in this set of tests could be subsequently
applied through the Panopticon software, as detailed in Section 6.4.
In order to determine the individual response of each pixel-readout channel couple,
measurements were taken using a flat-field x-ray source. This testing was carried out
at the Illawarra Cancer Care Centre (ICCC) using a Gulmay D3300, orthovoltage
machine.

The detector was connected to its readout electronics and aligned at a

source-detector distance (SDD) of 3 m from the beam source, see Figure 7.18 for an
annotated photograph.
The orthovoltage machine was used with a 10 cm circular applicator with a 50 cm
FSD (focus to surface distance). The intensity of profile of the largest available field
size (15 cm x 15 cm) is presented in Figure 7.19. The beam shows a flat response for
the 150 mm specified region and the region pertaining to the 10 cm applicator used
experimentally falls within this. Deviations in this field were diminished when the
focal spot was extended to the location of the detector at 3 m, where it became a
j2f60cm field. Given the active area of the detector is approximately 24 mm x 12 mm,
the resulting relative uniformity was sufficient for calibration.
The detector board was mounted within a thin PMMA box and encapsulated in
aluminium tape, which was grounded to the digital ground of the electronics. This acted
to shield the device from electromagnetic interference and inhibit the transmission of
light through the box to the detector. To further limit light exposure, the acquisitions
were performed in a dark room.
The readout ASICs were configured with the energy windows set fully open whilst
excluding dark noise, gain set to 0.75m V fC - 1 and shaping time set to 500 ns. Using a
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Detector

Figure 7.18: Photograph of flat field calibration experiment undertaken at the Illawarra
Cancer Care Centre, showing the source and detector, encapsulated in a shielded, dark
box.
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Figure 7.19: Profile of the 250 kV beam used for flat field calibration. This measurement
was performed on the surface of a Plastic W ater®[180] phantom using a 10 cm circular
application with a FSD of 50 cm.
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beam voltage of 250 kV, 100 acquisitions of 100 ms were taken and integrated to give
a total acquisition frame of 10 s. The dose rate was

6 8

cG ym in-1 , calibrated to water

at 500 mm. Table A .1 in Appendix A summarises the configuration parameters used
in this calibration.
The small and large pixel datasets in Figure 7.20 represent the calibration factors of
the individual pixels, normalised to the pixel with highest response (Pixel #30). The
mean calibration factor for the small and large pixels is 7.57 ± 0.59 and 1.09 ± 0.05,
respectively. From these mean values, the large pixels are approximately 6.9 times
more sensitive than the small pixels.
The overall uniformity of similarly sized pixels was good with a standard deviation
of 7.8% and 4.3% for small (300pm x 300pm) and large (1.0mm x 1.0mm) pixels,
respectively. This overall response implies that the detector substrate is relatively
homogeneous and that the performance of the readout channels of the HERMES ASIC
are also relatively uniform.
The colour coded pixel map shown in Figure 7.21 was generated with the Pantopicon
software interface and provides a visual representation of this information and the
number of counts that were recorded for the given calibration. The values presented
have been left as raw, showing that the count statistics ranged from about 579 x 103 61.4 x 103. The average statistical error to one standard deviation for the large pixels
was 0.16 % and for small was 0.41 %. These data are tabulated in Table A .2 in Appendix
A.

7.2.3

Combined Conversion and Equalisation

Combining the conversion factors from the Monte Carlo simulation and the calibration
factors, the pixel colour map in Figure 7.22 was produced. This plot illustrates the
corrections that were applied to the P a n o p t e s measurements taken in the following
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Figure 7.20: Calibration factors derived from flat field experiment plotted for small
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Figure 7.21: Visual representation of detector response from the flat field calibration
in raw counts taken as the summation of 100 x 0.1s acquisitions, as detailed in Table
A .1
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Figure 7.22: Visual representation of the combined flat-field and dose-to-water conver
sions. Performed using fully loaded ROPES 15 mm. Data are provided in Table A.2
in Appendix A

chapter. These data are tabulated in Table A .2 in Appendix A .
Equation 7.4a was used to calculate the dose to water, D Wi(9), at the location
of a given pixel, Pixel # i, and for a given angle, 9. Here, Ni(9) is the number of
counts measured at Pixel # i, bi is equalisation coefficient normalised to the most
sensitive pixel, Pixel #30, kiave is conversion coefficient for Pixel # i, averaged across
all simulated angles.

D wi(9) = Ni(9) x bi x kiave

(7.4a)

D Wi (9) = Ni(9) x bi x kiave x ai

(7.4b)

A more complete version of this equation, shown in Equation 7.4b, would also
include a factor for absolute calibration. In this case, ai is the conversion factor of the
number of counts measured in the detector to the dose in silicon. Determining this
calibration would involve placing a single seed in Plastic Water at 1 cm above a central
pixel, for example Pixel #34, with the equalisation coefficient equal to 1. The response
from each pixel would be recorded and compared to the expected dose at each point
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as per the TG-43U1 formalism and verified using Monte Carlo.

7.3

Discussion

The detector, as a standalone device and integrated into P a n o p t e s , was charac
terised to determine parameters to prepare it for use in accurate plaque brachytherapy
dosimetry. Current-voltage and capacitance-voltage curves were measured to quantify
device performance. The energy resolution of the detector was measured using alphaspectroscopy and ion beam induced charge collection. The latter process was also used
for geometric mapping of the sensitive volume of the selected pixels. Monte Carlo
simulators of the device were used to accommodate for energy corrections from silicon
to water. With the detector integrated into P a n o p t e s , a spectrum was taken using
single channel analysis, and finally, the P a n o p t e s was calibrated using a flat-field
photon beam.

7.3.1

Current-Voltage Characterisation

By measuring its current-voltage characteristics, the detector was shown to behave
as expected, with breakdown occurring at approximately 63 V. The large pixels were
shown to have a larger leakage current than the small pixels, as expected. This suggests
that a greater level of operational signal noise will occur in large pixels, though it will
be counter-balanced by their higher sensitivity and thus better count statistics. The
relatively low overall leakage current means that the device can be used safely at room
temperature which is important for clinical practice.
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7.3.2

Capacitance-Voltage Characterisation

Capacitance-voltage curves of many of the detector pixels were measured to get an
estimate of the expected signal quality for the device. It was shown that the track
length of a pixel had a greater overall contribution to the total pixel capacitance than
its geometry. Pixels far from the bonding pads had capacitance values of about twice
those that were close to the pads. The fact that this track capacitance is high, relative
to the pixel capacitance, makes it difficult to decouple them and determine the full
depletion voltage through plotting 1/C2 versus bias voltage. However, the capacitance
is not required to determine the depletion voltage, only the point when it is saturated.
Depletion characteristics of the pixels were investigated later using ion beam analysis.

7.3.3

Energy Resolution - Alpha Spectroscopy

The energy spectra of three pixels measured showed the detector to have good energy
resolution between 1.3% - 2.2% for the set. This is important in order to ensure
that the spectrum can be clearly identified and separated from noise using energy
thresholding on the readout electronics. Given the devices all performed with similar
energy peaks, common electronics parameters may be used for energy thresholding of
the 125I spectrum. It also addresses one of the aims of this study, showing that the
detector substrate has good uniformity and fabrication quality and suggests consistency
between both pixels and detectors, which is important for eye plaque dosimetry. Energy
resolution is also important, given differentiation of the spectral peaks is needed if
spectroscopic plaque dosimetry is to be investigated using the separate photopeaks.
Charge sharing between pixels was shown to be of negligible effect, ensuring that spatial
resolution of the detector is not effected, which is very important for the measurement
of steep dose gradients in plaque brachytherapy.
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7.3.4

Charge Collection - Ion Beam

Charge collection of the pixels of both sizes was uniform over the sensitive volumes
of the tested samples.

The surrounding contact pad is discernible in the charge

collection maps for the 5.5 MeV H+ 2 ions, due to energy loss in the aluminium and
silicon oxide over-layers around the periphery of the pixels. This has no effect in 125I
(~ 22 keV - 35 keV y ) and 106Ru (3.54MeV f3) isotopes commonly used in ophthalmic
plaque radiotherapy.
Charge collection efficiency was measured as a function of bias voltage to determine
an acceptable operating voltage for P a n o p t e s . The increase in bias voltage only caused
a marginal increase in collection efficiency between 10.0 V - 50.0 V. Despite this, it is
advantageous to operate the device at this voltage to ensure that capacitance induced
noise is minimised and collection rates are maximised at no significant detriment.
The leakage current at this voltage for a single pixel, was within about 1 nA, and no
over-heating effects were observed during the testing.
The sensitive volumes of the pixels measured were well defined spatially. This
provides accurate dose correction when converting from dose in silicon to dose in
water. In addition to this, during charge sharing tests, neighbouring diodes were not
visible on the median energy maps. Supporting the conclusions of the tests performed
using alpha-spectroscopy in Section 7.3.3, there was no significant charge sharing effect
present.

7.3.5

Monte Carlo Dose Response Simulations

Critical for dosimetry, calculating the energy correction factors for each pixel needed
to be performed over a range of angles. The dosimetry of the eye plaque is inherently
difficult due to the steep dose gradients, small overall size and low energy photons, and
is only worsened when angular dependence in detection is also considered. Through
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the Panopticon software, this angular dependence can be accounted for, as correction
factors can easily be applied to dose measurements made.
The angular response deviation for all pixels falls within around 4 % for the ROPES
15 mm plaque loaded with 1 0 x 125I seeds. In relation to other current systematic errors
in plaque brachytherapy, such as source activity variation and plaque placement, this
level of uncertainty is within similar limits.
The energy correction factors were calculated through simulation using a ROPES
15 mm eye plaque model. A generic correction factor for each pixel, accounting for
all plaques and angles, is not the optimal solution. The accuracy of said model will
determine the ultimate accuracy of the calculated silicon pixel response to dose in
water conversion. Plaque and angle specific conversion factors could be developed and
evaluated for other types of plaque, but would still be limited by simulation accuracy
and such optimisation is beyond the scope of this project.
The Monte Carlo simulations were performed, both to serve as a proof of concept
for the operation of the P a n o p t e s as a dose verification tool, and to generate the dose
to water conversion factors for use with the measured P a n o p t e s data.

7.3.6

Energy Resolution and Thresholding

The spectra taken for the pixels by the P a n o p t e s illustrates that the resolution is
good enough to identify individual peaks on the 125I spectrum.

By observing the

spectra from all the pixels, the global low energy cut-off could be determined as the
distinct minimal point between the low energy noise and the beginning for the first
125I peak. Based on this, the value was selected to be at Channel #300 or 17keV.
The measurement taken is not ideal in providing the original 125I spectrum, as it
used the P a n o p t e s phantom. While it gives an indication of the level of photopeak
identification possible, it was not used for energy calibration of the device. Instead, a
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phantomless calibration was performed.

7.3.7

System Equalisation

Equalisation was carried out using a flat-field calibration with a photon beam. This
enabled normalisation of the sensitivity of individual pixels and the amplification gain
by their corresponding readout electronics channels. The deviation in the calibration
factors of the small pixels was greater than that of the large pixels. This could be due
to the small pixels being located closer to the perimeter of the detector where crystal
defects, caused by cutting, are more likely. This simple calibration process would need
to be performed for the commissioning of any newly constructed P a n o p t e s device.
For correct calibration, these flat-field factors clearly need to be used in conjunction
with the silicon pixel response to water dose conversion factors. The calibration factor
map is dependant on specific detector and ASIC sensitivity, in addition to the silicon
detector response to water dose conversions.

7.4

Conclusion

The custom designed, semicircular, pixelated silicon detector was characterised as an
independent device and then also integrated in the rest of the P a n o p te s . Characterisa
tion of the device was done through generating I-V and C-V curves, alpha spectroscopy
and Monte Carlo simulation. The P a n o p te s was characterised through spectroscopy
and flat-field calibration.
Measurements of current-voltage curves showed that the detector was functioning
correctly, with leakage currents around less than

1

nA for most pixels. It also showed

that the breakdown voltage was around 63 V, so further testing and operation should
be done below this level.
The capacitance of the pixels was influenced more by the pixel track length, than
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the size of the pixel. The two capacitances were difficult to decouple, and as a result,
the full depletion voltage could not be determined from this. The overall capacitance
of the pixels was relatively low and should allow good signal quality.
The energy resolution of the detector was measured through alpha-spectroscopy.
The process showed the small and large pixels have similar energy responses and there
was negligible effect of charge sharing from neighbouring pixels, which is important in
energy preservation.
Extending upon the alpha-spectroscopy measurements, ion beam induced charge
collection showed that the detector pixels had well defined geometry, uniform charge
collection and, again, no influence from neighbouring pixels in regards to charge sharing.
The greatest observed charge collection efficiency occurred at a bias voltage of 50 V.
These factors are important to verify the accuracy of dose conversion factors.
These dose conversion factors were calculated using Monte Carlo simulations on
Geant4. The dose-to-water, energy conversion factors were calculated for each pixel,
averaged for all angles from 0° to 360° in 15° increments. The angular deviation of the
conversion factors fell to within about 4% for all pixels while the maximum deviation
across all pixels and angles was 7.4%.
The single channel analyser configuration of the P a n o p t e s is a useful tool in
commissioning the device. It allowed the energy threshold cut off to be determined
across all channels, accounting for individual device characteristics. The lower level
threshold cut off determined for operational use was Channel #300 (17keV).
The deviations in sensitive volume of the individual pixels and readout channels
were measured using the flat-field from an orthovoltage machine. Pixel geometry was
the major factor in dictating the sensitive volume for the detector. These values were
then normalised and used to apply calibration factors to the individual pixels through
the software interface.
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Characterisation of the P a n o p t e s has allowed for operational parameters to be
determined and to gain an understanding of the expected behaviour of the system
during the subsequent performance testing.

Chapter 8
Early Performance Testing
The previous chapters of Part III detailed the design and characterisation of the
Panoptes.

These characterisations demonstrated the capabilities of the design, and

the completion of the dosimetry system. In this chapter, dosimetry measurements
were taken with the complete P a n o p t e s using symmetric and asymmetric seed con
figurations to produce depth-dose plots and dose maps, and assess the potential of
interpolating these into dose volumes.
These planar dose map measurements were converted to dose in water, and repre
sented as isodose plots and three-dimensional sliced dose volumes. For clinical signifi
cance, comparisions to the depth-dose plots and dose maps were carried out against
the primary dose calulation methods used in eye brachytherapy. These included Monte
Carlo simulations, the Plaque Simulator software, and the TG-43U1 formalism.

8.1

System Measurements

The P a n o p t e s was tested using a ROPES 15 mm plaque loaded with Model 6711 125I
seeds. The activity of each seed was 45 pCi. For all measurements conducted in this
chapter the plaque was assembled normally using the acrylic insert and stainless steel
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Front
Plaque
PCB
Detector
Positioning
sysem box
(a) Fully loaded (10 seeds, shown at 0°)

(b) Asymmetrically loaded (5
seeds, shown at 90°)

Figure 8.1: The ROPES 15 mm eye plaque loaded with 125I seeds. The orientation
angle, 9, is normal to the detector plane, and indicates the amount which the plaque
was rotated with respect to the detector plane. The grey box and the adjacent green
line indicate the orientation of the detector and PCB, respectively. The numbers # 1
and # 6 4 represent the location those pixels on the detector. These diagrams are not
drawn to scale.
backing. Two seed configurations were used for the plaque in measuring planar and
volumetric doses across range of plaque-detector angles. These plaque configurations
are shown in Figure 8.1 and comprised:
• a symmetric ten seed layout (Figure 8.1a), and;
• an asymmetric five seed layout (Figure 8.1b).
The P a n o p t e s electronics hardware was configured with a 50 V bias voltage, for
full depletion as measured in Section 7.1.4. A shaping time of 500 ns was selected for
optimal resolution at the high count rates of imposed by the treatment. To ensure
events occurred within a measurable energy range, a gain of 0.75 m V fC - 1 was selected.
All energy windows were set with a lower threshold of 17 keV, and the upper thresholds
at maximum (

66

keV).

The acquisitions were each taken in single measurements and had a duration ranging
from 30.0 s -

1 0 0 .0

s. As activity of the seeds was low, this ensured that measured

counts had a statistical uncertainty within 1% for all pixels. In addition, the detector
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was light sensitive, and the entire positioning system was concealed within a box to
eliminate external light sources.
The plaques were configured with the front, corresponding to 9 = 0.0° as per Figure
8.1a. The plaques were loaded into the positioning system with the front facing outward
from the box, after the positioning shaft had been locked down. The top surface of
the detector was facing towards the back of the box, as shown earlier in Figure 6.14.
The dose distribution seen in Figure 8.2 shows an example response of a 100.0 s
acquisition using ten 125I seeds, orientated at 9 = 90.0° as a colour scaled, pixel map
output from the software interface. The response of each silicon pixel was adjusted with
the flat-field equalisation data and silicon-to-water dose conversion to give a corrected
response, as per Equation 7.4a, repeated below.

D Wi (9) = Ni (9) x bi x kiaVe

(7.4a)

The pixel count values range from around 26.2 x 103 - 553 x 103 counts, giving a
statistical error of 0.1% - 0 .6 %*. From this measurement the dose distribution can
clearly be seen to diminish with increasing distance from plaque, and takes a generally
symmetric, circular shape, originating from the apex of the detector. The top central
pixel, Pixel #32, appears to slightly under-respond relative to its neighbours. This is
most likely related to the seed distribution of the ROPES 15 mm plaque.
The colour scaled, pixel map shown in Figure 8.3 shows the converted response for
five seeds, with an axial alignment of 90.0° . Dose conversions were achieved using Equa
tion 7.4a. Across all pixels, the count magnitude ranges from 9.66 x

103

- 395 x

103

and their corresponding statistical errors, 0.2 % - 1.0 %. The detector plane bisects the
1
Using the Poisson distribution, where it is assumed v S 2 « a = yfx, which gives the fractional
standard deviation to be 1 / v N .
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Figure 8.2: Converted dose to water measurement taken with the P a n o p t e s using
a fully loaded ROPES 15mm eye plaque. The acquisition time was 100.0 s and the
detector plane was at 90° to the plaque angle. Counts are normalised to 100% relative
to the maximum pixel value, Pixel #39.
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Figure 8.3: Converted dose to water measurement taken with the P a n o p t e s using
a ROPES 15 mm eye plaque loaded with five seeds, as showing in Figure 8.1b. The
acquisition time was 100.0 s and detector plane was at 90.0° to the plaque angle. Counts
are normalised to 100% relative to the maximum pixel value, Pixel #19
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seed configuration symmetrically, resulting in the asymmetric dose distribution seen
in the pixel map. The dose gradient is steep, with an approximately 50 % reduction in
dose occurring between some pixels in high dose regions.

8.1.1

Planar Reconstruction

Whilst the individual pixel values are useful for point-wise dosimetry, a continuous plot
provides a better basis for dose distribution evaluation and comparison. Isodose plots
were calculated through MathWorks Matlab 2012a[199] after using bicubic interpolation
process on the pixel values and locations.
An isodose plot for the ten seed plaque configuration was generated for the orienta
tion angle of 90° and is shown in Figure 8.4. This plot illustrates the presence of two
possible hot spots to either side of the axis at the apex of the detector as a result of
the response of Pixel # 3 2, seen in Figure 8.2. The distribution depicts a reduction of
dose by half at about 3 mm. The plot features a distinct perturbation near the dose
periphery on the mid-right side, matching the calibration map from Figure 7.22 in
Chapter 7, and another near the bottom left. For comparison, an additional plot at a
plaque orientation of 0° is provided in Figure A.1 in Appendix A. The two plots are
very similar in dose distribution.
An isodose plot using the five seed configuration was also created for a 90° plaque
orientation and displayed in Figure 8.5. The 90° orientation shows strong asymmetry
towards the left side of the detector. The plot depicts a small non-uniform distribution
in the area of high activity, under the location of the seeds. An additional isodose
plot at a plaque orientation of 0° is provided in Figure A .2 in Appendix A , which is
symmetric by comparison.

SYSTEM MEASUREMENTS I 211

8.1.

n

12
10

8

100

80

Qj
£
O
m
0)

6

60

4

40

C
V
m

20

I

'-O

2
0

-1 2 -1 0

- 8

- 6

-4

-2

4

0

6

8

10

12

mm
Figure 8.4: Interpolated isodose curves of P a n o p t e s measurement converted to dose in
water with ten 125I seeds at 90°. Dimensions are in millimetres and dose is normalised
to 1 0 0 % at the maximum value.
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Figure 8.5: Interpolated isodose curves of P a n o p t e s measurement converted to dose in
water with five 125I seeds at 90°. Dimensions are in millimetres and dose is normalised
to 1 0 0 % at the maximum value.
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Volumetric Reconstruction

For every angle measured with the P a n o p t e s , a dose distribution map, such as the
isodose plots used in Figures 8.4 and 8.5, can be produced. This form of presentation
is useful in its own right, though for an overview of the dose distribution of the
entire plaque, it provides the intended foundation for three dimensional, or volumetric,
dosimetry.

To meet the aim of assessing the potential of interpolation for plaque

dosimetry, volumetric slicing was preferable overly purely 2D representation.
The P a n o p t e s was used to measure a 360° sweep of the plaque in small increments.
Varying the number of angle increments gives a trade-off between axial resolution,
9i, on one side, and acquisition time and processing complexity on the other. The
volumetric datasets presented here used either 9i =18.0° or 9.0° degree increments, but
the P a n o p t e s is capable of a resolution of 9i =0.18°. However, for clinical applications
this resolution may be superfluous and still limited by the xy resolution of the detector.
By collating the individual pixel values, their corresponding detector positions and
acquisition angles, three dimensional matrix operations were used to calculate and
convert from the original xy9 to an x yz coordinate system. These data sets were then
linearly interpolated in three dimensions to produce a matrix of values. To improve
the interpolation outcomes, only one half of the detector pixels (Pixels # 1 - #34) were
used in the spatial mapping. Using both halves simultaneously produced artefacts due
to attenuation induced variations in the measured dose at a point in space. This was
because symmetrically located pixels measured differently attenuated dose for similar
locations when the plaque was rotated 180°.
Using a slice function, values falling on specified planes were be plotted for vi
sualisation of the volumetric data. Acquisitions were taken for 30.0 s at each angle,
which allowed for sufficiently low statistical counting error ( < ~
activity.

1 %)

based on the seed
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Figure 8 .6 : Volumetric slice plot of ten 1251 seeds in a ROPES 15 mm plaque using
the P a n o p t e s acquired over 20 measurements. The slices are separated vertically by
2 mm increments. Dimensions are in millimetres and dose is normalised to 100% at
the maximum value.

Figure 8.7: Volumetric reconstruction of P a n o p t e s data taken with ten seeds and
40 angles, with an increment of 9.0°. The slices are separated vertically by 2 mm
increments. Dimensions are in millimetres and dose is normalised to 100% at the
maximum value.
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Figure 8 .8 : Mapped response difference between angular increments of 9 = 9° and
9 = 18°. The difference in response is calculated using Figure 8 . 6 (I20) and Figure
8 . 6 (I 4 0 ) as Diff = I 2 0 / I 40• The slices are separated vertically by 2 mm increments.
Dimensions are in millimetres.

Figure 8.9: Volumetric slice plot of five 1251 seeds in a ROPES 15 mm plaque using
the P a n o p t e s configured with 20 angles. The slices are separated vertically by 2 mm
increments. Dimensions are in millimetres and dose is normalised to 100% at the
maximum value.
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Figure 8.10: Volumetric slice in the xy plane 2 mm from the volume apex of five
1251 seeds in a ROPES 15 mm plaque using the P a n o p t e s configured with 20 angles.
Dimensions are in millimetres and dose is normalised to 100% at the maximum value.
The ten seed configuration was measured with ^ = 18° and is presented in Figure
8 .6

. The volume has been sliced in the xy plane at every 2.0 mm and axially at planes

x z and y z . It shows a dose volume which is maximal at the apex and quickly drops
off to less than

20

% after around

6

mm.

Better coverage of a three dimensional space can lead to more accurate and useful
interpolation results.

The dose volume in Figure 8.7 was created using twice the

angular resolution, at a total of 40 acquisitions and 6 = 9.0°. Figure

8 .8

shows that

differences occur as a function of angle. These differences have a mean of n = 100.6 %,
a standard deviation of o = 2.7% and an absolute maximum of 118.5%.
The dose volume for the five seed configuration is depicted in Figure 8.9 and a slice
through the xy plane at

2

mm is shown in Figure 8.10. The dose distribution of the

five seed data was generated from 20 angles, with an increment of 18°. On one side of
the central plaque axis, the dose reaches a maximum in a relatively small volume; the
other side of the axis exhibits a larger, lower intensity dose volume. The xy plane in
Figure 8.10 clearly shows this feature and illustrates the usefulness of a dose volume
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in generating dose planes in otherwise unavailable orientations. This xy plane also
reveals the steep dose gradients that can occur in plaque brachytherapy which, in this
case, may be partially attributed to dose attenuation through the detector board.

8.2

Verification

Dose verification of the P a n o p te s prototype was investigated through a comparison
with Monte Carlo simulations, Plaque Simulator[22] and the TG-43U1 formalism[20], as
they offered the most relevance to current clinical practice. This study was conducted
using the ten seed plaque configuration, also selected for clinical relevance, and involved
a comparison of planar dose contours and depth-dose curves.

8.2.1

Plaque Simulator Calculations

The BEBIG Plaque Simulator[22] was used to generate planar dose maps and depthdose data for the ROPES 15 mm plaque with ten seeds. The dose maps consisted of
a 32.0 mm x 32.0 mm dose field with increments of 200pm, centred about the centre
of the eye. The plaque orientation used for the calculations was 9 = 90°, and was
cropped to the area of the detector, as displayed in Figure 8.11. The dose map was
processed with MathWorks Matlab 2012a[199] to calculate pixel equivalent values, which
was interpolated to generate the isodose plot, displayed in Figure 8.12. The pixel value
calculations involved taking the mean of the values that fell within the area and location
of the pixels.
The dose distribution map generated through Plaque Simulator provides coverage
up to the brachytherapy seeds and extends out beyond the eye. The collimation effects
of the plaque are clear and the bisection of two seeds can been seen to match the
plaque configuration shown in Figure 8.1a.
The P a n o p t e s equivalent pixel values, taken from the calculated dose map, were
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Figure 8.11: Plaque Simulator calculation at 90° on plaque axis. The plaque was
a ROPES 15 mm with 10 x 125I seeds. Dimensions are in millimetres and dose is
normalised to 1 0 0 % at the maximum value.
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Figure 8.12: The equivalent pixel values from Figure 8.11 were taken to match the
P a n o p t e s detector and then interpolated to provide an isodose curve. Dimensions
are in millimetres and dose is normalised to 1 0 0 % at the maximum value.
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used to recalculate the isodose plots for demonstration purposes, and is shown in
Figure 8.12. A relative difference comparison of the calculated image matrix with
the original image showed good correlation, within 5% which was primarily located
at the image edges. There are no distinguishable seeds at the apex of the virtual
detector, in agreement with the original Plaque Simulator. This is because this region
lies within the plaque boundary and the seeds are simply out of the field of view. For
later comparison, the direct mean calculated pixel equivalent values were used, rather
than the interpolated map from Figure 8.12.

8.2.2

Monte Carlo Simulations

Using the Monte Carlo model and simulations detailed earlier in Section 7.1.5, the
pixel data for the

0 .0 °

orientation was used to produce additional isodose plots for

comparison, as shown in Figure 8.13. The model used an acrylic phantom, with a
silicon detector, metal backing and an environment of air. Pixel data was taken as the
total accumulated energy deposition in the sensitive volume of each pixel, with dose
normalised to 100% at the maximum value. The conversion factors from Section 7.1.5
were applied to convert to dose in water.
To gain an understanding of the effectiveness of the conversion factors, the simulated
detector response in water was compared to the dose converted detector response at
plaque-detector angle, 9 = 90°. The resulting differences are plotted in Figure 8.14
and show that most values fall within ± 2 % difference. This lies within some existing
uncertainties for plaque brachytherapy such as source activities uncertainty (see Section
2.2.4.3).
The overall distribution of the plot consists of a series of relatively uniform isodose
curves originating from the plaque region, shown in Figure 8.13. The Monte Carlo
isodose plot shows a similar dose profile to that seen in the reconstructed Plaque
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Figure 8.13: Monte Carlo calculation at 90° on plaque axis. The plaque was a ROPES
15 mm with 10 x 125I seeds. Dimensions are in millimetres and dose is normalised to
1 0 0 % at the maximum value.
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Figure 8.14: Through Monte Carlo simulations, the dose in silicon was converted to
dose in water, using the conversion factors from Figure 7.14. The plot shows the
percentage difference for a ROPES 15mm with 10 x 125I seeds at 9 = 90°.
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Simulator plot.

8.2.3

Comparison

Evaluation of the simulated, calculated and measured planar dose images in a water
eye was performed using a depth-dose comparison and a pixel-by-pixel comparison.
The depth-dose comparison consisted of using the four pixels on the central axis of the
detector (Pixels #32, #27, #3 4 and #33) for the P a n o p t e s data, the corresponding
Monte Carlo simulation, Plaque Simulator and TG-43U1 formalism data. The resulting
plots are presented together in Figure 8.15 where the data was normalised to 100% at
5.15mm (Pixel #34).
The Plaque Simulator and the TG-43U1 correlated very well along the available
range. The Monte Carlo simulation and the converted P a n o p t e s measured data
also agreed well, falling within approximately 3.5 % for the four points in the curve.
The P a n o p t e s dataset features a greater change in dose rate in comparison to the
other datasets, with a maximum discrepancy of less than 4% for any one of them.
This discrepancy falls within the uncertainties of low energy brachytherapy sources[116]
(Section 2.2.4.3).
For a pixel-by-pixel response comparison for the different means tested, the flat-field
and energy calibrated pixel values were calculated and plotted against each other in
Figure 8.16. The values were normalised to the central pixel, Pixel #34. In addition
to this, the percentage differences between each pixel in the normalised P a n o p t e s
measurement and the other three data sets were plotted and are presented in Figure
8.17.
The plots illustrate that overall, the P a n o p t e s dataset deviates from the Monte
Carlo simulation, the Plaque Simulator data and the TG-43U1 formalism. Discrepan
cies are largest for pixels that are close to the apex of the detector in comparison to
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Distance from surface of plaque at central axis [mm]
Figure 8.15: Depth-dose comparison of P a n o p t e s against several calculation methods
for the ten seed configuration of the ROPES 15 mm plaque at 90° orientation. For the
measured data, the central pixels were used, namely Pixels #32, #27, # 3 4 and #33.
All datasets are normalised at 5.15mm (Pixel # 3 4) to 100% and error bars on the
P a n o p t e s and Monte Carlo datasets are shown to 2a.
those at the base. In the P a n o p t e s data, the three topmost pixels on each side of Pixel
#3 2 (top-central pixel) over-respond compared to the other data. The Monte Carlo
simulation and TG-41U1 formalism over-responded with respect to the P a n o p t e s
data, whilst the Plaque Simulator data was most similar to the P a n o p t e s .
The response differences between the Monte Carlo dataset and the P a n o p t e s had
a mean value of 4.4 % and a standard deviation of 7.5 %, though the majority of pixels
fell to within ±15% . For the Plaque Simulator dataset, the mean response difference
was 0.0 % and the standard deviation was 5.3 %. Finally, the mean response difference
for the TG-43U1 formalism calculations was 4.3 % with a standard deviation of 10.6 %.
The differences in normalised response for each simulation method from Figure 8.17
are also presented on a spatially resolved detector map in Figures 8.18, 8.19 and 8.20
for Monte Carlo, Plaque Simulator and the TG-43U1 formalism, respectively. These
plots illustrate that deviation from the P a n o p t e s dataset occurs dominantly on the
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Figure 8.16: Pixel-by-pixel comparison of the normalised response of P a n o p t e s against
calculated methods for the ten seed configuration of the ROPES 15 mm plaque at 90°
orientation. Plaque Simulator values were taken as the mean value of the dose under
the area of each pixel. The error bars for P a n o p t e s and Monte Carlo datasets are
shown to 2a.
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Figure 8.17: The percentage difference for each pixel for Monte Carlo and Plaque
Simulator data with respect to the P a n o p t e s data; based on the data presented in
Figure 8.16. Error bars on the Monte Carlo dataset are shown to 2a.
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periphery of the detector, especially for the Monte Carlo and TG-43U1 datasets.

8.3

Discussion

The performance of the P a n o p t e s was observed and evaluated against calculated
datasets. Planar and volumetric visualisation demonstrated the potential of the device
and options that may be considered for clinical use. A dosimetry tool, such as the
Panoptes,

would allow for real-time treatment verification in clinical environments

that have no alternative. It would also provide the ability to verify optimised treatment
solutions that use methods such as plaque customisation and multiple seed activities.
The comparisons were made through depth-dose curves and on a pixel-by-pixel level,
and showed that there was some deviation between expected and measured results.

8.3.1

Planar Reconstruction

The isodose plots for the ten seed configuration in Figures 8.4 and A.1 show a low
response for Pixel # 3 2 . While it seems that it may be the result of individual seeds
causing hot spots, the Plaque Simulator and Monte Carlo results depict no indication
that the seeds could be discernible. The mid-right side of these isodose plot shows a
somewhat abrupt change in dose gradient. This feature occurred at the location of
lowest pixel density, where interpolation would be less accurate and more likely to
introduce such artefacts.
The two isodose plots for the five seed configuration in Figures 8.5 and A.2 clearly
demonstrate the asymmetry of the layout. This illustrates how modification of the
plaque seed configurations may be used to create dose distributions to meet patients
needs, and that they are clearly detectable in the measured data from the P a n o p t e s .
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Figure 8.18: Spatially resolves differences in pixe 1-by-pixel response of P a n o p t e s
versus Monte Carlo simulations; based on the data presented in Figure 8.17.
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Figure 8 .2 0 : Spatially resolves differences in pixel-by-pixel response of P a n o p t e s
versus TG-43U1; based on the data presented in Figure 8.17.

8.3.2

Volumetric Reconstruction

The volumetric plots produced from the P a n o p t e s data showed that reconstruction of
the five and ten seed plaque configurations yielded expected dose distributions. When
producing these dose volumes only about one half of the detector pixels (Pixel # 1 #3 4) were used in the interpolation process. Using all pixels gave rise to unwanted
artefact effects that originated when two dose points (spatially mapped pixel values)
from spatially symmetric pixels occupied a proximate space, but had different values.
When the interpolation algorithm attempted to map the points, an undesirable artefact
was produced due to these inhomogeneities. The variation in the values measured by
these symmetrically corresponding pixel pairs originated from the flipped detector
orientation (i.e. the pixels faced opposite directions when located in the same position)
and its impact on the dose attenuation.
In order to resolve the issue of these artefact effects while utilising the entire
pixel array, symmetrically corresponding pixel pairs could be averaged in space and
magnitude, reducing the angular dependance. However this would also act to reduce
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spatial resolution.
The xy slice in Figure 8.10 shows a low response in the region opposite the seeds
(left of image) which is expected due to the asymmetric five seed configuration. The
feature is exaggerated, however, due to attenuation effects through the silicon wafer
and detector board. These angular dependence effects could potentially be reduced
through the pixel pair averaging described above.
A comparison between the two angular resolutions measured showed radial wedge
features that may have been a function of angle due to interpolation. For the two
angle increments tested, the mean difference was

1 0 0 .6

% and the standard deviation

of the differences was relatively small, at 2.7%. The greatest differences occurred in
localised regions at the periphery of the dose volume and were most likely the result
of interpolation inaccuracies. Further optimisation of the P a n o p te s by performing a
detailed comparison across a range of angles would be useful to determine the ideal
angular resolution for clinical use.
Interpolated dose volumes derived from planar dose maps were shown to have
good potential for use in plaque dosimetry. Volumetric dose data used in this manner
provides an encompassing set of information across the volume of the eye.

Here,

dose from essentially any region of interest can be utilised. Whilst other volumetric
representations of the data are possible, such as isosurfaces, it is inherently difficult or
computationally expensive to compare entire 3D datasets visually. To gain the most
out of volumetric data, it should be used in conjunction with 1D and 2D representations
for viewing dose slices or profiles.

8.3.3

Verification

The primary measure of clinical suitability for a dosimetry system is comparison against
existing systems. As currently there are no methods used for dose verification in plaque
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brachytherapy, comparison with clinical dose calculation methods was used. These
methods included Monte Carlo, Plaque Simulator and the TG-43U1 formalism.
The Plaque Simulator dose contour, reconstructed from the P a n o p t e s detector
equivalent pixels, illustrated the resolution capabilities of the detector. The original
plot depicted uniform, concentric isodose lines, which matched remarkably well with
the reconstructed data. This demonstrates that the cubic interpolation process used
is suited to this form of image reconstruction, though artefacts seen in the calibration
isodose plot may suggest the sparse pixel regions are potentially problematic.
As the edge of the detector was not considered flush against the inner surface of the
plaque, but rather 500 pm from it, as per the phantom design, the details of individual
seeds are indistinguishable in the reconstruction. This could potentially be improved
if necessary, with refined and reduced phantom and detector tolerances.
The depth-dose curve taken through the central pixels of the P a n o p t e s detector
correlated well with the equivalent Monte Carlo simulation results.

This form of

comparison is useful and common practise for assessing the clinical suitability of
dosimeters. The TG-43U1 data and the Plaque Simulator data also correlate well with
each other, though this is expected as Plaque Simulation uses calculations adapted from
the TG-43U1 formalism. The P a n o p t e s and Monte Carlo data both incorporated
an eye phantom, and the dose-to-water conversion used for both was calculated based
on PMMA. The actual phantom, however, was fabricated from a proprietary acrylic
material for which details were limited, reducing the correlation between P a n o p t e s
and the Monte Carlo data. Dose correction to water would be improved with more
accurate simulation models.
The P a n o p t e s detector showed deviation from data produced with both the
Monte Carlo simulation and the Plaque Simulator. The data was normalised against
the top central pixel, which showed an under-response in the measurement, compared
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to calculations.

The phantom material may have contributed substantially to the

deviations seen in the pixel comparison of Figure 8.17. Furthermore, improving the
accuracy of the simulation model would account for the attenuation effects caused
by surrounding features that were not modelled.

These features include the PCB

materials, which included a high Zef f gold detector mounting pad, and the HERMES
ASICs.

The response of the TG-43U1 deviated by up to 30%, however, this was

expected due to the presence of the plaque backing and printed phantom material.

8.3.4

Potential Issues and Caveats

In addition to explanations provided above, there are several further issues that should
be considered in this study.
One potential issue with the P a n o p t e s in its current state, is plaque alignment.
Should the plaque be off axis from the shaft, its observable dose distribution will be
incorrect and greatest in the direction of the offset. Due to the design of the plaque
holder on the tip of the shaft, the plaque can only slot in concentrically and thus
cannot be off axis, with respect to the shaft. However, plaque misalignment may still
have occurred to some extent as the result of shaft eccentricity.
A flaw in the fabrication of the shaft meant it was not true. The components of
the lock-down shaft, shown in Figure B.4 of Appendix B were printed in the same
process as the phantom. Unfortunately, due to the physical length of the component,
it needed to be printed on horizontally, which caused distortion during the heated wax
removal process. The distortion caused slight eccentricity of the shaft which may have
lead to, what appeared as, an asymmetrically loaded plaque.
The sensitive volume of the detector did not perfectly align with the central plaque
axis within the phantom. This design oversight lead to an offset of up to 950 pm from
the centre of the sensitive volume to the plaque central axis. The issue was accounted
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for in the three-dimensional dose volumes, as the offset was included in the geometric
transformations. Discrepancies in the two-dimensional comparisons presented may be
attributed, in part, to this offset.

8.4

Conclusion

Throughout this thesis, the primary aim was to develop a preoperative dose verifica
tion system for plaque brachytherapy. This chapter brought the research and work
together from literature, concepts, design, development and characterisation to finally
present results on the function and performance of the P a n o p t e s as a whole. Two
dimensional dose maps were created through single measurements, whilst dose volumes
were generated through the collation of multiple measurements.
The P a n o p te s was not intended to replace the role of calculation based treatment
planning systems, but rather to supplement them through dose verification.

For

clinical relevance, the outcomes were compared to Monte Carlo simulation, the Plaque
Simulator TPS and TG-43U1.
Dosimetric pixel maps were generated with the P a n o p t e s and its software in
terface. Using the data in this form, isodose plots were generated, and provided an
improvement on the representation of dose distributions. Extending upon this further,
the individual pixel values taken from multiple angles covering 360° were translated to
an xy z coordinate system and interpolated using three dimensional linear interpolation.
The data was then plotted as volume slices for more advanced representation of dose
distribution, which showed good results from the five and ten seed configurations. Dose
distribution shapes may have been effected by angular dependence, shaft eccentricity,
plaque slipping or possibly cross-talk between channels.
Isodose curves were also interpolated based on both pixel equivalent values for
data taken from the Plaque Simulator TPS and from Monte Carlo simulation. The
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interpolation of calculated data gave distributions which showed excellent correlation
to the original data.
The depth-dose response through the central axis of the detector was compared to
Monte Carlo, Plaque Simulator and the TG-43U1, showing agreement within 4% for
most points. The clinical implications of this are likely to be inconsequential as source
uncertainties have been shown to be up to 8.7% [116]. The pixel-by-pixel comparisons
demonstrated that there were off-axis discrepancies generally within ±15% between the
Panoptes

simulations, Plaque Simulator calculations and the TG-43U1 formalism,

especially on the pixels closest to the source. This can be explained, in part, due
to slight geometric misrepresentation and inaccuracies in the simulation modelling.
These outcomes can be further improved with refined simulations and the subsequent
calibrations, as suggested in this chapter.
Through comparison against clinical dose calculation tools, the P a n o p t e s was
shown to be capable of measuring dose using automated position control and while
some discrepancies remain against theoretical values, the prototype design showed great
potential for producing a preoperative dose verification system for plaque brachytherapy.

Chapter 9
Contributions and
Recommendations
The primary aim of this thesis was to design, develop and evaluate the prototype
of a dose verification system for plaque brachytherapy. This was conducted in three
major parts: conducting a review of the current literature; proof of concepts for single
and pixelated detectors; and the design, development and testing of the P a n o p t e s
dose verification tool. This chapter presents a summary of the major contributions of
the thesis and offers some recommendations for future research and direction of the
project.

9.1

Summary of Contributions

After the introduction, the second chapter provided a review of the current literature in
the field. It began by presenting a summary of the anatomy of the eye for the benefit
of understanding the terms used in the study. It then covered the prevalence and
impact of ocular cancer and several of the current treatments, with a focus on plaque
brachytherapy. Building on this, the current clinical outcomes and limitations of plaque
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brachytherapy were also investigated. A comprehensive literature search on previously
used methods for plaque dosimetry was conducted, concluding that silicon detector
technology was suitable for pursuing as an eye brachytherapy dosimetry solution.
Following the literature review, Chapter 3 gave a brief background regarding semi
conductor technology and its application in dosimetry. The chapter covered material
that was relevant to the physics and electronic systems used throughout the study. It
outlined the generic model of a semiconductor radiation detection system and gave
details on the constituent parts. Finally, a discussion on dose equivalence was presented
along with its importance in this study.
Part II began with Chapter 4 , which evaluated the concept of using a miniature
detector, about 1mm3, to measure the depth-dose distribution of an eye plaque. The
aim of this single detector concept was to determine the feasibility of continued devel
opment into more complex and advantageous detector designs, in addition to providing
a simple dose verification tool for use in clinical environments. To do this, a detector
system comprising of a p-i-n diode detector, preamplifier and readout electronics was
developed.

The detector was characterised through measurement of both current-

voltage and capacitance-voltage responses, whilst for the assembled system, the energy
response, angular dependence and depth-dose response were measured. The overall
performance of the technology suggested that continued development towards volumet
ric plaque brachytherapy dosimetry should be undertaken, whilst there was room for
optimisation in the current single detector design.
Building upon the success of the single detector concept, Chapter 5 investigated two
concepts for volumetric dosimetry, the translation and the rotation concepts. These
were tested using the Medipix family of detectors, which had a 256 x 256 array of
pixels each 55 pm x 55 pm. The detectors were used to generate 3D dose volumes and
investigate several other plaque dosimetry aspects. This was conducted using a variety
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of eye phantoms, including a hemispherical, layered, PMMA phantom and a columnar
water phantom with movable plaque. Event counting above a threshold in each pixel
using the Medipix detector was compared to charge measurement, or deposited energy
in each pixel, using the TimePix detector running in TO T mode. The results showed a
strong correlation, to within

1

% in relative depth-dose measurements in the phantom

and within 5% of the TG-43U1 formalism at up to 5 mm from the plaque.

This

demonstrated that event counting with energy windows of 17keV - 45keV for 125I
would be effective in the subsequent P a n o p t e s design. Measurements of single seeds
in count mode on the surface of the Medipix detector showed that intra-batch activity
variation was around 11.5 %, which was worst at the ends of the seeds.
Tissue equivalent material was placed downstream from the Medipix detector in
the water phantom to model additional tissue outside the eye. It showed to influence
dose by up to nearly 7 % at 5 mm from the plaque, though the air-eye interface
location would vary relative to the plaque from case to case, making phantom design
challenging. Despite the advantages of the high spatial resolution in detectors, such
as the Medipix, it was demonstrated that a reduction in spatial resolution to a pixel
size of ~ 800 pm x 800 pm would provide sufficient information for 2D dosimetry and
lower production costs. The effectiveness of silicon pixelated detectors in measuring
beta emitting plaques was also considered and showed radionuclide deposition to be
non-uniform in the COB-type plaque, while the depth-dose response of the CCA-type
plaque correlated well to Plaque Simulator outputs.
Finally, the concept of spectroscopic dosimetry using pixelated silicon detectors
was introduced and the 3D volumetric dose reconstruction based on 2D dose images
sets was demonstrated. Using the Medipix detector as a model, customised pixelated
detectors with 64 and 127 pixels respectively, were proposed for use in the eye plaque
dose verification instrument, the P a n o p t e s .
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The final part of the thesis focused on the P a n o p t e s , starting with Chapter
6

, where the customised pixelated detector, data acquisition, phantom, positioning

and software systems for the P a n o p t e s were designed, developed and integrated to
produce the pixelated dosimetry system. Two detectors, rectangular and semicircular
in shape, were designed and fabricated to meet the needs of the translation and rotation
volumetric dosimetry concepts, respectively. Ultimately, the semicircular detector with
the rotation concept was chosen for use in the prototype design as it offered better dose
measurement near the plaque surface and simpler implementation. The semicircular
detector featured 64 pixels of two sizes, 300 pm x 300 pm and 1.00 mm x 1.00 mm.
The P a n o p t e s data acquisition system consisted of a multi-rail power supply,
FPGA interface board, detector board and stepper motor circuitry. The front-end
readout electronics used on the detector board were mixed-signal, low noise, 32-channel
ASICs called, HERMES4 and were bonded directly to the detector. A 3D printed,
hemispherical eye phantom was developed to encapsulate the detector, locate the
plaque during acquisitions and provide near tissue equivalence. The orientation of the
plaque was controlled using a stepper motor was via a spring loaded shaft. The host
computer software interface and FPGA interfaces coordinated all acquisitions, data
handling and control signals.
The semicircular, ion-implanted, passivated detector was designed, fabricated and
then characterised, both in isolation, and as an integrated part of the P a n o p t e s .
Investigation of I-V and C-V curves for the detector showed the breakdown voltage
to be ~ 63 V, operational voltage leakage current was less than ~

1

nA for all pixels,

and capacitance values had a mean of 13 ± 4pF and were strongly dependant on track
length. Alpha spectroscopy was performed with 241Am and demonstrated that pixels
at different locations had similar energy responses and that charge sharing between
neighbours was not significant. Monte Carlo simulation of the detector and phantom
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was performed to establish PMMA-to-water conversion factors for each pixel, with the
assumption the phantom was made from PMMA. Ion beam induced charge collection
showed that the detector pixels had well defined sensitive volumes, maximum charge
collection occurred at 50 V bias and charge sharing between pixels was very low.
The P a n o p t e s was characterised through spectroscopy and flat-field calibration.
Operating the P a n o p t e s as a single channel analyser showed that the 125I peaks were
clearly resolvable, enabling well defined energy thresholding. Using an orthovoltage
machine, flat-field calibration was conducted to equalise readout of the pixel response
across the detector.
Measurements were taken with the P a n o p t e s using a ROPES 15 mm eye plaque
and 125I seeds. The plaque was loaded in both ten and five seed configurations to observe
differences in dose distribution responses. Isodose curves were produced for corrected
Panoptes

data, reconstructed Monte Carlo simulation and Plaque Simulator data.

These were used in addition to the TG-43U1 formalism for a depth-dose comparison of
the central axis of the detector with ten seeds, which showed to be within 4%. Results
showed the P a n o p t e s correlated within around 15% for most values, though given
uncertainties in phantom material, these deviations could be expected.
Software was developed for the reconstruction of multiple 2D doses slices taken
over a series of angles for 3D volumetric doses of plaques loaded with both five and
ten seeds. Despite the remaining room for optimisation, the P a n o p t e s shows great
potential for providing fast, dose verification in plaque brachytherapy.
The overall aim of this thesis was to address the current lack of preoperative
treatment verification in plaque brachytherapy, which was achieved through:
• determining issues in current treatment planning systems,
• experimentally assessing the validity of using a single silicon diode detector for
plaque brachytherapy dosimetry,
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• experimentally assessing the validity of using a pixelated silicon detector for
plaque brachytherapy dosimetry through the Medipix detector family,
• design and fabrication of pixelated detectors for two plaque brachytherapy dosime
try concepts; translational and rotational,
• integration of the detector into a full dosimetry system, called the P a n o p t e s ,
for real-time, automated measurements, and
• evaluation of the P a n o ptes dosimetry system in plaque brachytherapy treat
ments.

9.2

Recommendations for Future Work

The P a n o p te s project essentially focused around the design of a prototype to act
as a proof of concept and offer a platform to determine areas for improvement. The
following includes several recommendations that could be adopted to improve the
outcomes of the dose verification process or P a n o p t e s :

1. Further calibration and characterisation
Further characterisation and improvements could be used to increase the per
formance of the P a n o p t e s . By performing simulations with a more accurate
representation of the detector in the phantom, including the circuit board with
the gold contacts, the measured silicon to tissue dose response conversion could
be determined with greater accuracy. A primary consideration would be to cor
rectly represent the 3D printer phantom material, rather than using PM M A in
simulations to determine the conversion factors from detector response to dose
in water. The flat-field response of an electron beam could also be measured for
comparison to the existing data. Channels of windows 1 and 2 of the HERMES
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front-end electronics could be individually threshold trimmed to ensure more
accurate event counting for the desired sources.
2. Phantom design
Design of a generic phantom for plaque brachytherapy is challenging. As tumour
location dictates plaque orientation, the relative position of the eye-air interface
can change between treatments. The effects of backscatter from tissue in and
around the eye have been shown to be significant. The development of a phan
tom that is able to accommodate these needs would be of benefit in improving
the treatment accuracy.

The effect on current clinical work flows should be

consideration when making such a modification to the existing system.
3. Software integration
The P a n o p t e s aimed to support treatment verification processes and the process
would be more streamlined if the efforts required for data handling were reduced.
The integration of the Panopticon acquisition interface, presented in this thesis,
into software such as Plaque Simulator would allow for treatment planning and
verification within the same software package and hence improve time efficiency.
4. Customised plaques
The plaque prescription needs of each patient vary depending on tumour location,
size and geometry. Dose distributions are currently limited to discreet plaque
configurations and are not optimised for individual patients. The current state
of 3D printing technologies and materials, along with the implementation of the
Panoptes

would allow custom designed plaques to be developed and verified at

low cost. Further research and development could involve the development of an
automated plaque designer based on patient geometry and its subsequent dose
verification with the P a n o p t e s .
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In summary, a single detector dose verification system was developed, and pixelated
dosimetry was deemed feasible through the design, development and testing of the
Panoptes.

Despite the room for further optimisation, the P a n o p t e s demonstrated

strong potential as a viable tool for addressing the current lack of preoperative dose
verification in plaque brachytherapy.

Part IV
References and Appendices
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Table A.1: Flat-field experimental details
Property
Beam voltage
Dose ratea
Frame time
Number of frames
Total exposure time
FSD
Detector bias voltage
Shaping time
Amplifier gain

Value
250
68
100
100
1 0 .0

3
50.0
0.5
0.75

a Surface dose to water at 500 mm

Units
kV
cGy min- 1
ms
Frames
s
m
V
ps
m V fC - 1
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Table A.2: Dose to water conversion and equalisation factors combined
Pixel #

Dose to Water

1
2

0.2110

3
4
5
6

7
8

9
10
11
12

13
14
15
16
17
18
19
20
21
22

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64

0.2003
0.1931
0.1832
0.1753
0.1995
0.1881
0.1794
0.1645
0.1608
0.1933
0.1591
0.1839
0.1754
0.1695
0.1648
0.1619
0.1654
0.1559
0.1899
0.1813
0.1740
0.1685
0.1622
0.1646
0.1561
0.1621
0.1869
0.1795
0.1736
0.1864
0.1561
0.1781
0.1684
0.1863
0.1736
0.1796
0.1867
0.1561
0.1649
0.1620
0.1686
0.1738
0.1812
0.1896
0.1563
0.1654
0.1620
0.1645
0.1695
0.1754
0.1842
0.1589
0.1936
0.1608
0.1650
0.1796
0.1879
0.1995
0.1753
0.1829
0.1938
0.1988
0.2120

Equalisation
9.4312
8.5261
7.5698
7.4600
7.5431
1.1956
1.1206
1.0911
7.3769
7.0813
1.1305
6.9788
1.0334
1.0798
1.0524
6.8867
6.6901
6.9657
6.9090
1.0567
1.0328
1.0502
1.0257
7.3696
6.8973
7.4071
7.2177
1.0321
1.0479
1.0000

1.0805
6.7174
1.0786
1.1391
1.0611
1.0444
1.0765
1.0933
7.5689
7.6678
7.5399
1.1401
1.0997
1.1025
1.1344
8.0607
7.6296
7.7287
7.2703
1.0852
1.1241
1.1559
8.2578
1.1637
7.8888
7.5050
1.1257
1.1283
1.1514
8.1111

8.2638
7.9509
7.6569
8.2422

Combined factors
1.9898
1.7081
1.4619
1.3665
1.3223
0.2386
0.2107
0.1958
1.2137
1.1384
0.2185
1.1104
0.1900
0.1894
0.1784
1.1350
1.0829
1.1523
1.0772
0.2007
0.1872
0.1827
0.1728
1.1953
1.1355
1.1565
1.1698
0.1929
0.1881
0.1736
0.2015
1.0485
0.1921
0.1919
0.1977
0.1813
0.1933
0.2041
1.1816
1.2642
1.2216
0.1922
0.1911
0.1997
0.2151
1.2603
1.2623
1.2521
1.1959
0.1840
0.1971
0.2129
1.3121
0.2253
1.2683
1.2384
0.2021
0.2121

0.2297
1.4216
1.5115
1.5409
1.5220
1.7471
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Figure A.1: Interpolated isodose curves of P a n o p t e s measurement converted to
dose in water with ten 125I seeds at 0.0°. Dimensions are in millimetres and dose is
normalised to 100% at the maximum value.

[mm]
Figure A.2: Interpolated isodose curves of P a n o p t e s measurement converted to
dose in water with five 125I seeds at 0.0°. Dimensions are in millimetres and dose is
normalised to 100% at the maximum value.
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Figure B.1: Dimensioned drawings of the preamplifier housing for the single detector
concept.
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Figure B.2: Dimensioned drawing of the phantom 3D printed for the cut version of
the semicircular detector. Dimensions are in millimetres.
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Figure B.3: Dimensioned drawing of the positioning system box and isometric render
of the assembled system included the detector board and phantom. Though not
shown, a front panel is also used to complete the box and block external noise sources.
Dimensions are in millimetres.
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Figure B.4: Dimensioned drawing of the lock-down shaft showing that a spring is used
to exert downward force onto the plaque, keeping it firmly in place during acquisitions.
Dimensions are in millimetres.
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(a) Front panel

(b) Back panel
Figure B.5: The front and back panels of the main electronics box. The top panel
features (from left) a power indication LED, stepper motor socket and detector board
interface. The back panel features (from left) a USB B socket for connection to the
host computer, high voltage enable override switch, a high voltage manual-remote
control switch, a high voltage adjustment dial and a fused IEC [215] power socket.
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Figure C.1: Circuit schematic of the detector board showing main circuit. (1 of 3)
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Figure C.2: Circuit schematic of the detector board HERMES ASIC connections. (2
of 3)
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Figure C.3: Circuit schematic of the detector board showing connections to the detector.
(3 of 3)
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Figure C.4: Printed circuit board layout of the detector board.
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Table C.1: Connection scheme for the detector board-interface board
Pin

Cable

Net

1

A
B
C
D
E
F
G
H
J
K
Z
L
M
Z
N
P
Z
R
S
Z
T
U

SDI
SDO
SCK
SDAC
WR
EN
RST
CS1
CS2
CAL
VSS
+5VD
VSSD
VSS
+5VA
DETBIAS
VSS
OLK1
OAN1
VSS
OLK2
OAN2

2

3
4
5
6

7
8

9
10
11
12

13
14
15
16
17
18
19
20
21
22

23
24
25
26
27
28
29
30
31
32
33
34
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Figure C.5: Circuit schematic of the power supply board. (1 of 2)
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Figure C.6: Circuit schematic of the power supply board. (2 of 2)
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Figure C.7: Printed circuit board layout of the power supply board showing.
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Figure C.8: Circuit schematic of the interface board. (1 of 5)
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Figure C.10: Circuit schematic of the interface board. (3 of 5)
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Figure C.11: Circuit schematic of the interface board. (4 of 5)
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Figure C.12: Circuit schematic of the interface board. (5 of 5)
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Figure C.13: Printed circuit board layout of the interface board.
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Figure D.1: Fabrication mask of the semicircular detector showing the whole wafer
and the various implantation layers.

Figure D.2: Fabrication mask of the semicircular detector showing the p+-type (blue)
and n+-type (orange) implantation regions at the top of the wafer.
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Figure D.3: Fabrication mask of the semicircular detector showing the aluminium
tracks (green) that route current signal through to the bonding pads at the bottom of
the wafer.

Figure D.4: Fabrication mask of the semicircular detector showing the locations of the
diodes within the n+-type layer (orange).
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Figure D.5: Fabrication mask of the semicircular detector showing the aluminium layer
and tracks (green) that route current signal through to the passivation layer (red) at
the bonding pads at the bottom of the wafer.
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acquisition_handler

hermes SDO handler

FDS

HV driver 00
CLK

dac_cs

hv_set

dac_sck

hv_reset

dac_sdi

motor_control
motor_pos(10:0)

|dac_value(11:0) hv_sel_clk

motor_spd(2:0)

|adc_value(11:0)

motor_dir_iscw

adc_status
hv_control
hv_er

adc_cmd
hv_value(11:0)

start_motor

hv_en_clk

motor_dir
motor_step

adc_ready
disable ir

motor_disable_in motor_disable

Figure E.1: FPGA firmware schematic at the main module level, showing the sub
modules and their ports.

Figure E.2: FPGA firmware schematics of the chip selector, which functions to access
the appropriate HERMES ASIC.
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Figure E.3: FPGA firmware schematics of the SDI line which handles serial data
transfers from the FPGA to the HERMES ASIC.

Figure E.4: FPGA firmware schematics of the SDO line which handles serial data
transfers from the HERMES ASIC to the FPGA.
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Figure E.5: FPGA firmware schematic for the high voltage system, including the ADC
and DAC components.
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Figure E.6 : FPGA firmware schematic for the ADC module of the high voltage system,
responsible for measuring the voltage from the EMCO module.

Figure E.7: FPGA firmware schematic for the DAC module of the high voltage system,
responsible for setting the voltage on the EMCO module.
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E.2

Verilog Firmware Modules

Listing E . 1 : acquisition_handler.v - A firmware module that aims coordinates the
timing and signalling for acquisitions.

module a cq ui s i t i o n _ h a n d l e r (
in put
wi re
[15:0] a c q _ t i m e ,
i nput
wi re
s t art _ ac q ,
in put
wi re
CLK ,
in put
wi re
RST ,
output
reg
EN ,
output
reg
ack_start ,
output
wi re
[15:0] c u r r e n t _ c o u n t
);

reg
reg
reg
reg

[15:0] q u o t i e n t = 3 1 2 5 0 ;
[15:0] Q = 0;
[15: 0] c o u n t e r = 0;
s t a r t _ s t a t u s = 0;

assign

current_count

/ / Count
always @
begin

=

//

Quotient , used

to

slow

the

c l oc k

c o u n t e r [15:0];

u s i n g the d o u b l e d f r e q u e n c y clock.
(p o s e d g e CLK or p o s e d g e RST)
i f (R S T ) b e g i n
Q

<=

0;
s t a r t _ s t a t u s <=
<= 0;

0;

counter
end

els e
begin
if

(!start_status && start_acq)
a c k _ s t a r t <= 1;
c o u n t e r <= a c q _ t i m e - 1 ;
Q <= 0;
EN <= 1;
e nd e l s e b e g i n
a c k _ s t a r t <= 0;
end
s t a r t _ s t a t u s <= s t a r t _ a c q ;
for posedge detection
if

(EN)

begin
if (Q ==

//

begin

store

the

start_acq

(q u o t i e n t -1) ) b e g i n
/ / W e ’re at the m a x i m u m v a l u e ,
/ / R e s e t the d i v i d e r c o u n t e r
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Q <= 0;
if ( c o u n t e r > 0) b e g i n
c o u n t e r <= c o u n t e r
end e l s e b e g i n
EN <= 0;
end
el s e b e g i n
Q <= Q + 1;

end

-

1;

end
end
end
end
endmodule

Listing E.2: motor_control.v - A firmware module for controlling the stepping, direc
tion and enable signalling to the stepper motor.

‘t i m e s c a l e 1ns / 1ps
module mot or _c on tr ol (
i n p u t [10:0] m o t o r _ p o s ,
/ / M o t o r p o s t i o n [0-360 degrees
] - > [ 0 - 2 0 0 0 ] 0 . 1 8 deg / step
input m o t o r _ d i r _ i s c w ,
/ / if true m o t o r d i r e c t i o n is C W
i n p u t [2:0] m o t o r _ s p d ,
// motor speed
[n1 k H z - n 2
H z ] - > [ 0 - 7 ] ( this b e h a l v e s m o r e like p u l s e s k i p p e r )
input
input
input
input

wi re

wi re

st art _ m o t o r ,
wire
motor
wire
CLK ,
RST ,

output

reg

ack_motor ,

output
output
output

reg
reg
reg

motor _step =
mot or _dir = 1
motor _disable

);
/ / r e g [15:0] q u o t i e n t = 3 1 2 5 0 ;
r e g [10:0] c o u n t e r _ s t e p = 0;
r e g [15:0] d l y = 0;
r e g [15:0] c o u n t e r _ d l y = 0; / /
r e g s t a r t _ s t a t u s = 0;
always
begin

@

(p o s e d g e
i f (RST)
begin

CLK

or

//

Quotient,

this

posedge

is

RST)

based

used

on

to

slow

the

2~(motor_spd)

c lo c k
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end

else

//

s t a r t _ s t a t u s <= 0;
c o u n t e r _ s t e p <= 0;
d l y <= 0;
c o u n t e r _ d l y <= 0;
m o t o r _ d i s a b l e <= 1;
m o t o r _ d i r <= 0;
end r e s e t s e c t i o n

begin
a c k _ m o t o r <= s t a r t _ m o t o r ;
m o t o r _ d i s a b l e <= m o t o r _ d i s a b l e _ i n ;
if ( a c k _ m o t o r )
begin
c o u n t e r _ s t e p <= m o t o r _ p o s ; / / m o t o r p o s i t i o n
is d i t a c t e d by the n u m b e r of p u l s e s sent
to the c o u n t e r
d l y <= ( 1 < < m o t o r _ s p d + 6 ) -1; / / e q u a l to 2 ~ (
m o t o r _ s p d + n ) -1 : N O T E : the n is u s e d to
s l o w the m o t o r o t h e r w i s e it is too f a s t
c o u n t e r _ d l y <= dly;
m o t o r _ d i r <= m o t o r _ d i r _ i s c w ;
m o t o r _ s t e p <= 0;
s t a r t _ s t a t u s <= 1;
end e l s e / / end init s e c t i o n
if ( s t a r t _ s t a t u s )
begin
a c k _ m o t o r <= 0; / / T O D O : C h e c k that this is
not too f a s t f o r the U S B i n t e r f a c e to
catch
if ( c o u n t e r _ s t e p > 0)
begin
if ( c o u n t e r _ d l y > ( d l y > > 1 ) )
/ / if f i r s t h a l f of p e r i o d
- ste p is 1
m o t o r _ s t e p <= 1;
e l s e / / s e c o n d h a l f of p e r i o d
m o t o r _ s t e p <= 0;
i f ( c o u n t e r _ d l y > 0)
c o u n t e r _ d l y <=
counter_dly
if ( c o u n t e r _ d l y == 0)
begin
c o u n t e r _ s t e p <=

end e l s e
begin

end
//

counter_step

- 1;
c o u n t e r _ d l y <=
dly;
/ / e n d s e t t i ng p ul s e h ig h
end m o v e c o u n t e r i t e r a t i o n

m o t o r _ s t e p <= 0;
s t a r t _ s t a t u s <= 0;

-1;
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end
end

//

// p os edg e

endmodule

e nd / / end of ste ps
e n d / / e n d s t ep p i n g p h a s e
e n d i n i t a n d s t ep p i n g m a c ro p h a s e
an d

r eset p hase

Appendix F
Code
Listing F.1: A sample P a n o p t e s data file, showing the variation acquisition parame
ters and the channel data at the end.

Panopticon
S t a r t Tim e
End Time

- Data

Acquisition
:
03:08:18.018PM
:
03:09:30.611PM

Acq. T y p e
Acq. N u m b e r
T o t a l Acq. N u m b e r
Acq. T i m e [s]
Positions:
Motor Increment
Motor Position

:
:

:
:

Global Settings:
P e a k i n g Time
Gai n
Threshold
WL 0
WL1
WH1
WL 2
WH 2
B ia s

[V]

Details

Acquisition(s)

18
108

:
:

0. 5 m i c r o s e c o n d s
0.75

Settings:
:
:
:
:
:

Voltage

Additional

Single
1
1
10

21-11-13
21-11-13

:

mV/fC

300
300
102 3
300
102 3
49.8935

: {
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F. CODE |312

N3
10 s e e d s - I 125 - R O P E 1 5 m m
P l a c e d in s h i e l d e d box , w i t h b l a c k c l o t h a n d c a r d b o a r d b o x o v e r t o p
for
l i g h t i n h i b i t i o n o r i e n t a t i o n of p l a q u e
i n n e r t r i a n g l e ( the p o i n t
f a c i n g the s i n g l e p e r p e n d i c u l a r s e ed) is
p o i n t i n g t o w a r d b a c k w a ll
of
box phantom ( before spring loaded, which causes rotation )
}
Channel
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

W0
1210
1378
1668
2052
2908
4003
585 5
8738
46 9 1
6418
46 9 1
8081
6976
10204
16823
4663
6463
4624
9007
5123
7570
1 11 3 2
1 72 6 0
6062
470 1
8618
573 2
558 5
7729
1 13 7 0
5641
8465
7960
1 68 5 4
562 4
1 11 1 6
7306
523 0
8622
4286
563 5

W1
1207
1375
1 668
20 4 7
28 8 4
39 9 8
5842
8738
4670
64 1 9
4677
79 6 4
6977
10248
16879
4650
63 3 9
4577
8123
5119
7564
11065
17224
5999
4688
81 0 6
5613
5598
7738
11284
5601
7573
7901
16504
5585
11047
7229
5173
8376
4205
5547

W2
1207
1378
1662
2045
2890
3988
58 4 2
8729
4686
6419
4678
7977
6943
10223
1 68 3 5
4605
6237
4598
8119
50 9 6
7553
1 10 6 8
1 7 191
6001
4710
8167
56 9 0
55 6 6
7729
1 13 0 5
56 2 4
7475
7970
1 65 5 0
56 1 6
11123
7304
51 9 9
8590
4229
55 3 9

F. CODE |313

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62

15712
10147
6830
4788
7517
4200
52 9 3
4146
14535
8834
580 5
595 0
4175
4408
3265
7066
4868
3761
2207
1742
1471
1330
1236

15560
10089
6791
4768
7223
4084
518 6
41 01
14395
8701
576 7
571 9
41 44
41 47
3239
7012
4843
3736
2129
1 712
1 466
1 324
1 230

15670
10150
6819
4770
7427
4173
5203
4136
14447
8775
5810
5840
4149
420 1
3272
7037
4853
3756
2162
1737
1466
1327
1234
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K eyw ords:
Brachytherapy
Ocular cancer
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A B S T R A C T
T r e a t m e n t o f o c u la r c a n c e r s u s in g e y e p la q u e b r a c h y th e r a p y is n o w a n e s ta b lis h e d m e d ic a l p r o c e d u r e .
H o w e v e r, c u r r e n t QA fo r t h e s e e y e p la q u e s is q u it e r u d im e n ta r y , lim itin g th e o p p o r tu n itie s fo r p r e c is e
p r e -tu m o u r p la q u e c u s t o m is a tio n . T h is p a p e r p r o p o s e s a n d e x p e r im e n ta lly v a lid a te s a n e w te c h n iq u e
fo r im a g in g o f e y e p la q u e d o s e d is tr ib u tio n s u s in g a h ig h - r e s o lu tio n p ix e la t e d s ilic o n d e te c to r . R e su lts
a r e p r e s e n te d d e m o n s tr a t in g th e 2 D a n d 3 D is o d o s e s u r fa c e s p r o d u c e d u s in g e x p e r im e n ta l d a ta
c o lle c te d u s in g th is m e th o d .
© 2 0 1 0 E ls e v ie r B.V. All r ig h ts re s e r v e d .
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Dosimetry verification in eye brachytherapy using silicon pixelated detectors
M. W eaver3,*, M. Petasecca3, M.L.F. Lercha, D. Cutajar3, J. JakUbekb, S. Pospisilb, A.B. Rosenfeld3,**
a Centre o f M edical R adiation Physics, University o f W ollongong, N orthfields Ave., W ollongong, NSW, A ustralia
b Institute o f E xperim en tal an d A pplied Physics, Czech Technical University in Prague, Prague, Czech R epublic
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A B S T R A C T

Article history:

T h is s tu d y p r e s e n ts a h ig h s p a tia l r e s o lu tio n d o s im e tr y s y s te m fo r q u a lity a s s u r a n c e o f I- 1 2 5 e y e p la q u e s .

Received 30 Novem ber 2010

T h e s y s te m is b a s e d o n a s ilic o n p ix e la te d d e t e c t o r a n d is c a p a b le o f d e riv in g 3 D d o s e d is tr ib u tio n s . A

Received in revised form

s im p le d e s ig n w a s im p le m e n te d , in c o rp o ra tin g a m o v a b le e y e p la q u e in a s m a ll w a te r p h a n to m a b o v e

17 Septem ber 2011
Accepted 5 October 2011

th e s ilic o n M e d ip ix 2 d e te c to r . It is d e s ig n e d fo r o b ta in in g 2 D d o s e d is tr ib u tio n s a t d if f e r e n t d e p th s in
.
,
K
„
.,
,
.
w a te r, fo r s u b s e q u e n t 3 D d o s e m a p p in g . T h e e f f e c t o f b a c k s c a tte r in g in a m e d iu m p la c e d b e h in d th e

--------------------------------------------------------------------

M e d ip ix 2 to s im u la te s u rro u n d in g tis s u e h a s b e e n s tu d ie d in te r m s o f d o s e d is tr ib u tio n . A d d itio n a lly , tw o

«

m o d e s o f a c q u is itio n , e v e n t c o u n tin g m o d e a n d th e m o r e c o m p le x tim e - o v e r - th r e s h o ld m o d e , w e re

Brachytherapy
Dosim e try
Tim epix
Medipix2
Iodine-125

c o m p a re d to th e T G -4 3 p r o to c o l fo r th e d e te r m in a tio n o f th e ir s u ita b ility fo r d o s im e tr y .
® 2 0 1 1 E ls e v ie r Ltd. All rig h ts re s e rv e d .

Radiation Measurements 71 (2014) 310—314

Contents lists available at ScienceDirect

Radiation Measurements

Radiation Measurements
ELSEVIER

jo u rn a l h o m e p a g e : w w w .e ls e v ie r.c o m /lo c a te /ra d m e a s

Panoptes: Calibration of a dosimetry system for eye brachytherapy
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H I G H L I G H T S
• V o lu m e tr ic d e t e c t o r s y s te m p ro d u c e d fo r p la q u e b r a c h y th e r a p y .
• O r th o v o lta g e , fla t-fie ld c a lib r a tio n p e rfo r m e d fo r d e te c to r p ix e ls .
• M o n te C arlo s im u la tio n s h o w e d m o s tly little a n g u la r d e v ia tio n a c r o s s a ll a n g le s .
• Io n b e a m in d u c e d c h a r g e c o lle c tio n s h o w e d p ix e ls u n ifo r m a n d fu lly d e p le te d .
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Article history:

In tr a o c u la r c a n c e r is a s e rio u s t h r e a t to th e liv es o f th o s e th a t s u ffe r fro m it. D o s im e tr y fo r e y e

A raikM e °n lin e 13 April 2014

b r a c h y th e r a p y p r e s e n ts a s ig n ific a n t c h a lle n g e d u e to th e in h e r e n tly s te e p d o s e g ra d ie n ts t h a t a re n e e d e d
to tr e a t s u ch s m a ll tu m o u r s in c lo s e p r o x im ity to s e n s itiv e n o r m a l s tr u c tu r e s . T h is is s u e is a d d re s s e d b y

K eyw ords:
Eye plaque
Brachytherapy
Dosim etry
HERMES
IBICC

p ro v id in g m u c h n e e d e d q u a lity a s s u r a n c e to e y e b ra c h y th e r a p y , a n o v e l v o lu m e tr ic d o s im e tr y sy ste m ,
c a lle d P a n o p te s w a s d e v e lo p e d . T h is s tu d y fo c u s e s o n th e p r e lim in a r y c h a r a c te r is a tio n a n d c a lib r a tio n o f
th e s y s te m . U sin g io n b e a m fa c ilitie s , th e c u s to m , p ix e la te d s ilic o n d e t e c t o r o f P a n o p te s w a s s h o w n to h av e
g o o d c h a r g e c o lle c tio n u n ifo r m ity a n d a w e ll d e fin e d s e n s itiv e v o lu m e . F la t-fie ld c a lib r a tio n w a s c o n 
d u c te d o n th e d e v ic e u s in g a 2 5 0 kV p o rth o v o lta g e b e a m . F in ally , th e d e t e c t o r a n d p h a n to m w e re
s im u la te d w ith M o n te C arlo in G e a n t4 , to c r e a te w a te r e q u iv a le n t d o s e c o r r e c tio n fa c to rs fo r e a c h p ix e l
a c r o s s a ra n g e o f a n g le s .
© 2 0 1 4 E ls e v ie r Ltd. All rig h ts re s e rv e d .
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